CA2069906C - Uncharged morpholino-based polymers having achiral intersubunit linkages - Google Patents

Uncharged morpholino-based polymers having achiral intersubunit linkages

Info

Publication number
CA2069906C
CA2069906C CA002069906A CA2069906A CA2069906C CA 2069906 C CA2069906 C CA 2069906C CA 002069906 A CA002069906 A CA 002069906A CA 2069906 A CA2069906 A CA 2069906A CA 2069906 C CA2069906 C CA 2069906C
Authority
CA
Canada
Prior art keywords
polymer
base
subunit
morpholino
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002069906A
Other languages
French (fr)
Other versions
CA2069906A1 (en
Inventor
James E. Summerton
Dwight D. Weller
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2069906A1 publication Critical patent/CA2069906A1/en
Application granted granted Critical
Publication of CA2069906C publication Critical patent/CA2069906C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G75/00Macromolecular compounds obtained by reactions forming a linkage containing sulfur with or without nitrogen, oxygen, or carbon in the main chain of the macromolecule
    • C08G75/18Polysulfoxides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/548Phosphates or phosphonates, e.g. bone-seeking
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/001Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
    • C07K14/003Peptide-nucleic acids (PNAs)
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G75/00Macromolecular compounds obtained by reactions forming a linkage containing sulfur with or without nitrogen, oxygen, or carbon in the main chain of the macromolecule
    • C08G75/20Polysulfones
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G75/00Macromolecular compounds obtained by reactions forming a linkage containing sulfur with or without nitrogen, oxygen, or carbon in the main chain of the macromolecule
    • C08G75/24Polysulfonates
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6816Hybridisation assays characterised by the detection means
    • C12Q1/682Signal amplification
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813Hybridisation assays
    • C12Q1/6839Triple helix formation or other higher order conformations in hybridisation assays
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2219/00Chemical, physical or physico-chemical processes in general; Their relevant apparatus
    • B01J2219/00274Sequential or parallel reactions; Apparatus and devices for combinatorial chemistry or for making arrays; Chemical library technology
    • B01J2219/00718Type of compounds synthesised
    • B01J2219/0072Organic compounds

Abstract

A polymer composition is disclosed composed of morpholino subunit structures which are linked together by uncharged achiral linkages. These linkages are one to three atoms in length, joining the morpholino nitrogen of one subunit to the 5' exocyc-lic carbon of an adjacent subunit. Each subunit contains a purine or pyrimidine base-paring moiety effective to bind by hydrogen bonding to a specific base or base-pair in a target polynucleotide.

Description

WO 91/09073 1 PCr/US90/07565 20fi99~6 UNCHARGED MORPHOLINO-BASED POLYMERS
HAVING AC~IRAL INTERSUBUNIT LINKAGES
5 FiQld of the Ir~ . l 1sn The present invention relaces to morpholino-based polymers .
References 10 Agarwal, Proc Nat Acad Sci USA, 85:7079 (1988) .
Balgobin, N., et al., Tetrahedron Lett, - 22:3667 (1981) .
Belikova, Tetrahedron Lett, 37:3557 (1967).
Blake et al., Biochem, 24: 6132 (1985a) .
Blake et al., Biochem 24: 6139 (1985b) .
Dikshit et al., r;ln~ n J Chem, 66:2989 (1988).
Fild et al., Chem Ber, 113:142 (1980) .
Froehler, et al., Nuclelc Acids Res. 16:4831 (1988).
Fox, J.J., et al., J Am Chem Soc, 80:1669 (1958) .
Gait, "Oligonucleotide S~nthesis, A practical Ap-proach, " pages 31-33, IRL Press, Oxford, ~ngland (1984) .
Goldberg, M. L. et al; Methods in Enzymology 68:206 (1979) -Greenlee, J Org Chem, 49 2632 (1984).
Grunstein, M. et al; ~ethods in Enzymology 68:379 (1979) .
1 cl~ach, F., and W. Pfleiderer, ~etrahedron WO 9l/09073 PCI/US90/07565 2~6g~

Lett, 24:3583 (1983).
Jayaraman, et al ., Proc Natl Acad Sci USA 78 :1537 (1981) .
Kamimura et al., Chemistry Letters (The Chem. Soc.
of Japan) pg. 1051 (1983).
Lerman, L . S ., "DNA Probes: Applications in Genetic and Infectious Disease and Cancer, " Current Comm in Molec Biol, Co:Ld Spring Harbor Laboratory (1986) .
Letsinger and Miller, J Amer Chem Soc, 91:3356 (1969).
McBride et al., J Amer Chem Soc 108:2040 (1986).
Miller, et al., Biochemistry 18:5134 (1979) .
~iller, et al., J Biol Chem 255 6959 (1980).
Miller, et al., Blochimie 67:769 (1985).
~urakami, et al., Biochemistry 24:4041 (1985).
Niedballa, U., and H. Vorbruggen, J Org Chem, 39:3668 (1974).
Pitha, Biochem Biophys Acta 204:39 (1970a).
Pitha, Biopolymers 9. 965 (1970b) .
Reese, C.B., and R.S. Saffhill, J Chem Soc Perkin Trans, 1:2937 (1972) .
Smith, et al ., J Amer Chem Soc 80: 6204 (1958) .
Smith, et al., Proc Natl Acad Sci USA 83:2787 (1986). Southern, E.; Methods in ~nzymology 68:152 (1979) Stirchak E.P. et al., Organic Chem. 52:4202 (1987).
Summerton, et al., J Molec Biol, 122:145 (1978).
Summerton, et al ., J TheQr Biol, 78: 61 (1979a) .
Summerton, J Theor Biol, 78:77 (1979b) .
Szostak, J. W. et al; Methods in Enzymolcgy 68:419 (1979) .
Thomas, P.; Methods in Enzymology 100:255 (1983).
Toulme et al., Proc Nat Acad Sci, USA 83 :1227 (1986) .
3 PCI/US90/0~565 ,=
Z~i990~i Trichtinger et al., ~etrahedron Lecters 24: 71I
(1983) .
sackground of the Inv~ntion Polymers which are designed for base-specifLc bind-ing to polynucleotides have significant potential both for in vitro detection of specific genetic sequences characteristic of pathogens (Lerman) and for in vivo inactivation of genetic sequences causing many diseases--particularly viral diseases ~elikova, Summerton).
Standard ribo- and deoxyribonucleotide polymers have been widely used both for detection of complementary genetic sequences, and more recently, for inactivating targeted genetic sequences. However, standard polynucle-otides suffer ~rom a number of limitations when used for base-specific binding to target oligonucleotides. These limitations include (i) restricted passage across biolo-gical membranes, ~ii) nuclease sensitivity, (iii) target binding which is sensitive to ionic conc~ntration, and (iv) susceptibility to cell~lAr strand-separating mecha-nisms .
In principle, the above limitations can be overcome or minimized by designing polynucleic acid analogs in which the bases are linked along an uncharged backbone.
Examples of uncharged nucleic acid analogs have been reported. Pitha et al (1970a, b) have disclosed a vari-ety of homopolymeric polynucleotide analogs in which the normal sugar-phosphate backbone of nucleic acids is replaced by a polyvinyl backbone. These nucleic acid analogs were reported to have the expected Watson/Crick pairing specificities with complementary polynucleotides, but with substantially reduced Tm values (Pitha, 1970a).
One serious limitation of this approach is the inability to construct polymers by sequential subunit addition, for WO 91/09073 PCr/US90/07~65 20699~6 producing polymers with a desired base sequence. Thus the polymers cannot be used for base-specific binding to selected target sequence~Dlynucleotide analogs ~ nt~ning uncharged, but stereoisomeric, methylphospho-5 nate linkages between the deoxyribonucleoside subunitshave been reported (Miller, 1979, 1980; Jayaraman;
Murakami; Blake, 1985a, 1985b; Smith). More recently a variety of analogous uncharged phosphoramidate-linked oligonucleotide analogs have also been reported 10 (Froehler, 1988). These polymers comprise deoxynucleo-sides linked by the 3' OH group of one subunit and the 5' OH grou~ of another subunit via an uncharged chiral phosphorous-containing group. These compounds have been shown to bind to and selectively block single-strand 15 polynucleotide target sequences. E~owever, uncharged phosphorous-linked polynucleotide analogs of the type just described have limitations, particularly the cost and difficulty of preparing the polymers.
More recently, deoxyribonucleotide analogs having 20 un- charged and achiral intersubunit linkages have been constructed (Stirchak 1987). Since these polymers are stereoregular, all polymers having a given subunit se-quence will have the same Tm value for a given target nucleotide sequence, thus avoiding some of the limita-25 tions inherent in chirally-linked polymers. These un-charged, a~chiral== deoxyribonucleoside-derived analogs, however, are limited by relatively high cost of starting materials .
3 0 Summary of the Invention It is therefore one general object of the invention to provide a polymer capable of sequence-specific binding to polynucleotides and which overcomes or minimizes many of the problems and limitations associated with poly-WO 91/09073 PCr/US90/07S65 Z0Çi~9906 nucleotide analog polymers noted above.
The invention includes a polymer composition con-taining morpholino ring structures of the form:
5' P.
--/ O ~ 1 ~ 4~
(A) 3 ~N ~2 I

The ring structures are linked together by uncharged, achiral linkages, one to three atoms long, joining the morpholino nitrogen of one ring structure to the 5 ' exocyclic carbon of an adjacent ring structure.
Each ring structure ; nr~ c a purine or pyrimidine base-pairing moiety P~ which is effective to bind by base-specif ic hydrogen bonding to a base in a target sequence in a polynucleotide.
These and other objects and features of the invention will become more fully apparent when the following detailed description of the invention is read in conjunction with the ~ nying examples and f igures .
Brief De~cri~tion of the Fiqure~
Figure 1 shows a basic ,~-morpholino ring structure which is linked through uncharged, achiral linkages to f orm the polymer of the present invention . P; is a purine or pyrimidine base pairing moiety.
Flgure 2 shows several exemplary purine- and pyrimidine base-pairing moieties (represented as Pj of the ring structures shown in Figure 1), where X = H, CH3, F, Cl, Br, or I.
Figure 3 shows several pref erred subunits having 5-atom (A), six-atom (B and C) and seven-atom (D-G) linking WO 91/09073 PCr/US90/07565 .
20699~6 .

groups suitable for forming polymers. Y = O or S. X1 =
O or S X2 = O, S, CH2, or NR1 X3 = O, S, CHz, or NR2 X4 = O, S, or NR1 X5 = O, 5, CH2, NR2, or SO2 n = 0, l, or 2; when n = 0, X5 is not SO2 When n = l, X5 is CH2 or 5 SO2. R1 = H, CH3, or other group which does not interfere with sequence-specific }1ydLuyel~-bonding of the polymer to its target polynucleotide. R2 is an electron withdrawing group, such as methane-sulfonyl, which reduces the pKa of the nitrogen to which it is attached to less than pKa=6.
Figure- 4 shows a repeating subunit segment of exemplary morpholino-based polymers, designated A-A
through G-G, constructed using subunits A-G, respectively, of Figurè 3. Y, X1, X2, X3, X4, X5, n, R
and R2 are a~s in Figure 3.
Figure 5 shows the steps in the synthesis of several types of morpholino subunits from a ribonucleoside.
Figure 6 shows an alternative synthesis of the basic morpholino subunit.
Figure 7 shows the steps in the synthesis of a mor-20 pholino subunit designed for construction of polymerswith seven-atom repeating-unit backbones.
Figure 8 shows the binding ~ode f or 2 -amine-containing purines to polar major-groove sites of respective target base-pairs (Figure 8a) and a 25 ~ s~1lLative base sequence of a duplex-binding polymer (Figure 8b). In Figure 8b, a = Adenine; c = cytosine; g = guanine; t = thymine; u = uracil; D = 2,6-Diaminopurine or 2-aminopurine; G = Guanine or thioguanine; ¦ = high specif icity hydrogen bonding; and : = low specif icity 3 0 hydrogen bonding .
Figure 9 shows the steps in linking two morpholino subunits through a carbamate linkage.
Figure lO shows the activation of sulfamic acid and coupling to form a sulfamide linkage.
=

WO 9l/09073 PCr/US90/0756S
.
Z069g~6 Figure 11 shows the activation of sulfonic acid and coupling to form a sulfonamide linkage.
Figure 12 shows the steps in linking two morpholino subunits through a sulfamate linkage.
Figure 13 shows the steps in linking two morpholino subunits through an amide linkage.
Figure 14 shows a subunit coupling procedure which simultaneously generates the morpholino ring structure.
Figure 15 shows thermal denaturation plots for poly(dC) /poly(dG) and poly(C morpholino) /poly(dG) duplexes where the poly (C morpholino) was constructed according to the present invention.
Figure 16 illustrates a diagnostic solid-support particle employing polymers of the present invention for use in a probe-diagnostic assay.
Det~iled De~criPtion of the Invention -WO 9l/09073 PCr/US90/07565 206~9~6 .

The present invention lncludes a morpholino-based polymer which is designed for base-specific binding to a targe~ sequence of a polynucleotide. The polymer is composed of morpholino-based ring structures which are 5 linked tog~Lher by uncharged, achiral linkages, one to three atoms long, ~oining the morpholino nitrogen of one structure to the 5' exocyclic carbon o~ an ad~acent structure .
10 A. Morpholino-Based Subunits Figure 1 shows the ~-morpholino ring structures on which the polymer subunits are based, where the morpho-lino carbon atoms are numbered as in the parent ribose.
As seen in Figure 1, the ring structure contains a 5' 15 methylene attached to the 4' carbon in the 13-orientation.
Each ring structure includes a purine or pyrimidine or related-= hydrogen-bonding moiety, P~, attached to the backbone morpholine moiety through a linkage in the ,~
20 orientation.
The purine hydrogen-bonding moieties or bases in-clude purines as well as purine-like planar ring struc-tures having a 5-6 fused ring in which one or more of the atoms, such as N3, N7, or N9 is replaced by a suitable 25 atom, such as carbon. The pyrimidine moieties likewise include pyrimidines as well as pyrimidine-like planar 6-membered rings in which one or more of the atoms, such as N1, is repIaced by a suitable atom, such as carbon.
Preferred hydrogen-bonding moieties in the invention 30 include the set of purines and pyrimidines shown in Figure 2. Each base includes at least two hydrogen-bondlng sites specific for a polynucleotide base or base-pair. Where the polymers are used for sequence-speclfic binding to single-stranded polynucleo~ides, the purine WO 91/09073 PCr/US90/07565 2~99~6 structures 1-3 are designed to bind to thymine or uracil bases; structures 7-8, to guanine bases; structures 4-6, to cytoslne bases; and structure 9, to adenine bases.
The polymers of the invention are also effective to 5 bind to hydrogen-bonding sites accessible through the ma~or-groove in duplex polynucleotldes having mostly purine bases in one strand and mostly pyrimidine bases in the complementary strand, as discussed below.
Because of the similar type and positioning of the 10 two central polar ma~or-groove sites among the different base-pairs of duplex nucleic acids (i . e ., the NH4 and 06 of a CG base-pair present the same ~I-bonding array as the NH6 and 04 of an AT base-pair), the H-bonding moiety of a duplex-binding polymer must hydrogen-bond to the N7 of 15 its target base-pair in order to uniquely recognize a given base-pair in a target genetic duplex. Thus, where the polymers of the present invention are targeted against duplex genetic sequences (containing pre~ n;?nt-ly purines in one strand and prPr~o~;n~ntly pyrimidines in 20 the other strand), the hydrogen-bonding moieties of the polymer preferably contain purines having an amine at the 2 position since that amine is suitably positioned for H-bonding to the N7 of the target base-pair. Structures 2 and 3 of Figure 2 provide for specific binding to a TA or 25 UA base-pair, and Structures 4 and 6 provide for specific binding to a CG base-pair. Two bases which are parti-cularly useful in a duplex-binding polymer are 2, 6-diami-nopurine (Structure 3) and guanine (Structure 4) . Figure 8 illustrates the binding of these two bases to the polar 30 major-groove sites of their respective target base-pairs in duplex nucleic acids.
The morpholino subunlts oi' the instant invention are combined to form polymers by linking the subunits through stable, achiral, uncharged linkages. The linking group -WO 9l/09073 PCI`/US90/07565 , of a subunit usually includes a carbonyl or sulfonyl electrophile for reaction with a nucleophile of the subunit to which it is ~ to be linked. As used herein "carbonyl" means a -C=0 or -C=S group, and "sulfonyl"
5 means an 0=S~0 group.
The selection of subunit linking groups for use in polymer synthesis is guided by several considerations.
Initial screening of promising intersubunit linkages (i.e., those linkages which are ~predicted to not be 10 unstable and which allow either free rotation about the linkage or-~which exist in a single conformation) typical-ly involves the llse of space-fiLling CPK or computer molecular models of duplex DNA or RNA. The DNA and RNA
duplexes are constructed according to parameters deter-15 mined by x-ray diffraction of oligodeoxyribonucleotides in the B-form and oligoribonucleotide-cnntaln~ng duplexes in the A-fDrm.
In each of these constructed duplexes, one of the two sugar=phosphate backbones is removed, and the pro-20 spective backbone, including the morpholino ring andintersubunit linkage, is replaced, if possible, on the sites of the bases from which the original sugar-phos-phate backbone has been removed. Each resulting poly-nucleotide~polymer dupLex is then r~Y~ml n~d for coplana-25 rity of the Watson/Crick base pairs, torsional and anglestrain in the prospective binding polymer backbone, degree of distortion imposed on the nucleic acid strand, and interstrand and intrastrand nonbonded interactions.
In the case o~ amide-containing linkages, special 30 attention ls paid to whether or not: amide-containing backbones can readily adopt a conformation in which the amide moieties are planar. This is important because of the suDstantial energy cost required to force an amide into a nonplanar conformation.

WO 9l/09073 PCr/US90/07~6~
ZC~699~6 Initial studies of this type carried out in support of the present invention showed that for morpholino-based polymers the preferred unit backbone length ~i.e., the number of atoms in a repeating backbone chain in the 5 polymer) is 6 atoms. However, the modeling studies also show that cer~ain 5-atom and 7-atom repeating-unit mor-pholino-base~ backbones meet the requirements for binding to targeted genetic sequences.
Since the morpholino structure itself contributes 4 10 atoms to each rer~ n~ backbone unit, the linkages in the five-atom, six-atom, and seven-atom repeating-unit backbone contribute one, two, and three atoms to the backbone length, respectively. In all cases, the linkage between the ring structures is ~a) uncharged, ~b) achi-15 ral, (c) stable, and (d) must permit adoption of a con-formation suitable for binding to the target polynucleo-tide .
Subunit backbone structures ~udged acceptable in the above modeling studies were then assessed for feasibility 20 of synthesis. ~he actual chemical stability of the intersliounit linkage was assessed with model compounds or dimers .
Figure 3 shows several preferred ~-morpholino sub-unit types, including linkage groups, which meet the 25 constraints and requirements outlined above. It will be appreciated that a polymer may contain more than one linkage type.
Subunit A in Figure 3 contains a 1-atom sulfonyl linkage which forms the five atom repeating-unit backbone 30 shown at A-A in Figure 4, where the morpholino rings are linked by a 1-atom sulfonamide linkage. It is noted here that the corresponding amide linkage ~substituting a carbonyl for sulfonyl linkage) is not acceptable due to lack of rotational freedom about the carbon-nitrogen WO 9l/09073 PCr/US90/07565 Z1~99~36 tertiary amide bond.
Subunits B and C in Figure 3 are designed for 6-atom repeating-unit backbones, as shown at B-B and C-C, re-spectively, in Figure 4. In Structure B, the atom X
5 linking the 5' morpholino carbon tD the carbonyl group may be oxygen or sulfur, but not nitrogen or carbon, due to lack of free rotation about the resultant intersubunit linkage. The C=Y carbonyl group may be either C=0 or C=S, as note~ above.
In Structure C, the moiety X linking the 5'morpho-lino carbon to the sulfonyl ~O=S~O) group may be a methy-lene, oxygen, sulfur, or a nitrogen. The nitrogen may be secondary (NH), or tertiary (NR), where R is a methyl or other group which does not interfere with polymer binding 15 to the target polynucleotide ( as can be easily determined from molecular modeling studies such as those outlined above) .
Subunits D-G in Figure 3 are designed for 7-atom repeating-unit backbones, as shown at D-D through G-G, 20 respectively, in Figure 4. In Structure E;, the X can be a secondary nitrogen tNX), or a tertiary nitrogen (NR) where R is a is a methyl or other group which does not interfere with polymer binding to the target polynucleo-tide, as can be detPrm; n.od from molecular modeling stu-25 dies. In addition, X in Structure ~ can be an oxygensince the 5' methylene in such morpholino structures is surprisingly resistant to nucleophilic attack.
Base~ on the molecular modeling s~udies of the type described above, both the sulfamate (Structure C-C of 30 Figure 4 wherein X is oxygen) and sulfonate (structure E-E of Figure 4 wherein X is oxygen) linkages were good candidates. Experiments conducted in support of the present invention indicated that the 5' tosylate of the basic morpholino cytosine subunit (Structure 8 of Figure WO 9l/09073 PCI/US90/07565 20~9~ 6 5, where Pi is N4-benzoylated cytosine) are surprisingly - resistant to both intermolecular and intramolecular nucleophilic attack on the 5' methylene. This suggested that the corresponding sulfamate, and possibly the sul-5 fonate also, may be sufficiently stable for intersubunit linkages. Accordingly, a sulfamate-linked dimer (Struc-ture C-C of Figure 4, where X ls oxygen) was prepared, and assessed for linkage stability under conditions commonly used for polymer synthesis (i.e., detritylation 10 conditions, base-deprotection conditions, and puriflca-tion conditions, such as detailed in Example 19). These studies confirmed that such linkages are adequately stable under conditions typically required for synthesis, deprotection, purification and various applications.
In Structure G-G of ~igure 4, when n is zero, X must not be S0" and when n is one, X is Cl12 or SO2.
B. Subunit Synthesis The most economical starting materials for t~e 20 synthesis of morpholino-subunits are generally ribon-ucleosides. Typically, ribonucleosides c~nt~;n;n~ hydro-gen-bonding moieties or bases (e . g ., A, U, G, C) are transformed to their morpholino derivatives to provide a complete set of subunits for polymer synthesis. Where a 25 suitable ribonucleoside is not available, a l-haloribose or, preferably, a l-bromoglucose derivative, can be linked to a suitable base and this nucleoside analog then converted to the desired ~-morpholino structure via peri-odate cleavage, and closing the resultant dialdehyde on a 30 suitable amine.
Because of the reactivity of the compounds used for subunit synthesis, activation, and/or coupling, it is generally desirable, and often necessary, to protect the exocyclic ring nitrogens of the bases and sometimes the WO 91/09073 PCr/US90/07565 2Q~99t:3~i 13 oxygens of U and G. Selection of these protectlve groups is determined by (i) the relative reactivity of the molety to be protected, (ii) the type of reactions in-volved in subunit synthesis and coupling, and (iii) the 5 stability of the completed polymer prior to base depro-tection .
Methods for base protecting a number of the more common ribonucleosides are given in Example 1. The methods detailed ln the example are generally applicable 10 for forming nucleosides with amine-protective groups.
Standard base- protective groups used ~or nucleic acid chemistry are often suitable including the following groups : benzoyl for the N4 of cytosine (C); benzoyl or p-nitrobenzoyl for the N6 of adenine (A); acetyl, phenyl-15 acetyl or ~isobutyryl for the N2 of guanine (G); andN2,N6-bisisobutyryl for 2,6-~l;Am;nopurine residues.
These protective groups can be removed after polymer assembly by treatment with ammonium hydroxide.
It is sometimes desirable to protect the base por-20 tion of the morpholino subunit with a group which can bereadily removed by other than a nucleophilic base.
Suitable base protective groups removable by a strong non-nucleophilic base via a ,~-elimination mechanism in-clude: 2= (4-nitrophenyl) ethoxy carbonyl or 2- (phenyl 25 sulfonyl) ethoxycarbonyl for both the N4 of C and the N6 of A; and the 9-fluorenyl methoxycarbonyl for the N2 of G and the N2 and N6 of 2, 6-diaminopurine. These groups can be removed after polymer a=ssembly by treatment with the strong nonnucleophilic base 1,8-diazabicyclo[5.4.0]-30 undec-7-ene ~DB~), under stringently anhydrous condi-tions .
The syntheses of representative morpholino subunits follow here and are descrlbed in detail in Examples 2-10.
With r~fo~nc~ to the synthesis scheme depicted in Figure WO 91/09073 PCr/US90/07565 = ,~.

5, a base-protected ribonucleoside is reacted with sodium periodate to form a transient 2', 3'-dialdehyde which then closes upon ammonia to form a morpholino-ring having 2 ' and 3 ' hydroxyl groups ~numbered as in the parent 5 ribose, see Figure l). The compound is then treated with sodium cyanoborohydride to reduce the ring hydroxyl groups. The ring nitrogen is preferably protected by trityl derlvatization or by a benzhydraloxycarbonyl group for subsequent subunit coupling. The protective group lO can be added by reacting the morpholino subunit with trityl chloride or with nitrophenyl benzhydryl carbonate or by reacting the dialdehyde with a primary amlne, as illustrated in Figure 6 and described in Example 3. The stereochemistry of the nucleoside starting material is 15 retained as long as the pH of the reaction mixture at the iminium stage is not allowed to go above about lO.
The above synthesis results in a morpholino-ri~lg with an available 5'-hydroxyl. The 5'-hydroxl can be converted to other active groups including 5' amine 20 ~Example 5) and 5'-sulfonate ~Example 6).
In the above morpholino synthesis a variety of nitrogen sources can be used -- including ammonia, ammo-nium hydroxide, ammonium carbonate, and ammonium bicar-bonate. ~3est results are obtained when the reaction 25 solution is ~-~nt~ned near neutrality during the oxida-tion and morpholino ring closure reaCtionS. This can be accomplished by continually titrating the reaction mix or, more conveniently, by using ammonium biborate as the ammonia source. ~hen the solution is too acidic the 30 yield of product is low and when it is too basic, side products (possibly due to epimerization o~ the l' and/or 4' carbons) are produced which are ~1;f~;rll1t to separate from the desired product. It is also noted that the reducing agent can be added before, during, or after the WO 9l/09073 PCr/US90/07565 ;~ ~,699~6 oxidation step with little noticeable effect on product yield .
Ribonucleosides lacking base protection groups can also be sllccessfully oxidized, ring closed, and reduced in aqueous solution to generate the morpholino ring.
However, without base protectLon the number and quantity of undesired side products frequently increases, par-ticularly in the case Qf cytldine.
The subunits formed by the above methods contain a 5'-OH, SH, or amine which is modified, reacted with, and/or activated, to be suitable for coupling to a second morpholino ~subunlt (see below) . For example, Figure 5 shows the conversion of a 5'-OH of a morpholino subunit to a sulfonyl linking moiety to form a subunit (Structure 10) which is linked to form a 5-atom unit-length backbone polymer. Details of the subunit synthesis are given in Example 6.
Alternatively, the subunits are designed to include a sulfonyl or carbonyl group attached directly or in-directly to- the morpholino ring nitrogen, which is cou-pled to a 5' moiety of a second morpholino subunit (Fi-gures 12~ and 13) . Subunits of this type are suitable for constructing morpholino polymers with 6-atom (Figure 12 or 7-atom (Figure 13) repeating-unit backbones.
An exa-mple of the synthesis of a subunit suitable for 7-atom unit-length backbones having an amine at the 5'-carbon atom, and a sulfonyl group linked to the ring nitrogen thrDugh a methylene group is detailed in Example 9 (with reference to Figure 7) .
A similar synthesis, described in Example 10, is used to prepare morpholino subunits having a 5'-linked primary amine and an acetyl group linked to the ring nitrogen. This subunit is formed by coupling glycine, rather than AMSA, to the 5' rib~nllrlencide aldehyde .
~699~6 group. Examples 11 and 12 describe, with reference to Structure G of Figure 3, the preparation of non-morpho-lino subunits which are converted into morpholino struc-tures during polymer assembly.

C. Activation and Coupling Reactions The subunits prepared as above are coupled, in a controlled, sequential manner, generally by activating the carbonyl or sulfonyl group on one subunit ~having 10 protected nitrogen groups) and contacting this activated subunit with another subunit having an unprotected nitro-gen. Different types of linkages, such as those illust-rated below, may be employed in the construction of a single polymer.
A number of closely related variations are possible for the carbonyl-containing linkages giving six-atom backbones, corresponding to Structure B-B in Figure 4. A
typical activation and coupling reaction for forming a carbamate linkage (where X is 0 in Structure B-B~ is 20 illustrated in Figure 9. Here a base-protected morpho-lino subunit with a 5'-OH is reacted with bis- (p-nitro-phenyl) carbonate and triethylamine to yield an activated carbonyl subunit (Structure 2, Figure 9). This activated subunit is then combined with a second base-protected 25 morpholino subunit which may be blocked at the 5 ' -OH .
Bond formation between the subunits occurs between the annular nitrogen on the morpholino ring of subunit 2 and electrophilic carbonyl group of the first subunit, to form a carbamate linkage, where the carbonyl qroup is 30 C=O. Details of the coupling reaction are given in Example 13.
Activation of the 5 ' -OH morpholino subunit with p-nitrophenylchlorothioformate and coupling to a second subunit with an unprotected ring nitrogen yields a thio-WO 91/OgO73 PCr/US90/07~6~
Z~99~6 1 7 carbamate linkage (where Y is S in structure B-B of Figure 4 ) .
The simplest- and most obvious morpholino-type bind-ing polymers are the carbamate-linked polymers (type B-B
5 of Figure ~=~) where X is oxygen. The polymer has been found to effec~ively bind to its single-stranded DNA
target sequence. E~owever, in binding studies with an RNA
target, the polymer exhibited unusual binding, as evi-denced by a highly atypical hypochromicity profile in the 320 to 230 nm spectral range and lack of a normal thermal denaturation .
Modeling studies conducted in support of the ap-plication indicate that in a ~-~rh~te-linked polymer bound to DNA existing in a B conformation the backbone of 15 the polymer provides adequate length for binding and the carbamate moieties of the polymer backbone can assume a nearly planar conformation. This modeling result was in good accord with the effective binding of the carbamate-linked polymers to DNA. In cantrast, similar modeling 20 studies suggested that binding of the carbamate-linked polymer to an RNA target requires one of the following:
(i) the carbamate linkage of the polymer adopt a substan-tially nonplanar conformation, or (ii) the RNA target sequence adopt a strained conformation in which base-25 stacking interactions are quite different from that in anormal A conformation. This observation may explain the atypical binding of a carbamate-linked polymer to an RNA
target sequence.
The modeLing work further ~n~c~ted that replacing 30 the carbonyl intersubunit linking moiety with either an achiral sliLfonyl-c~nt~n~ng intersubunit linkage or with a chiral phosphorous-containing linkage would provide added length of about 0 . 32 angstrom per intersubunit linkage. This sulfonyl linkaqe also provides greater WO 9l/09073 PCr/US90/07565 Z~ 36 rotatlonal freedom about key bonds, and bond angles of - the lntersubunit linkage compatible wlth an oligomer backbone conformatlon suitable for palring to both RNA
and DNA target sequences in their standard conformatlons.
5 Based on these findings, a number of syntheses of oligo-mer structures ln which morphoLino subunits are ~oined by suLfonyl moieties were subsequently developed and are described below (Structures A-A, C-C, D-D, and E-E of Figure 4 ) .
The linkage in structure A-A in Figure 4 (five-atom backbone) can be formed according to the reaction scheme shown in Flgure 11, and detalled ln Example 14. Briefly, a 5'-OH morpholino subunlt ls protected at its ring nltrogen, converted to a 5' SH subunit, then oxidized to convert the 5'-linked sulhydral group to a sulfonyl group. The sulfonyl group is activated with phosgene, and coupled to a second subunit having an unprotected ring nitrogen, as shown. The polymer assembly is con-tinued by deprotecting the morpholino ring nitrogen of the dimer, and reacting the dimer with a third activated subun it .
The sulfamide linkage (correspondlng to the linkage in structure C-C in Figure 4, where X is an amine), is formed by sulfating the 5'-linked amine in a subunit having a protected morpholino ring nitrogen, and then activating with phosgene and reacting this subunit with a second subunit having an unprotected ring nitrogen, as illustrated in Figure 10. Details of the coupling reac-tion are given in Example 14.
The sulfamate linkage (corresponding to the linkage in Structure C-C in Figure 4, wherein X is O) is produced by sulfating the morpholino ring nitrogen of a 5' protec-ted subunit, then using phosgene to generate the sulf-amoyl chloride. This activated subunlt ls then mlxed WO 91/09073 PCr/US90/07565 .
~ ~6~9~6 wlth another subunit or= ollgomer having a free 5' OH.
Coupling o~ the subunits is achieved either with a cata-lyst such as silver trifluoromethanesulfonate or use of a strong base to convert the 5 ' hydroxyl to the anlonic 5 form. Conversion o~ the 5' hydroxyl to the alkoxy can be achieved by KOH and a suitable phase transfer catalyst.
Thls sulfamate coupllng is illustrated in Figure 12 and details are~ given in Example 15.
A number of 7-atom unit length backbones prepared 10 from the morpholino-subunlts (correspondlng to structures D-D through F-F in Figure 4) allow even more flexibility in the construction of polymers which have specified distances between the base-pairing moieties. Using the 7-atom unit length linkages, distances between the mor-15 pholino-subunits, and consequently between the base pairing moieties, can be lengthened. Such lengthening of the intersubunlt linkage is particularly useful when targeting duplex genetic sequences ln a B conformation.
The 7-atom backbone polymers can be readily syn-20 thesized ~rom the subunits D-F constructed as above, employing the general coupling r=A- t 1 nn.C described above .
For example, Structure D-D in Figure 4 can be produced by (a) reacting the sulfonyl group of subunit D (Figure 3) with phosgene, and (b) coupllng the activated subunlt 25 with a second subunit having an unprotected morpholino ring nitrogen.
Simllarly, Structure ~-E in Figure 4 can be produced by activating the sulfonyl group with phosgene, and coup-ling the activated subunit with a second subunit having 30 an unpro~ec~ed 5'-linked amine.
Structure F-F in Figure 4 can be produced by a similar syn~hetic method in which the carboxyl group is activated with carbonyldiimidazole or a czrbodiimide, and the activated compound is reacted with a second subunit WO 9l/09073 PCl[/US90/07565 -~ z~99~6 having an unprotected 5 ' -linked primary amine .
A novel class of linkages corresponding to Structure G-G of Figure 4 can be produced by oxidizing vicinyl hydroxyls of one ribonucleoside subunit and closing the resultant dialdehyde on a primary amine of another sub-unit followed by reduction with cyanoborohydride. In principle this same scheme could also be used to couple a secondary amine of one subunit and a mono-aldehyde of a second subuniti however, the coupling of a ribose-derived dialdehyde to a primary amine proceeds subSt~nt~ y faster and provides a better yield. Examples 11 and 12 describe the synthesis of ribonucleosides containing a primary amine at the 5'. Their use in formation of mor-pholino polymers is illustrated in Figure 14.
D. Assembly of Polymers After selecting a desired polymer length and recog-nition moiety sequence (guidelines for this are presented below), the polymer is assembled using the general proce-dures described above. One method of polymer assembly involves initial preparation of an appropriate set of di-mers, linking selected dimers to form tetramers, linking these to form octamers, and so on. This method is car-ried out in solution, substantially according to the coupling methods described with reference to Examples 13-17. Example 18 outlines such a block assembly synthesis using monomers to form dimers, and dimers to form tetra-mers. The synthesis need not involve oligomers of equal size .
A particular merit of this block assembly method is that each coupling product is roughly twice the length of its precursors, so purification of the product of each coupling is simplified. Example 18 details the assembly of a 4-subunit polymer formed by this method.

WO 91/09073 PCr/US9~/07565 Z1~9~)6 The po~lymers may also be synthesized by stepwise subunit addition on a solid support. However, the op-timal synthetic approach often uses a combination of the solution and solld support assembly methods where dimers, 5 trimers, or tetramers are synthesized by solution phase and subsequently assembled into the full-length polymer on a solid support, as described in Example l9.
Typically, a solid support, such as glass beads derivatized with acid-stable, long-chain cleavable lin-10 kers, are employed as the support material, and preparedfor attachment of the first subunit, or block of sub-units, as described in Example 19. The glass beads are reacted with a subunit which generally has a readily cleavable protective group on a nltrogen. Whether the 15 morpholino subunit is linked to the support via its morpholino nitrogen or a group at the 5' position depends on the direction of polymer synthesis, i.e., to which group the ne~t subunit will be attached.
After coupling the second subunlt (or oligomer which 20 may be assembled in solution) to the support, any un-reacted nucLeophilic sites can be capped by additlon of a suitable capping reagent, such as p-nitrophenyl acetate or acetic anhydride, and thereafter the support is washed. The protecting group on the nitrogen of the 25 terminal subunit is removed, typically by acld treatment, and after neutralization, the support is reacted with an excess of the next-i~- sequence subunit (or polymer unit) which is activated by one of the methods outlined above.
One feature of the solid support assembly method is the 30 need for high coupling efficiencies at each subunit addition step. This high coupling efficiency is general-ly achieved by addition of an exceSs of the activated subunit whic~ maximizes the number of support-bound chains which are chain-elongated.

WO 91/09~)73 PCr/US90/07565 20699~6 Chain elongation is contlnued in this manner, with optional capping of failure sequences after each subunit addition, untll the polymer of the desired length and sequence is achieved.
After addition of the final subunit, the terminal backbone moiety may be reacted with a suitable charged or uncharged group, as described in Example 19. The polymer is then cleaved from the support, e.g., by treatment with either ammonium hydroxide or a non-nucleophilic base suitable for effecting ~-elimination in the linker ~oin-ing the polymer to the support. The bases are deprotec-ted and the polymer is purified as described below and in Example 19.
E. Polymer Processing and Purification Binding polymers assembled in solution (Examples 18 and 20) are typically base-deprotected by suspending in DMSO or DMF and layering on the suspension an equal volume of concentrated ammonium hydroxide. The prepara-tion is mixed with shaking and incubated at 30C for 16 hrs. Workup includes removing the ammonia under reduced pressure. If a protective group (generally trityl or a related acid-labile moiety~ is present, this group is cleaved and the crude polymer preparation is suspended in the appropriate buffer for purification ~Example 19).
Binding polymers assembled by a solid-phase method (Example l9) wherein they are linked to the support via an ester linkage can be cleaved from the support by suspending the drled support in DMSO, layering on an equal volume of concentrated NH~OH, capping tightly, and slowly agitating for 16 hrs at 30C. The solid support material is removed by filtration and the filtrate is treated as described above.
Alternatively, binding polymers linked to the sup-WO 9l/09073 PCr/US90/0~56 69~6 ~ 23 port via a ~-elimination-sensitive linker can be cleaved from the support using a strong non-nucleophilic base l, 8 diazabicyclo (5 . 4 . 0 . ) undec-7-ene ~DBU) in DMF . Using this approach one can release the polymer with its bases still protected and thus the polymer is sultable for further modification and/or structural confirmation via fast atom bombardment mass spectroscopy.
Purification of the base-deprotected polymer is preferably carried out at pH 2.5 or pH 11, depending on the pKs of ~ the base moleties in the polymer. At pH 2.5 cytosine, adenine, and 2-6-diaminopurine moieties carry a positive charge and guanine carries a partial positive charge. At pH 11 guanine, uracil and hypoxanthine carry a negative charge. For pQlymers in which about = 50%
or more of the base- pairing moieties are ionized at pH
2.5, the purification can be carried out by cation ex-change on a column of S-Sepharose fast-flow ~ph~ c~ A) developed with a shallow ~aCl gradient buffered at pH
2.5. The effluent~ is monitored at 254 nm and collected in a fraction collector. The full length polymer, which elutes after the shorter failure sequences, can be fur-ther purifled and desalted on a column of chromatogra-phic grade polypropylene (Polysciences Inc. ), eluted with an aqueous gradient of acetonitrile ad~usted to pH 2 . 5 with formic acid, with the eluant being monitored at 254 nm. The fractions crnt~n~ng the pure product are neutralized and dried under reduced pressure. Salts may be discarded by dissolving the polymer in trifluoroe-thanol, filtering, and evaporating the trifluoroethanol.
For polymers in which about 50% or more of the base-pairing moieties are ionized at pH ll, the purification may be performed on an anion exchange column of Q Sepha-rose fast-flow tphA~ ~rl A) developed with an aqueous pH
11 gradient of NaCl. The full-length polymer, which C~G99(~6 -=

elutes after shorter failure sequences, is further puri-- fied and desalted on a polypropylene column eluted with an aqueous pH 11 gradient of acetonitrile. Fractions containing the pure product are processed as above.
The purification methods described above should be carried out so that polymers contalning adenine base-pairing moieties are not exposed to pH 11 for more than a few hours at room temperature, to avoid potential base lability problems. The detalls of the purification methods are outlined in Example 19.
In neutral, aqueous solutlon, longer morpholino polymers may have solubilities only in the sub-micromolar range. Therefore, it may be advantageous to enhance polymer solubility by addition o~ one or more hydrophilic moieties, e.g., polyethylene glycol. For most of the polymer types disclosed herein, this can be accomplished by cleaving the terminal backbone protective group from the completed polymer, and reacting the polymer, with the bases still in the protected state, with excess of car-bonyldiimidazole-activated polyethylene glycol (PEG~.
Thereafter the binding polymer is treated with ammonium hydroxide to remove the base-protected groups, and the polymer is purified as above. The level of solubiliza-tion is easily ad~usted through proper selection of the PEG material. Suitable PE;G fractions having average molecular welghts of 200, 400, 600, 1,000, 1,540, 3,400, 4,000, 6,000, 7,500, and 18,500 daltons are commerclally available (e.g., Polysciences, Inc.) with PEG1000 often providing the best solubilization. The solubllizing moiety may be linked to the polymer through a cleavable linkage, if desired, to allow the polymer to be released from the solubilizing agent, e . g ., by esterase or pep-tidase enzymes.

WO 91/09073 PCr/US90/07565 .
o69~6 25 It will be appreciated that the polymer may be further derivatized or labeled accordlng to known proce-dures. For example, the polymer may be radiolabeled by preparing the polymer subunits from radiolabeled ribonu-rl eQS~ or by attaching a radiolabeled amino acid at one terminus. The polymer may be readily derivatized, e.g., employing modifications of the above subunit cou-pling reactions, with enzymes, chromophoric groups, or the like, where the polymer is to be used as a diagnostic probe. Further, the polymer may be derivatized with biomolecules which serve to target the polymers to speci-fic tissues or cell types.
F . Structural Char;lrtr~ 7~t 1 on Fully-protected binding polymers of moderate size (10 to 20 subunits) often give a strong molecular ion in FAB (Fast Atom Bombardment) mass spectroscopy, providing a key confirmation of the polymer length.
Further, COSY-NMR (two-dimensional correlated spec-troscopy) of the deprotected and purified polymer pro-vides information on the ratio of the different base-pairing moieties in the polymer as well as quantita-tive information on the ratio of binding polymer to any solubilizing or other type moiety which may have been linked thereto.
Mobilities on ion exchange columns also provide information on the number of C + A base-pairing moieties in a polymer when purification is carried out at pH 2.5 and information on the number of G + U residues when the purification is run at pH 11. Structural verification is easiest when the polymers have been assembled from oligo-mer blocks, such as in Examples 18, 19 and 20, since any failure sequences then differ more substantially from the full-length sequences.

WO 91/09073 PCr/US90/07565 699~6 The W profiles of the polymers at pH l, 7, and 13 - can provide informatlon about the relative nucleotide composition of the polymer.
Assessment of a morpholino-based polymer' s affinity for its target sequence is carried out by ~ m1nlng the melting curve of the polymer/target duplex, as illustra-ted in Examples 2 0 and 2 l .
Further, comparisons can be made between the melting curve of a regular nucleic acid duplex (such as p (dC) ~/p (dG) 6) and the melting curve of a hybrid duplex containing a corresponding morpholino-based polymer (such as ~morpholino-based C) 6/P (dG) 6) . Characterization of the synthetic intermediates and the full-length oligomer was achieved by proton NMR and negative ion FAB mass spec-troscopy. With these carbamates of the morpholino oligo-mers, the fra' -nt~1 on of the oligomers is greatly suppressed so that little sequence information is avail-able. However, the parent ion signal is quite strong and allows confirmation of the composition of the morpholino oligomer (see Example 20). High resolution mass spectro-metry of the morpholino-based poly C hexamer provided a satisfactory elemental analysis.
Several features of the proton spectrum of the oligomers were of interest. For example, the length of the oligomers could be ascertained by comparing the integration of the various signals. For example, in a dimer the two 2' protons were separated by 0.5 ppm and gave a l . 02/l ratio of integrations and for the hexamer, this ratio was 4 . 65/l against the expected value of 5/l .
The bases of the above hexamer were deprotected by treatment with concentrated ammonia for 24 hours. The 4'-terminal morpholino ring nitrogen was liberated by treat-ment of the crude oligomer ~rith l96 formic acid in tri-fluoroethanol. In order to assess the stability of these WO 91/09073 PCr/US90/07565 Z~699~1~6 _ 27 molecules under these conditions, a precursor dimer was treated with concentrated ammonia for 60 hours; no clea-vage of the intersubunit linkage was observed. Under all conditions ~lsed to date, no cleavage of the c~rh~ te linkage under acidic conditions has occurred.
The hexamer was taken up in pH 2.5 buffer and puri-fied by cation exchange chromatography on S-Sepharose Fast FlowT", eluting with potassium chloride gradients.
The chromatograms showed one ma~or peak comprising over 95% of the cytosine- cnnt;~ning materials in the mixture, and confirming that little or no cleavage of the oligomer occurs in the deprotection of the bases and the morpho-lino-amine. After neutralization the hexamer was desalted on a polypropylene column eluted with a water-acetonit-rile gradient.
The purified hexamer was analyzed by IH NMR. The assignment ~or the protons was made on the basis of a COSY plot. One cytosine base has signals that were found downfield relative to the other bases ~8 . 04 to 7 . 65 and 6.78 to 5.85 ppm). The relatlve lntegratlons of these peaks conflrmed that the hexamer was deprotected and has been purlfied intact. The 5' protons were assigned to the slgnal at 4.35-4.15 downfield of the 1' proton signal at 4.14-3 . 90 ppm. These chemical shifts run against the trend identified in the protected oligomers where the 1' proton of the same base ~s) was always downfield of the 5' protons of the same base ~s) . Apparently the benzoyl groups in the protected oligomers play a role in shaping the e~vironment of the 1 ' and 5 ' protons .
The solubility of the hexamer was found to be 4 IIM
in pH 7 . 5 buffer. In order to increase water solubility of ~he hexamer a polyethylene glycol ~P~G) tail was attached to the oligomers. 5 equivalents of P~G 1000 was treated with one equivalent of bis ~p-n:trophenyl) carbo-WO 91/09073 PCr/US90/07565 .
2~!699~6 -nate to give monoactivated PEG. Detritylation of the hexamer with 1% formic acld in trifluoroethanol afforded a free amine. Treatment of the hexamer containing the free amine with activated PEG1000 under standard coupling 5 cQnditions resulted ln attachment of the PEG tail to the hexamer. The bases were deprotected by treatment of the tailed hexamer with concentrated ammonia for 24 hours.
The tailed hexamer was taken up in pH 2.5 buffer and purified by cation exchange chromatography on S-Sepharose 10 Fast Flow~ eluted with a potassium chlorlde gradlent.
After neutralizatlon the eluant was desalted on a poly-propylene column eluted wlth a water/acetonltrile gradi-ent. The tailed hexamer was found to be freely soluble in pH 7.5 buffer in c~ncPntrations up to 2 mM.
The characterlzatlon of the talled hexamer by the 'H
NMR methods employed above was not possible. In the spectrum of the tailed hexamer there was no differentia-tlon between the signals of the base protons, thus pre-cluding the assessment of the oligomer length. Addltlon-20 ally, the envelope c~nt~ i nl n~ the PEG tall slgnals ob-scured the majority of the slgnals of the morphollno rings. However, the ion exchange chromatography of the tailed hexamer gave one ma~or peak indicating little or no cleavage of the oligomer during deprotection. The 25 pattern of the chromatogram of the tailed hexamer was the same as found for the free hexamer, except that the tailed hexamer elutes faster than the free hexamer.
The stability of complexes of the tailed hexamer with complementary nucleic acids was investigated by 30 thermal denaturatlon experlments. Dlfference spectra between mlxed and unmlxed samples of the talled hexamer and the selected phosphodlester complement were obtalned from 14C to 85C and over the 320 to 2~0 nm range (see Example 20) . As a control, the duplex of p) dC) 6 wlth WO9l/09073 PCI/US90/0756~
.
~69~~6 29 p(dG)C was thf-~-lly denatured. The difference W
spectrum of the t ~ led hexamer (morphC), with p ~dG) 6 was slmilar to that of the control DNA duplex, p (dC) G wlth p (dG) ~, except that the amount o~ hypochromlcity before 5 denaturation of the (morphC) 6/P (dG) ~ duplex was much greater than that of the control. The thermal denatura-tion of the p (morphC) 6/P (dG) 6 duplex gave a T, value of 62.5C (see ~xample 20 and Figure 15). The corresponding DNA/DNA duplex gave a Tm value of 26.5C.
G. Diagnostlc Applications The target-specific polymers of the invention can be used in a variety of diagnostic assays for detection of RNA or DNA having a given target se~uence. In one gene-15 ral application, the polymers are labeled with a suitableradiolabel or other detectable reporter group. Target polynucleotide, typically a single stranded polynucleo-tide which is bound to a solid support, is reacted with the polymer under hybridization conditions, allowed to 20 anneal, and then the sample is f~ m~ nFld for the presence of p~olymer reporter group.
The diagnostic assay can be carried out according to standard procedures, with suitable ad~ustment of the hybridization conditions to allow polymer hybridization 25 with the target region. In this regard, it is noted that the polymer can be designed for hybridization with the target at a higher melting temperature than the comple-mentary polynucleotide strand, since polymer binding does not entail backbone charge repulsion effects. Therefore, 30 the polymer can bind to the target at a temperature above the normal polynucleotide melting temperature, an impor-tant advantage of the polymer over conventional oligo-nucleotide probes. This binding at elevated temperature minimizes the problem of competition for binding to the ;~069906 target between the probe and any corresponding single-- strand oligonucleQtide which may be present in the diag-nostic mixture.
In a second general type of diagnostic application, 5 the polymers are linked to a solid support, for capture of target ~NA or DNA to the support. The solid support, e.g., polymeric microparticles, can be prepared by link-ing the polymers to the support ~cor~1~ ng to the methods described above or by conventlonal derlvatizatlon proce-10 dures. A'ternatlvely, where the polymers are synthesizedon a solid support thls support may also serve as the assay support.
According to an important feature of this assay system, the target polynucleotide molecules which are 15 captured on the support by base-specific bindlng to the polymers can be detected on the basis of their backbone charge, since the support-bound polymers are themselves substantially uncharged. To this end, the assay system may also include polycationic reporter molecules which 20 are deslgned to bind to the ~ully charged analyte back-bone, but not the uncharged (or substantially uncharged~
polymer backbone, under selected binding conditions.
In one embodiment the reporter molecules are com-posed of~ a polycationic moiety or tail designed to bind 25 electrostatically to a fully charged polynucleotide, under conditions where the reporter does not bind to the less charged or uncharged binding polymer carIied on the diagnostic reagent; one or more reporter groups may be attached to the tail, adapted to produce a signal by 30 which the presence of the reporter can be detected.
Methods for forming polycationic molecules and for at-taching reporter molecules to cationic compounds are known in the art.

WO 9l/09073 PCr/US90/07565 2~9~; 31 Each reporter molecule carries one or more reporter groups, and each polynucleotide can accommodate binding of typically several thousand or more reporter molecules.
Thus the system has an amplification factor, in terms of reporter signal per bound analyte molecule, of several orders of magnitude. In additlon, the method has the advantage, noted above, that the polynucleotide binding reaction can be carried out under conditions in which binding competition with complementary nucleotide strands does not occur.
The design considerations applied ln preparing a polynucleotide binding polymer ~or use as a diagnostic reagent are =governed by the nature of the target analyte and the reaction conditions under which the analyte is to be assayed. As a first consideration, there is selected a non-homopolymeric target base sequence against which the polymer is directed. This target sequence is gener-ally single-stranded and preferably unique to the ana-lyte being assayed.
The probability o~ occurrence of a given n-base target sequence is approximately ll/4)n. Accordingly, a glven n-base target sequence would be expected to occur approximately once in a polymer containing 4n bases.
Therefore, the probability P that a given n-base sequence will occur in polynucleotides r~nt~;nlng a total of N
unique-sequence bases is approximately P=N/4n. To illu-strate, the probability P that a 9-base target se~uence will be found in a 20 kilobase polynucleotide is about 20x103/2xlOs or 0.08, the probability that a 16-base target sequence will be present is about 20x103/4.3x109 or 0. 0000047 . From these calculations, it can be seen that a polymer having 9-16 recoqnition moieties specific for a de~ined 9-16 base target sequence should have high speci-ficity for the target se~uence in an assay mixture con-Wo 91/09073 PCI/US90/07565 2~699~)6 32 ' ;
talning only viral genomes, whose greatest complexities correspond to about ~OOK of unique-sequence bases.
Similar c~Llculations show that a 12 to 16 subunit polymer can provide adequate specificity for a viral or 5 bacterial target sequence in an assay mixture containing viral and bacterial genomic material only; largest geno-mic sizes about 5, 000 kilobases. A 16 to 22 subunit polymer can provide adequate specificity for a target sequence in a polynucleotide mixture containing mammalian 10 genomic DNA material; genomic sizes of about 5 billion base pairs of unlque-sequence DNA.
The polymer/analyte binding ai'finity, and particu-larly the temperature at which the polymer ~ust binds with the target sequence (the melting temperature, or Tm) 15 can be selectively varied according to the following criteria: (a) number of subunits in the polymer; (b) the number of hydrogen bonds that can be formed between the base-pairing moieties and the corresponding, complemen-tary bases of the analyte target sequence; (c) unit 20 length of the polymer backbone; (d) the partlcular inter-subunit linkages; and (e) concentration of denaturants, such as formamide, which reduces the temperature of melt ing .
From a number of studies on model nucleic acid 25 duplexes it is known that the melting temperature of oligonucleotide duplexes in the 10 to 20 bp range in-creases roughly 3C per additional base pair formed by two hydrogen bonds, and about 6C per additlonal base pair formed by three hydrogen bonds. Therefore, the 30 target sequence length originally selected to insure high binding specificity with the polymer may be extended to achieve a desired melting temperature under selected assay conditions.
Also, where the recognitlon moieties used in con-WO 91/09073 P~r/US90/07565 .
2~ 6 .-=

structing the polymer are the standard nucleic acid bases the target sequence may be selected to have a high per-centage of guanine plus cytosine bases to achieve a relatively high polymer/analyte melting temperature. On 5 the other hand to achieve a lower melting temperature a target sequence is selected which -nntA~nq a relatively high percentaqe Qf adenine plus thymine bases.
~ he binding components in the diagnostic system, as they functiQn in the solid-support diagnostic method just 10 described, are illustrated in Figure 16. ~ere "S", the assay reagent, is the solid support having a number of binding polymers attached to its surface through spacer arms indicated by sawtooth lines. In the assay proce-dure, the target DNA in single strand form is reacted 15 with the support-bound polymers under hybridization conditions, and the solid support is then washed to remove non-hybridized nucleic acid material.
~ he washed support is then reacted with the repor-ter, under conditions which favor electrostatic binding 20 of the reporter cationic moiety to the target DNA back-bone. The reporter shown in Figure 16 is a dicationic molecule having a reporter group R.
After reaction with the reporter solution, typically at room temperature for 1-2 minutes, the reagent is 25 washed to r--emove unbound reporter, and then the assay reagent is assessed for bound reporter. One approach in determining the amount of reporter associated with the reagent, particularly in the case of fluorescent or chromophoric reporter groups, is to elute the reporter 30 from the reagent with a high salt solution and then assess the eluate for reporte3~he polymer of the invention can undergo sequence-specific binding to duplex nucleic acids via base-pair-specific hydrogen bonding sites which are accessible through the major groove of WO 91/09073 PCr/US90/07565 20699 [)6 the double helix. This bondlng can occur in a duplex region in which at least 709; of the bases on one strand are purines and a corresponding percent of the bases on - the other strand are pyrimidines. The duplex binding 5 polymer preferably includes 2-aminopurine or 2, 6-diamino-purine hydrogen bonding moietles for bindlng to T-A or U-A base pairs, and guanine or thioguanine hydrogen-bonding moleties for binding to C-G base pairs as illustrated in Figure 8A. Thus, for these speclal target sequences (an 10 example o- whlch is shown ln Flgure 8B), the polymer of the lnventlon can be used for dlagnostic assays of the types ~ust described, but where the target nucleic acid ls ln nondenatured, duplex form.
15 H. Other Appllcatlons The polymers of the instant lnventlon can be used in place of standard RNA or DNA ollgomers for a number of standard laboratory procedures. As mentioned above, mor-phollno-based polymers can be fixed to a solid support 20 and used to isolate complementary nucleic acid ser~uences, for example, purificatlon of a speclfic mRNA from a poly-A fraction (Goldberg et al). The instant polymers are advantageous for such appllcatlons since they are inex-pensive and straightforward to prepare from activated 25 subunlts.
A large number of appllcatlons in molecular biology can be found for labeled morpholino-based polymers.
Morphollno-based polymers can be easily and e~ficiently end-labelled by the inclusion ln the last step of the 30 polymer synthesls an actlvated and labelled morpholino-based subunlt or, preferably, an 35S-labelled methionine.
The type of label to be used ls dependent on the final appllcation of the polymer, and lncludes radloactlve (3H, ~C, 32p, or 35S) nucleosldes and blotin. Labelled mor-WO 9l/09073 PCr~US90/07565 9~6 ~ --pholino-based oligonucleotide analogs can act as efficient probes in, for example, colony hybridization (Grunstein et al), RNA hybridizations ~Thomas), DNA
hybridizatlons (Southern), and gene bank screening (Szostak et al).
The polymers of the invention also have important potential use as therapeutic agents. Recently, uncharged anti-sense nucleic acid analogs, which are nearly iso-structural with DNA, have been used as anti-viral and anti-tumor agents. The polymers of the present invention provide several advantages over the more conventional anti-sense agents.
First, the morpholino polymers are substantially less expensive to synthesize than oligonucleotides. This is due in part to the fact that the morpholino subunits used in polymer synthesis are derived from ribonucleo-sides, rather than the much more expensive deoxyribonu-cleosides. Also, as noted above, the coupling reaction between a phosphorous and an amine of a second subunit occurs under relatively mild conditions, so that protec-tion steps and other precautions needed to avoid unwanted r~r~;nn~ are simplified. This is in contrast to stan-dard ribo- and deoxyribonucleotide polymer synthesis where coupling through a phosphate ester linkage requires that the coupling reagents be highly reactive and that the reaction be carried out under stringent reaction/pro-tection conditions. This advantage in polymer synthesis also applies, of course, to diagnostic uses of the poly-mer .
Second, polymer binding to its target may give sub-stantially better target inactivation, since the polymer-/target duplex is not susceptible to duplex unwinding mf~rh;~n~ in the cell.

WO 91/09073 PCr/US90/07565 20~;99~6 ~ ~

Third, the morpholino-based polymer is also more stable within the cç~ll; the polymer backbone linkage is not susceptible to degradation by cellular nucleases.
Fourth, in therapeutic applications involving cel-5 lular uptake of the compound, the uncharged morpholinopolymer is more likely to efficiently enter :cells than a charged oligonucleotide.
In the context of therapeutic applications, the morpholino polymers of the present invention may be 10 targeted against double-stranded genetic sequences in which one strand contains predominantly purines and the other strand contains predominantly pyr;m;~1in~oq ~e.g., Figure 8B) .
Further, when a messenger RNA is coded by the mostly 15 purine strand of the duplex target sequence, morpholino binding polymers targeted to the duplex have potential for also inactivating the mRNA. Thus such a polymer has the potential for inactivating key genetic sequences of a pathogen in both single-stranded and double-stranded 20 forms.
In 1981 it was reported that short (3 to 7 subunits) methylphosphonate-linked DNA analogs complementary to portions of the Shine-Dalgarano consensus sequence of procaryotic mRNAs were e~fective in disrupting bacterial 25 protein synthesis in bacterial lysates and in a special p~rm.o;:hl~ strain of bacteria. However, such agents failed to inhibit protein synthesis in normal bacteria ( Jayaramon, l 9 81 ) .
Experiments performed in support of the instant 30 invention show that polymers o~ 3 to 5 suhunits in length can be effective to block protein synthesis in normal bacterla by using a combination of bases which result in a high target-binding a~finity. More specificaLly, the following oligomers and oligomer combinations can perturb WO 9l/09073 PCI/US90/07565 2~699~6 ~ = --proteln synthesis in nor~al intact bacteria Iwhere D is 2, 6-Diaminopurine or adenine; G is Guanine; B is 5-Bromo-uracil, other ~ alouracil or uracil; sequences are shown with their 5' end to the left): DGG, BDDG, DDGG;
5 DGGD; GGDG; GDGG; DGGB; GGBG; GGAGG; GGDGG; and the combinations BDD + GGDG; DDG + GDGG; DGG + DGGB; GGD +
GGBG; BDDG ~ GDG; DDGG + DGG; DGeD + GGB GGDG + GBG; BDD
+ GGDG + GBG.
While other backbone types may be sultable for such 10 binding-~nhAn~ ~d short oligomers (e.g., carbamate-linked deoxyribonucleosides; Stirchak, 1987), the morpholino type Qligomers of ~he present invention are preferred on the basis of starting material costs and ease of assem-bly .
The use of short binding-~onhAn~ed oligomers to disrupt the biological activity of an RNA sequence which plays a key role in the metabolism of a target class of organisms but not a correspondingly important role in higher organisms should be broadly adaptable to a variety of pathogenic organisms (e.g., bacteria and fungi) having a cell wall which ~x~ the entrance of longer poly-mers .
The foTlowing examples illustrate methods of subunit and polymer synthesis, and uses of the polymer composi-tion of the invention. The examples are in no way in-tended to limit the scope of the invention.
Bxample 1 - ~
Base Protection of Ribonucleosides The following ribonucleosides are obtained from Sigma Chemical Co. (St. ~ouis, M0): uridine, guanosine, 5-methyluridine, adenoslne, cytidine, 5-bromouridine, and inosine.

Wo 9l/09073 PCI`/US90/07565 2~9906 ~ -2, 6-diamino-9- (s-D-ribofuranosyl) -9H-purine (2, 6-di-aminopurine riboside) is obtained from Pfaltz and Bauer, Inc., Division of Aceto Chemical Co., Inc. tWaterbury~
CT). The ~ollowing nucleosides are prepared by the literature methods indicated:
l-~-D-ribofuranosyl)-2-pyrimidinone (2-hydroxy-pyrl-mldine riboside) is prepared by . the procedure of Niedballa .
2-amino-9-~-D-ribofuranosyl) -1, 6-dihydro-6hpurine-6 -thione (thioguanosine) is prepared by the procedure of Fox. Dimethoxytrityl chloride, N-6-benzoyladeno-sine, N-4-benzoylcytidine, and N-2-benzoylguanosine are obtained from Sigma Chemlcals. 9-fluorenyImethoxycar-bonyl chloride (FMOC chloride), trimethylchlorosilane, isobutyric anhydride, 4-nitrobenzoyl chloride, n~phth~l 1 c anhydride, and all organic solvents for reactions and chromatography were obtained from Aldrich Chemical Co.
(Milwaukee, WI). Silica Gel is obtained from EM Science ~Cherry Hill, NJ).
When activation of the subunlts is achieved using dihalogenated electrophiles (eg. COCl, or SOzClF), better yields of activated subunits are often obtained by using protective - groups which leave no acidic protons on the purine and pyrimidine exocyclic amines. Examples of such exocyclic amine moieties are as follows: the N6 of adenine, the N4 of cytosine, the N2 of guanlne, and the N2 and N6 of diaminopuriné. Sultable protectlve groups for this purpose include the naphthaloyl group (Dlckshlt) and the aminidlne groups developed by McBride et al (1986). In addltion, use of dihalogenated electrophiles for subunit activation generally requlres that the 06 of guanine moieties is protected; thls protection is achieved using the diphenylcarboamoyl group ~Trichtinger). Chem Soc 80:6204 (1958).

WO 9l/09073 PCr/US90/0756 ..
2~)~99~6 Guanosine In order to minimize side reactions during subunit activations it is often desirable to protect the guanine moiety on both the N2 and 06 using the procedure of Trichtinger et al (1983). The N-2 9-fluorenylmethoxy-carbonyl derivative of guanosine is prepared by the procedure below which is general for the protection of nucleoside amino groups: guanosine (1 mmol) is suspended in pyridine 15 ml) and treated with trimethyl-chlorosilane (5 mmol). After the solution is stirred for 15 minutes, 9-fluorenylmethoxycarbonyl chloride (5 mmol) is added and the solution is ~;nt~;n~l at room temperature~ for 3 hours. The reaction is cooled in an ice bath and water (l ml) is added. After stirring for 5 minutes conc. ammonia (l ml) is added, and the reaction is stirred for 15 minutes. The solution is evaporated to near dryness and the residue is dissolved in chloroform ~10 ml). This solution is washed with sodium bicarbonate solution (5 ml, 1096), dried over sodium sulfate and evaporated. The residue is coevaporated several times with toluene and the product chromatographed on silica gel using a gradient Qf methanol in methylene chloride (0-5Q96).
N-2-Isobutyrylguanosine is prepared by the method of l.etsinger .
N-2-acetylguanosine is obtained by the method of Reese. N-2-naphthaylguanosine is prepared by the method of Dikshit; this reference provides a general method for ~he protection of nucleoside amine groups.
Adenos ine The N-6 2- (4-nitrophenyl) -ethoxycarbonyl derivative is prepared by the method of F~l -1 shach.

WO 9l/09073 PCr/US90/07565 2C!699~6 N-6 (~-nitrobenzoyl) adenoslne is prepared using the procedure above for FMOC-guanosine except that 4-nitro-benzoyl chloride is substltuted for FMOC chloride.
The N-6 2- (phenylsulfonyl) -ethoxycarbonyl derivative 5 is prepared by the procedure for F~IOC guanosine except the 2- (phenylsulfonyl) -ethyl chloroformate (Balgobin) is used as the acylating agent and N-methylimidazole or pyridine is used as the solvent.
N-6 naphthoyladenosine is prepared by the method of 10 Dikshit; ' his reference provides a general method for the protection of nucleoside amine groups.
2, 6-diaminopurineriboside The N-2,N-6-bis (9-fluorenylmethoxycarbonyl) 15 derivative of 2, 6-diaminopurine riboside is prepared by the general procedure described for guanosine.
The N-2,N-6-bis (isobutyryl) derivative is prepared by the general procedure described for guanosine.
20 Thioguanosine The N-2 (9-fluorenylmethoxycarbonyl) derivative of thioguanosine is prepared by the general procedure described for guanosine.
25 Uridine To minimize undesired side products during the subunit activation step it is sometimes desirable to protect the N3 of the uracil moiety. 5' O-tritylated uridine-2', 3'-acetonide is converted to the N3 anisoyl 30 derivative by the procedure of Kamimura et al (1983).
The product is then treated with hot 80% acetic acid or 0.1 N HCl in THF to creave the protective groups on the ribose moiety.

WO 9l/09073 PCI/US90/0756~
2Q~;~906 Example 2 Synthesis of 5 ' -OH Morpholino Subunits The steps in the method are illustrated in Figure 5, with reference to structures shown in Figure 5.
The base-protected ribonucleosLde is oxidized with periodate to a 2'-3' dialdehyde (Structure 1). The dialdehyde is closed on ammonia or primary amine ~Structure 2) and the 2' and 3' hydroxyls (numbered as in the paren~ ribose) are removed by reduction with cyanoborohydride (Structure 3).
An example of this general synthetic scheme is de-scribed below with reference to ~he synthesis of a base-protected cytosine (Pl* ) morpholino subunit . To 1. 6 1 of methanol is added, with stirring, 0.1 mole of N-4-benzoylcy~idine and D.105 mole sodium periodate dissolved in 100 ml of water. After 5 minutes, 0.12 mole of ammonium biborate is added, and the mixture is stirred 1 hour at room temperature, chilled and filtered. To the filtrate is added 0.12 mole sodium cyanoborohydride.
After 10 minutes, 0 . 20 mole of toluenesulfonic acid is added. After another 30 minutes, another 0.20 mole of toluenesulfonic acid is added and the mixture is chilled and filtered. The solid precipitate is washed with two 500 ml portions of water and dried under vacuum to give the tosylate salt of the free amine shown in Structure 3.
The use of a moderately strong (pKa < 3 ) aromatic acid, such as toluenesulfonic acid or 2-n;~ph~hiql enesulfonic acid, provides ease of handling, significantly improved yields, and a high level of 30 product purlty.
The base-protected morpholino subunit is then pro-tected at the annular nitrogen of the morpholino ring using trityl chloride or benzyhydral nitrophenyl carbonate (Structure 4). Alternatively, the 5' hydroxyl 2~!fi9906 can be protected with a trialkylsilyl group.
As an example of a protection step, to 2 liters of acetonitrile is added, with stirrlng, 0.1 mole of the tosylate salt from above followed by 0.26 mole of tri-5 ethylamine and 0.15 mole of trityl chloride. The mixtureis covered and stirred for 1 hour at room temperature after which 100 ml methanol is added, followed by stir-ring for 15 minutes. After drying by rotovaping, 400 ml of methanol is added. After the solid is thoroughly sus-10 pended as a slurry, 5 liters of water is added, themixture is stirred for 30 minutes and filtered. The solid is washed with 1 liter of water, filtered, and dried under vacuum. The solid is resuspended in 500 ml of dichloromethane, filtered, and rotovaped until 15 precipitation ~ust begins, after which 1 liter of hexane is added and stirred for 15 minutes. The solid is removed by filtering, and dried under vacuum.
The above procedure yields the base-protected morpholino subunit tritylated on the morpholino nitrogen 20 and having a free 5' hydroxyl.
Example 3 Alternative Synthesis of Morpholino Subunits This example describes an alternative preparatiOn of 25 a morpholino subunit containing an acid-labile moiety linked to the morpholino ring nitrogen. The steps are described with respect to Figure 6.
The subunit is prepared by ~ ; 7; n~ a ribonucleoslde with periodate, as in Example 2, and 30 closlng the resultant dialdehyde (Structure l) on the primary amine 4,4'-dimethoxybenzhydrylamine (which can be prepared by the method of Greenlee, 1984) buffered wlth benzotriazole, or p-nitrophenol. Reduction wlth sodlum cyanoborohydride, carried out as in Example 2, gives a -WO 91/09073 PCr/US90/07~65 ~Q~ j 43 morpholino subunit ~Structure 2) having a 4, 4'-dimethoxybenzhydryl group on the morpholino nitrogen.
This procedure is particularly useful for preparing morpholino subunlts from ribonucleosides which do not 5 have a protective group on the base (e . g ., uridine) .
Example 4 N-Sulfation of Morpholino Subunit This example describes the preparation of a morpholino subunit protected on its 5' oxygen and sulfated on its morpholino ring nitrogen. The steps are described with reference to Figure 12.
Structure 3 of Figure 5 is silylated with t-butyldi-15 methlsilyl chloride to give Structure 1 of Figure 12.This product is then treated with S0~/pyridine complex (with excess pyridine) in dimethylformamide (DMF) to give Structure 2 o f Figure 12 .
It should be r-nt ~ ~ne~ t~at the salts of sulfamic 20 acids (e.g., Structure 7 of Figure 5, and Structure 2 of Figure 12) and the salts of sulfonic acids (e.g., Structure 10 of Figure 5, and Structure 5 of Figure 7) can be easily chromatographed on silica gel using triethylamine/methanol/chloroform mixtures if the silica 25 is first pre-eluted with 2% triethylamine in chloroform.
Example 5 Synthesis of 5'-Sulfamic Acid Morpholino Subunits The steps in the synthesis of 5'-sulfamic acid mor-30 pholino subunits are described with reference tostructures shown in Figure 5. The 5 ' hydroxyl of the doubly-,,orotected morpholino subunit (Structure 4, Figure 5) can be converted to the amine as follows. To 500 ml of D~qSO is added 1. 0 mole of WO 9l/09073 PCI`/US90/07S65 Z~i9906 pyridine (Pyr), 0 . 5 mole of triflouroacetic acid (TFA), and 0.1 mole of the morpholino subunit. The mixture is stirred until dissolved, and then 0 . 5 mole of diisopro-pylcarbodilmide (DIC) or dicyclohexylcarbodiimide (DCC) is added. After 2 hours the reaction mixture is added to 8 liters of rapidly stirred brine, which is stirred for 30 minutes and flltered. The solid is drled brlefly, washed with l liter :of ice cold hexanes, filtered, and the solid is added to 0 . 2 mole of sodium cyanoborohydride in 1 liter of methanol, stirred for 10 minutes, 0 . q mole of benzotriazole or p-nitrophenol is added, followed by 0.2 mole of methylamine (40% in H2O) and the preparation is stirred four hours at room temperature [Note: the benzotriazole or p-nitrophenol buffers the reaction mixture to prevent racemization at the 4' carbon of the subunit at the iminium stage of the reductive alkyla-tion]. Finally, the reaction mixture is poured into 5 liters of water, stirred until a good precipitate forms, and the solid (Structure 6, Figure 5) is collected and dried. This dried product is next suspended in DMF and 4 equivalents of 503/pyridine complex is added. Over a period of several hours, ~ equivalents of triethylamine is added dropwise with stirring. After an additional two hours the preparation is dumped into a large volume of brine and the solid collected by filtration and dried.
This sulfamic acid preparation is then purified by silica gel chromatography.
~xample 6 Synthesis of 5'-Sulfonate Morpholino Subunits The steps in the synthesis of 5'-sulfonate morpholino subunits are described with reference to structures shown in Figure 5.
.

WO 9l~09073 PCr/US9O/07565 ~C~99~6 For the following synthesis the morpholino nitrogen should be protected as a carbamate (e . g ., Structure 4 of Flgure 5~ instead of with a trltyl group.
The 5' hydroxyl o~ the doubly-protected morpholino subunit is converted to a sulfhydral as follows. 0.1 mole of the 5'-hydroxyl subunit (Structure 4, Figure 5) is added to 1 liter of pyridine followed by 0.12 mole of toluenesulfonylchloride, and stirred for 3 hours at room temperature to give Structure 8 of Figure 5. After removing the pyridine by rotovapping, 0 . 5 mole of fresh sodium hydrosulfide in 1 liter of methanol/DMF ct~nt~n~n~
NaI is added and the mixture is stirred at room temperature overnight. ~he reaction mix is added to 5 liters of water, stirred 20 minutes, and the solid material is collected by filtration and dried to give Structure 9 of Figure 5. ~his sulfhydral product is next oxidized to the sulfonate IStructure 10 of Flgure 5) by dissolving in acetone or t-butanol/water mixture.
Magnesium sulfate (0.2 mole) and potassium permanganate (0.5 mole) are added. The mixture is stirred at room temperature until reaction is complete, then filtered, and treated with excess aqueous NaHSO, to decompose KMnO, and MnO,. The filtrate is partitioned between water containing triethylamine hydrochloride and chloroform.
The chloroform layer is dried down and purified by silica gel chromatography to give Structure 10 of Figure 5.
~xample 7 Synthesis of 5'=Methylenesulfonate Subunit This example describes the preparation of a subunit suitable for use in preparing polymers with 6-atom unit-length backbones having sulfonamide linkages.
For the preparation o~ subnits having Structure C of Figure 3 wherein X~ is CH2 the startinq material is the WO 91/09073 PCr/US90/07565 ~CÇ~991D6 5' aldehyde (Structure 5 of Figure 5) . This material is treated with phenyl diphenylphosphinylmethane sulfonate ~Fild), then reduced with H,/Pd on charcoal in a polar sQlvent, and lastly treated with alcoholic KOH in DMF.
5 The product is reprotected on the morpholino nitrogen with trityl chloride and then purified by silica gel chromatography .
Example 8 Preparation of 5'-aminomethanesulfonate Subunit This example describes the preparation of a subunit suitable for use in preparing polymers with 7-atom unit-length backbones having sulfonamide linkages.
For the preparation of subnits having Structure D of Figure 3 wherein X~ is a methanesulfonated amine, the 15 starting material is the 5 ' aldehyde (Structure 5 of Figure 5). The 5' aldehyde is converted by reductive alkylatiQn to a secondary amine by the method illustrated in Example 5, except that aminomethanesulfonic acid comprises the amine and ethylmorpholine is used to assure 20 av~ h~ 1~ ty o~ the amine moiety for reaction with the aldehyde. This product is then reacted with methanesulfonyl chloride in the presence of triehtylamine to give the desired product, which is purified by silica ge l chromat o graphy .
Example 9 Synthesis of N-methanesulfonate Subunit This example describes the preparation of a subunit containing a sulfonate moiety linked to the morpholino 30 ring nitrogen suitable for preparing polymers with 7-atom unit-length backbones. The steps are described with respect to structures shown in Figure 7.
The subunit is prepared by oxidizing a ribonucleoside (Structure l) with periodate in the ;; ~69~0~; 47 presence of aminomethanesulfonic acld ~AMSA) and N-ethyl morpholine. The oxidation is followed by reduction with sodium cyanoborohydride in the presence of benzotriazole (used to buffer the reaction mix) to give a morpholino 5 subunit having a met~rane sulfonic acid group on the morpholino nitrogen (Structure 2).
The 5'hydroxyl (numbered as in the parent ribose) is then oxidized to an aldehyde (Structure 3) and converted to a primary or secondary amine (Structure 4) by 10 reductive alkylation as in Example 5, and tritylated to give the desired subunit of Structure 5.
Example 10 Preparation of N-methanecarboxylate Subunit This example describes the preparation of a subunit ~nt~n1n~ a carboxylate moiety linked via a methylene to the morphoiino ring nitrogen suitable for preparing polymers with 7-atom unit-length backbones.
The subnit can be prepared essentially as in Example 20 9, but substituting glycine for ~m1n~ -thanesulfonic acid. Alternatively, it is generally more convenient to prepare it ~starting with Structure 3 of Figure 5. This is readily alkylated on the morpholino ring nitrogen using chloroacetic acid or bromoacetic acid. The 5' 25 hydroxyl is then converted to a primary amine and tritylated as in Example 9.
Example 11 Synthesis of 5'-aminomethyl Riboside Subunit N4-Benzoylcytidine-2', 3' -acetonide (1 mmole) was 30 converted to the 5'-~odo derivative by reaction with methyltriphenoxyphosphonium iodide in DMF = (20ml) under argon at room temperature: for 20 hours. Methanol (5 ml) was added and after 30 minutes the mlxture was evaporated in vacuo. The residue was dissolvea in ethyl acetate and Wo 91/09073 PCT/US90/07565 2C!~i9~6 the solution washed with aqueous sodium thiosulfate, then brine. After drying with sodium sulfate and evaporation of the solvent the product was purified by chromatography on silica using isopropanol/chloroform mixtures.
The iodo compound (l mmole) is reacted with potassium cyanide (5 mmol) in Dimethylsulfoxide for 12 hours under argon atmosphere. The nitrile is isolated by pouring the reaction mixture into saturated aqueous sodium dihydrogen phosphate. The mixture is extracted with ethyl acetate, the organic layer washed well with water, dried over sodium sulfate and evaporated in vacuo.
The nitrile is purified by chromatography on silica using chloroform/ethylacetate mixtures.
The nitrile from the previous paragraph is treated with a mixture of equal parts of :DI~ and aqueous ammonia at 25C for 24 hours. The mixture is treated with rhodium on alumina and hydrogenated in a hydrogen atmosphere to provide the amine. After filtration and evaporation, the residue is dissolved in 0.2 N EICl to cleave the acetonide. After evaporation the amine diol may be purifled by ion exchange on a cation exchange column. When appropriate, the amine moiety may be tritylated as in Example 2 to give the amine-protected 2', 3' -diol.
Example 12 Synthesis of 5'-aminoethylsulfonyl Riboside Subunit 2-Aminoethanethiol (2 mmol) is reacted with carbobenzoxychloride (l mmol) in pyridine. The protected thiol carbamate is purified by SiO2 using ethylacetate/hexane mixtures. Under an argon atmosphere the thiol (l mmol) is dissolved in oxygen-free D~E
cc~nt~n~ng 1.1 mmol oil-free sodium hydride. After evolution of gases the mixture is treated with the N4-WO 91/09073 PCr/US90/07565 Z~i99~6 benzoylcytidine-2', 3' -acetonide iodo-compound from Example 11 (at 0C. ) and the mixture stirred at room temperature for 12 hours. The solvent was evaporated in vacuo. A~ter redissolution ln chloroform the solution 5 was washed with sodium bicarbonata, then brine, then dried over Na,SO~, filtered and evaporated in vacuo. The residue was purified by chromatography on silica gel using chloroform/methanol mixtures.
The sulfide from the previous paragraph was oxidized 10 with exccss perbenzoic acid in chloroform to the sulfone.
This was immediately treated with 0.2 N HClldioxane to cleave the acetonide group. The diol was purified by chromatography on silica using methanol/chloroform mixtures .
The diol sulfone from above is reduced with hydrogen/ palladium on carbon in DMF/methanol in the presence oi acetic acid to remove the carbobenzoxy group.
One equivalent of toslc acid is added to the mix, the solution is filtered and the filtrate evaporated. When 20 appropriata the pendant amine is tritylated as in Example 2 to give the amine-protected 2', 3' -diol. If required, the benzoyl group on the base is removed by treatment with equal amounts of DMF and CMC aqueous ammonia at room temperature for 24 hours.
Example 13 Activation and Coupling To Give Carbamate Linkage This example describes the activation of morpholino-subunits, ~such as prepared ln Example 2, and their sub-30 sequent coupling via a carbamate linkage to yield a 6-atom unit-length backbone. The example is described with reference ~o the Structures in Figure 9.
Activation Step Dry, N-protected, 5'hydroxyl morpholino nucleoside WO 9l/09073 PCr/US90/0~565 2~g9~6 (Structure 1) (1 mmol), prepared as in Example 2, is treated with bis- (p-nitrophenyl) carbonate (BNPC) and tri-ethylamine (TEA) in DMF under anhydrous conditions. The solution is stirred for three hours, then evaporated to 5 dryness. The residue is dissolved in chloroform and chromatographed on silica gel eluting with an approprlate chloroform/methanol/ 0.196 TBA mixture to glve activated subunit (Structure 2).
Deprotection Step 1.1 mmole morpholino nucleoside (Structure 1) is dissolved in 10 ml trifluoroethanol and 0.1 ml formic acid (or 0.2 ml acetic acid) added - giving a strong yellow color from the trityl carbonium ion - which fades on standing a few minutes. After five minutes the 15 trifluoroethanol and acid are removed under reduced pressure and the deprotected subunit (Structure 3) resuspended in 5 ml DMF containing 0 . 5 ml triethylamine .
Coupl ing The activated subunit (Structure 2) is added to the 20 DMF solution of unprotected subunit and incubated at room temperature for 1 hour to give coupled product (Structure 4) .
Example 14 Activation of Sulfamic and Sulfonic Acids and Coupling to Give Sulfamide and Sulfonamide Linkages This example describes the activation of sulfamic acld salts (such as prepared in Examples 4 and 5) and the activation of sulfonic acid salts (such as prepared in Examples 6, 7, 8 and 9) and thelr coupling to form sulfamide and sulfonamide linkages, ~espectively. The example is described with reference to the structures in Figures 10 and 11.

.
~20~99~6 Activation Ten mmole of the triethylamine salt of sulfated subunlt protected on the base and on the nltrogen of the morpholino ring (e.g., Structure 1 of Figures 10 and 11) 5 is dissolved in 10 ml of dichloL~ - h~n~ and then 40 mmole of pyridlne ls added. This solution is chilled for 15 minutes on a bed of dry ice and then 1.1 mmole of phosgene (20% in Toluene) is slowly added while the solution ls rapidly stirred. After addition the solution 10 is allowed to come to room temperature and then washed with aqueous NaHCO~, dried, and chromatographed on silica gel eluted with a mixture of ~ chloroform and acetone to give the desired sulfamoyl chloride (e. g., Structure 2 of Figure 10) or sulfonyl chloride (e.g., Structure 2 of 15 Figure 11).
Deprotection Eleven mmole of the triethylamine salt of sulfated subunit (e.g., Structure 1 of Figure 10 or 11) is dissolved in 200 ml of trifluoroethanol and 0 . 2 ml of 20 formic acid ~or 0 . 4 ml acetic- acid) added. After 5 minutes the solution is concentrated under reduced pressure and the deprotected subunit (e . g ., Structure 3 of Figure 10 or 11) precipitated with ether. The preci-pitate is then washed thoroughly with ether and then 25 resuspended in 5 ml of DMF containing 0 . 6 ml of triethyl-amine. If an appreciable amount of residual formic or acetic acid remains in the deprotected subunit preparation the subse~uent coupling efflciency can be seriously reduced. This reduction in efficiency is 30 probably the result of the sulfamoyl chloride or sulfonyl chlorlde component reacting with these carboxylate salts to form mixed anhydrides, which in turn fail to react in the desired manner with the morpholino nitrogen of the deprotected component.

Wo 91/09073 PCrtUS90/07565 2~699~t~

Coupling The activated subunit (Structure 2) is added to the D~F solution of deprotected subunit (Structure 3) and incubated at room temperature for 1 hour to give coupled 5 product (Structure 4).
Example 15 Coupling of sulfamoyl Chloride with Alcohol to Give Sulfamate Linkage Thls example describes the coupling of a sulfamoyl chloride (prepared as in Example 4 and activated as in Example 14) with a 5' hydroxyl subunit. This example is described with reference to the structures in Figure 12.
One mmole of the sulfamoyl chlorlde, prepared as in Example 4 and activated as in Example 14 (Structure 3), 1 mmole 2, 6-di-t-butyl-4-methylpyridine, 0.5 mmole of the alcohol component (Structure 4), and 20 ml of dry toluene are placed in an oven-dried round-bottom flask. After dissolution the reaction mixture is evaporated under 20 reduced pressure and residual toluene removed under high vacuum. The residue is redissolved in methylene chloride (10 ml) and treated with silver tri~luoromethanesulfonate (2 mmole). The reaction mixture is stirred at room temperature for several hours to complete cooling.
25 Chloroform (20 ml) is added and the resulting milky suspension added to an acetonitrile solution (20 ml) of tetraethylammonium chloride (5 mmole). After stirring at room temperature for 30 minutes the excess solvent is removed by rotary evaporator, the residue dissolved in 30 chloroform (150 ml) and filtered into a separatory funnel containing 0.05 N HCl (20 ml). Following washing, the organic layer is washed with 20 ml water, dried over sodium sulfate, and then dried under vacuum. The resldue is chromatographed on silica gel developed with a WO 91/09073 PCr/US90/07565 ~9~

chloroform/methanol mixture to give the desired product (Structure 5).
Example 1 6 Activation and Coupling To GiYe Amide Linkage This example describes the activation of the carboxylate subunit prepared in Example 10 and coupling to iorm an amide linkage. The example is described with reference to the Structures in Figure 13.
Activation 10 mmole of the subunit prepared in Example 10 (Structure ~ l) is dissolYed in DMF containing 20 mmole of p-nitrophenol and 15 mmo1e of dicyclohexylcarbodiimide.
After 1 hour the product is rotovaped and then purified by silica g-el chromatography to give Structure 2.
Deprotection Eleven mmole of the subunlt prepared in Example 10 (Structure 1) is dissolved in 100 ml of dichloromethane, 1 ml of me~hanol and 1 ml of dichloroacetic acid. After 5 minutes the CEI2Cl, is removed under reduced pressure and the product washed with ether, dried and dissolved in 20 ml D~ containing 1 ml triethylamine to give Structure 3.
Coupling The activated subunit (Structure 2) is added to the DMF solution of deprotected subunit (Structure 3) and incubated at room temperature for 1 hour to give coupled product (Structure 4).
Example 17 Simultaneous Morpholino Ring Formation and Subunit Coupling This example describes the oxidation of a ribonu-cleoside containing a protecte~ amine linked through the 5' methylene, such as prepared in Example 11 or 12, and WO 91/09073 PCr/US90/0~565 99~G

coupling to the unprotected amlne of another subunit to simultaneously form a morpholino ring structure and ~oin the subunits. The example is described with reference to the structures in Figure 14.
5 Amine Protection Ten mmole of ribonucleoside contA1n~ng a 1 amine linked through the 5' methylene (Structure l) is reacted with 11 mmole of trityl chloride to protect the amlne ( Structure 2 ~ .
10 Oxidation ~ ritylated subunit (Structure 2), in methanol, is reacted with ll mmole of NaIO~ to give the dialdehyde (Structure 3).
Coupling If the coupling solution is too acidic the reaction is very slow and if the solution is too basic epimerization of the Structure 3 component appears to occur. A weak acid is used to neutralize the amlne component (Structure 1) and buffer the reaction in this 20 coupling step. Weak acids which have been found suitable for this purpose are: carbonic, ortho and para nitrophenol, and benzotriazole. Accordingly, the dialdehyde (Structure 3) is combined with a suitable salt of Structure l in a water/methanol mixture to give the 25 coupled product (Structure 4).
Reduction Either during or after the morpholino ring closure step sodium cyanoborohydride is added to reduce the 2', 3' 30 dihydroxymorphollno ring (Structure 4) to the desired morpholino product (Structure 5 ) .
Example 18 Solution-Phase Block Assembly of Sulfamide-Linked ~_ WO 91/09073 PCr/US90/07565 ~6~

Oligomer of the Sequence 5' -CUGU
This ~ample descrlbes the assembly of a short oligomer _containing a sulfamide-linked backbone ~Structure C-C of Figure 4, wherein X2 is a nitrogen) 5 coupled as in Example 14. This solution assembly method is particularly useful for large-scare synthesis o~ short oligomers suitable for subsequent assembly into longer oligomers using the solid-phase method ~Example 19).
5' Sulfamic acid subunits Qf C, U, and G tritylated 10 on the morpholino ring nitrogen are ~repared as in Example 5. ~ The U subunit ls then activated by conversion to the sulfamoyl chloride form as in Example 14. The C
subunit and the G subunit are deprotected as in Example 14. The deprotected C component (1.1 m mole) is 15 dissolved in 5 ml DMF and 0.3 ml TEA, followed by addition of 1. 0 m mole of the activated U component .
Likewise, the deprotected G component is reacted with the activated U component.
After one hour each of these preparations is added 20 to 100 ml of rapidly stirred hrine and the solid collected and washed with water. The GU dimer is dried thoroughly under high vacuum and then activated as in Example 14. The best tetramer coupling results are obtained when purification of the dimer, via silica gel 25 chromatography, is carried out after, rather than before, this activation step.
The CU dimer is deprotected as in Example 14.
Better yields of tetramer are obtained when the dimer, after the ~ initial e~her ~precipitation, is thoroughly 30 resuspended in about 2 ml of trifluoroethanol, reprecipitated with 30 ml of ether, and then resuspended in DMF and TEA f Qr subsequent coupling .
Coupling to form the desired tetramer entails simply adding 1 m mole of activated GU dimer to the DMF/TEA

WO 91/09073 PCr/US90/07S6S
~C69906 solution containing 1.1 m mole of deprotected CU dimer.
Workup of the tetramer entails adding the reaction mixture to brine, washing the solid with water, and drying under vacuum to give the desired tetramer: 5'-5 CUGU having a sulfamic acid salt at the 5' end and atrityl on the morpholino nitrogen of the terminal U
subunit. The structure of this tetramer is most easily c~nfl -~1 by negative ion Fast Atom Bombardment mass spectroscopy. As a rule the dominant specie in the 10 spectrum is the molecular ion.
Example 19 Solid-Phase Assembly of Sulfamide-~inked Morpholino Polymer This example describes the use of tetramer blocks, prepared as per Example 18, for solid-phase assembly of a morpholino polymer containing sulfamide intersubunit linkages. Solid-phase assembly provides a rapid method for assembly of longer binding polymers. The use of short oligomer blocks instead of monomers greatly simplifies separation of the final product from failure sequences .
A. Synthesis of short oligomers The following tetramers are synthesized in solution:
5'-CUGU ~Example 18~; 5'-UCGG; 5'-GCGC; 5'-CACU.
These tetramers are converted to thelr activated sulfomoyl chloride form by the general method described in Example 14.
B. Preparation of the first monomer with a cleavable linker and attachment to the solid support Morpholino C subunit containing a trityl moiety on the morpholino ring nitrogen and having a methylamine on the 5'methylene, prepared as in Example 5, is reacted with a 3-fold molar excess of Bis[2-(s~ c;n;m;dooxycar-WO 91/09073 PCr/US90/07565 ~9~36 5 7 bonyloxy)ethyl]sulfone from Pierce of Rockford, Illinois, USA. This product is purified by silica gel chromatography and then added to a suitable solid support containing primary amine functions (e . g ., Long Chain 5 Alkyl Amine Controlled Pore Glass, from Pierce of Rockford, Ill;n~c). This procedure links the first tritylated 3ubunit to the synthesis support via a linker which is stable to the acidic conditions used for detritylations, but which can be readily cleaved via a lO beta elimination mechanism using a strong non-nucleophilic base, such as a 1, 8-Diazabicyclo [5 . 4 . 0] undec-7-ene (DBU) .
C. Stepwise assembly of the polymer bound to the solid support The coupling cycle for addition of each subunit or oligomer block generally includes deprotection of the terminal backbone moiety, a thorough wash, addition of the next activated subunit or oligomer block, and a thorough wash. The coupling efficiency for each addition 20 can be ~ t~rm1nPr~ by collecting each detritylation solu-tion and subsequent wash and quantitating the trityl therein .
Detritylation in the present sufamide-linked polymer is achieved by slowly passing through the column a solu-25 tion of 2% formic acid in trifluoroethanol (or 296 dichlo-roacetic acld in dicloL, h~ne) until the eluant no longer tests positive for ~ trityl (readily determined by adding a drop of eluant to 100 1ll methanesulfonic acid and inspecting for the~ visible yellow color characteris-30 tic of the_trityl carbonium ion). Thereafter the supportis thoroughly washed to remove e~cess acid and then washed wit~ DMF containing 1% by volume of N-ethylmor-pholine (NEM) . Coupling of the next subunit or oligomer block in the desired polymer sequence entails addition of WO 91/09073 PCl/US90/0756~
O ZO~i99G6 a concentrated DMF solution containing the activated monomer or oligomer and a molar equivalent of NEM. Since the rate of coupling is a function of concentratlon it is desirable to add a substantial molar excess of monomer or 5 oligomer relative to the concentration of support-bound growing chains. A 5-fold molar excess of activated monomer or oligomer over t~at of the growing chains often gives acceptable coupling ~ff;~ n~;es. Required cou-pling times can be determined by removing at specified 10 time intervals small defined quantities of the support material, thoroughly washing, treating the support with methanesulfonic acid, and then spectrophotometrically quantitating the released trityl carbonium ion (molar absorbance at 409 nm is 45, 000 in methane sulfonic acid) .
15 After coupling is complete the unreacte-d subunit or oligomer is washed from the support~ with D~F. The un-reacted subunit is generally recovered, purified by chromatography, and reused for later synthesis. The sup-port is thoroughly washed with the solvent trifluoro-20 ethanol, without added acid. Washing is complete whenaddition of a drop of the wash eluant to 100 1ll methane-sulfonic acid shows no yellow color.
The above coupling cycle is used to add, in order, the four activated tetramers 5'-CUGU; 5'-UCGG; 5'-25 GCGC; and 5'-CACU. This results in the following poly-mer: support-linker-CCUGUUCGGGCGCCACU-trityl.
D. Cleavage from the support The synthesis support is treated with 20% DBU in DMF
for two hours at room temperature in the presence of 2%
30 diethylmalonate, to tie up the vinylsulfone generated during cleavage of the linker. The released morpholino polymer is washed from the support with DMF and precipi-tated by adding ethylacetate. The ~recipitate contains full-length polymer having a 5' methylamine, the bases WO 91/09073 PCr/US90/07565 zC~699~S~ O

still protected and a trityl moiety on the terminal morpholino nitrogen. In addition, the precipitate con-tains small amounts of failure sequences. At thLs stage the polymer size can be conf; rm~rl by positive ion fast atom mass spectrometry.
E. Addition of sol~lh;l;7;ng moieties If it is desired to add two solubilizing groups to the morpholino polymer this can be done conveniently by detritylting the N-tPrm; n~ 1 morpholino nitrogen using 2%
formic aci~ in trifluoroethanol. Alternatively, if only one solllh~l;7;ng moiety is to be ad ed, then the 5'me-thylamine is acetylated with acetic anhydride before the detritylation step.
Polyethylene glycol 1000 (from Polysciences Inc., Warrington, Pennsylvania, USA) is thoroughly dried by dissolving in dry DMF and then evaporating the solvent under vacuum. The solid is resuspended in a minimal volume of pure dry DMF and 0.5 mole equivalent ~relative to PEG 10DD) of bis (p-nitrophenyl) car~onate and 1 mole equivalent of TEA is added and the preparation sealed and incubated overnight at 30C to give p-nitrophenyl car-bonate-activated PEG 10 0 0 .
The full-length morpholino polymer which has been detritylated is added to a substantial molar excess ~generally 10- to 20-fold) of activated PEG 1000 and ' nrllh~te~l two hours at room temperature. -- Unreacted PEG
1000 is removed by precipitation of the tailed polymer with ether.
F. Base deprotection The dried polymer is suspended in DMS0, the DMS0 solution chilled, and an equal volume of concentrated NH~OH is carefully layered on top of the chilled DMSO, and the ~-ont~;n~r tightly capped. The preparation is ; nf llhatecl at 30C for eighteen hours . Thereafter, the WO 91/09073 ZC599~6 PCI/US90/0?565 solution is briefly exposed to aspirator vacuum to remove ammonia .
G. Purification of morpholino polymer Purifica~ion at pH 2.5 is general fQr binding poly-5 mers wherein about half or more of the base-pairing moieties are of types 1, 2, 3, and 7 of Figure 2.
Water to be used for chromatography is degassed under aspirator vacuum and phosphoric acid added to give pH 2.5 ~solvent A). A corresponding pH 2.5 solution is 10 made 2 N in KCl (solvent B) . Solvent A is mixed 1:1 by volume with chromatographic-grade acetonitrile to give solvent C .
Load up to about 10 mg of this polymer in 10 ml of solvent A on a chromatography column 1 cm in diameter and 15 10 to 20 cm in length which is packed with the cation-exchange support S-Sepharose Fast Flow (Pharmacia).
Proportionately larger quantities can be loaded on larger columns of the same length, e . g ., up to 60 mg can be loaded on a 2 . 5 cm 20 diameter column and 250 mg on a 5 cm diameter column.
After washing the column thorough with solvent A elute with a linear gradient ranging from 100% solvent A to 100% solvent B and monitor the eluant to 254 nm. The desired binding polymer is generally the last and the 25 largest peak to elute from the column. When the polymer is prepared by block assembly, base-line separations are often achieved. When peak shapes are unsymmetrical the problem generally has been due to insolubility of the binding polymer rather than a lack of capacity of the 30 chromatographic packing. Such a problem, which is most common when the binding polymers do not contain a solubi-lizing moiety, can often be solved by reduclng the quan-tity of binding polymer loaded in a given run. When peaks are symmetrical but base-line separation is not WO 9l/09073 ~ PCr/US90/07565 i99~6 achleved, substantlal improvements are usually attained simply by eluting with a shallower gradient.
The eluant containing the polymer is desalted by loading on an eriuivalent-sized coIumn packed with 35 5 micron chromatographic polypropylene (Cat. No. 4342 from Polysciences, Inc. ) and washing thoroughly with solvent A. If baseline separation was achieved in the foregoing cation exchange chromatography, then pure product ls obtained simply by eluting with solvent C; otherwise, the 10 product is ~eluted with a linear gradient ranging from 10096 solvent A to 10096 solvent C. When the product is somewhat acid sensitive the solution is neutralized with dilute NaOH before drying under reduced pressure.
p~lrl f; r;~; on at high pEI
Purification at pH 11 is generally used for binding polymers wherein above half or more of the base-pairing moieties are at type 4, 5, 6 and 9 of Figure 2.
N, N-diethylethanolamine (Aldrich) is added to degas-sed water to ad~ust the pH to 11. 0 (solvent D) . A cor-20 responding pH 11 solution 2 N in KCl (solvent E) isprepared. A third pH 11 solution is prepared by mixing Solvent D 1:1 by volume with chromatographic grade aceto-nitrile (solvent F).
The fu1 1 y-deprotected binding polymer, prepared as 25 above, is suspended in solvent D at a rr~nrPr~tration of about 1 mg/ml. The pH is ad~usted, i~ necessary, to pH
11 with N,N-diethylethanol-amine. About 10 ml of this polymer solutlon is placed on a chromatography column 1 cm in diameter and 10 to 20 cm in length which is packed 30 with anion-exchange support Q-Sepharose Fast Flow (Phar-macia). After washing the column thoroughly with solvent D, the column is eluted with a linear gradient ranging from 100% solvent D to 100% solvent E and the eluant is monitored at 254 nm.

20~99~6 The eluant contalnlng the polymer is desalted by loading on an equivalent-sized column of polypropylene and washing thoroughly with solvent D. If baseline separation is achieved in the foregoing anion exchange chromatography then pure product is obtained simply by eluting with solvent F; otherwise, the product is eluted with a linear gradient ranging ~rom 100% solvent D to 100% solvent F. Fractions cnnt~ln1ng the product are dried under reduced pressure.
H. Ser~uence confirmation While mass spectral analysis of the full-length polymer in the fully-protected state, as described ear-lier, does serve to confirm both the polymer length and the base composition, it does not provide information on the subunit ser~uence. Significant ser~uence information can be obtained from f, _ nt~tion patterns of deoxyribo-nucleic acids and carbamate-linked deoxyribonucleoside-derived polymers (Griffin et al. (1987), Biomed. ~ Environ. 15ass Spectro-metry 17 : 105); however, many of the morpholino polymers of t~e instant invention are r~uite resistant to fragmen-tation and give pr~ ~ 1 n~nt 1 y the molecular ion with only minimal fragments.
One method for rf~nfl rm~ ng the serluence of the poly-mer is to take a small portion of the growing polymer after coupling each oligomer block and use mass spectral analysis to ~ollow the elongation of the polymer. This method is applicable except for those rare cases where two blocks used in the synthesis happen to have exactly the same mass.
An indirect method to help verify the correctness of the polymer subunit ser~uence is to pair the morpholino polymer with its complementary DNA (whose ser~uence can be rr)nf~ ?d by established ~nethods) and with DNA ser~uences WO 9l/09073 PCr/US90/07565 z~j,99~ ~3 which might have resulted if the blocks were assembled in the wrong order. Pairlng Petween the polymer and DNA can be evaluated by the occurrence of a hypochromic shift in the 240 to=~290 nm waveIength region; such a shift occurs only between the polymer and its complementary sequence.
The polymer/DNA duplex can also be distinguished from any partially-mismatched duplex by slowly raising the temper-ature while monitoring the absorbance in the 240 to 290 nm wavelength region. The perfect duplex will have a melting temperature (corresponding to a 50% reduction in the hypochromicity) generally 10 degrees or more above that of any mismatched duplex.

Example 20 Solution-Phase Assembly of Simple Prototype Morpholino Polymer, Structural Confirmation, Deprotection, Purification, and Assessment of Binding to Target DNA Sequence This example describes the preparation, structural c~nf~ r~t~ on, and assessment of target binding affinlty of a simple carbamate-linked morpholino polymer.
A carbamate-linked morpholino hexamer wherein all P1 moieties are cytosines is assempled from dimer prepared as in ~3xample 13. One third of that dlmer preparation is detritylated (as in E~xample 13) and the remaining two thirds is activated (again as in ~xample 13). Half of the activated dimer is reacted with the detritylated dimer to give tetramer, which is purified by silica gel chromatography developed with 6% methanol/94%chloroform.
The tetramer is detritylated and reacted with the remain-ing activate~l dimer to give hexamer, which is purified by silica gel chromatography developed with 10% methanol/90%

WO 9l/09073 PCI/US90/07565 20~;~9~ -chloroform .
This carbamate-linked 5'0H, base-protected hexamer havlng a trityl moiety on the morpholino nitrogen is designated c ~mC ) 6-trityl. Photon NMR gives:
5~ = 8.25-7.90 (18H, m), 7 65-7.05 (39H, m), 6.16 (lH, bd), 5.77 (4H, m), 5.69 (lH, bd), 4.46 (lH, m), 4.35-3.80 (25H, m), 3.56 (2H, m), 3.25-2.75 (12H, m), 1.47 )lH, m), 1.24 (lH, m).
The mass spectrum (3-nitrobenzyl alcohol matri~) l O shows:
M-1 = 2352.6 (2), 459.2 (30), 306.2 (100) .
The high-resolution mass spectrum shows an ~-1 of 2352. 8197, which is in good agreement for Cl20Hl12N2.O29 calculated as 2352 . 8026.
This c(mC ) 6-trityl polymer is next detritylated as in Example 13, and then a polyethylene glycol 1000 tail is added followed by base deprotection, as in Example 19.
Purification is by cation exchange chromatography fol-lowed by desalting on a column of polypropylene, as 20 described in Example 19.
This purified tailed hexamer, c (mC-) 6-PEG1000, shows an absorption maximum at 2 67 .1 nm in neutral ar~ueous solution, with a calculated molar absorbance of 42, 800 .
In aqueous solution at pH 1, the same material shows an 25 absorption maximum at 275 . 7 nm, with a calculated molar absorbance of 77,100. Proton N~ data for this final product is as follows:
~ = 7.74 (6H, broad d), 5.97 (6H, broad D), 5.65 (6H, broad D), 4.30-4.05 (12H, m), 4.04-3.80 (18H, 30 m), a large envelope containing the P~G protons, and several signals of the oligomer, 2 . 99-2 . 80 (120H, m) .
To assess target binding affinity 20 A26~ units of DNA target p (dG) 6~ purchased from pl~ArTn~rl A LKB, is dis-solved in 50 microliters of deionized water and 200 WO 91/09073 PCr/US90/0756~
2~{i99~6 microliters of DMSO (spectrophotometric grade from Ald-rich Chem. Co . ) is added (stock solution A) . 1. 8 mg of the tailed morpholino hexamer, c (mC) 6-PEG1000, is dis-sQlved in 0 . 36 ml of spectrophotometric grade DMSO (stock solution B). Phosphate buffer ~s prepared by ad~ustlng the pE of 0 . 05 N NaOH to 7 . 4 using phosphoric acid, followed by addition of EDTA to a final concentration of 0 . 001 N (Buf~er C) .
Stock solutlons A and B are assayed for the actual c~nr~ntrati~n of polymer by W; the absorbance of stock solution A is measured in 0.1 N NaOH and stock solution B
is measurad in 0.1 N HCl. Measurements at these pH
extremes minimize base stacking and other polymer inter-actions which can give absorbance values not proportional to the component monomers. Stock solutions A and B are diluted with Buffer C to give solutions of a final con-centration of 10 micromolar in polymer. The required dilutions are calculated using molar absorbencies of 65, 000 for solution A, p (dG) 6, and 77,100 for solution B, c(mC )6-PEG1000.
Assessment of target blnding affinity is carried out in a double-beam scanning spectrophotometer having a temperature-sontrolled cell housing which will accom-modate two cells in the reference beam and two in the sample beam.
Using four matched Q;uartz cuvettes, one is filled with 0.5 ml of 10 micromolar p (dG) ~ and 0.5 ml of Buffer C and a second is ~illed with 0.5 ml of 10 micromolar c (mC ) 6-PEG1000 and 0.5 ml of Buffer C. These two cu-vettes are placed in the reference beam of the tempera-ture-controlled cell housing. Next, a third cuvette is filled with 1 ml of Buffer C and a fourth is filled with 0.5 ml of 10 micromolar p(dG)6 and 0.5 ml of 10 micromo-lar c(mC ),-PEG1000. These two cuvettes are placed in the WO 91/09073 PCr/US90/07S6S
2~i99~6 sample beam of the cell houslng. The cell housing is then heated to 60 C and allowed to cool slowly to 14 C
to assure complete pairing between the polymer and its-DNA target in the fourth cuvette. A scan is then taken from 320 nm to 240 nm - which shows a substantial absorb-ance difference due to a hypochromic shift in polymer-target mixture, centered around 273 nm. The temperature of the cell holder is then raised in 2-degree in.~ ntc to 80C, with scans taken after each 2-degree rise.
For comparison, the same procedure is used for assessing the binding affinity of p (dC) 6 DNA for its target p (dG) ~, which gives a similar but less intense hypochromic shift in the paired state.
Plots of the absorbance difference as a function of temperature for both the morpholino polymer/DNA and the analogous DNA/DNA complexes are shown in Figure 15. The melting t~ dLule:~ Tc~ wherein the complex is half melted, is seen to be 62C for the morpholino polymer/DNA
and 30 C for the DNA/DNA. At low salt concentrations such as used here, the charge repulsion between the anionic DNA backbones substAnt~ ly destabilizes the DNA/DNA duplex, while there is no corresponding electro-static repulsion between the morpholino polymer and its DNA target .
Example 21 Solution-phase Assembly of Simple Prototype Sulfamide-linked Mor,oholino Polymer and Aq~e~! L of Binding to RNA and DNA Target Sequences ~his example describes the preparation and target binding of a simple sulfamide-linked morpholino polymer.
A sulfamide-linked morpholino hexamer, wherein all P~ moieties are cytosines, is assembled from 5' sulfated WO 91/09073 ~ PCr/US90/07565 2~9~

methylamine subunit (R is methyl ) prepared as in Example 5 and activated as in Example 14. P.ctivated monomer is reacted in DMF with an excess of 5' OH subunit lacking a protective group on the morpholino nitrogen, prepared as 5 in Example 2. The resultant dimer is purified by silica gel chromatography developed with methanol/chloroform mixtures and then deprotected as in Example 14. This product is then reacted with more activated monomer, the chain-extended product purified, and deprotected as 10 above. Thls cycle is repeated until hexamer is obtained.
BefQre - the last detrltylatIon, the mass of the hexamer was ~nfi~m~d by negative ion FAB mass spectro-scopy, which showed M-1 = 2598.9 ~100).
As in Example 20, the sulfamide-linked hexamer is 15 tailed with PEG-1000, deprotected, purified, and tested for binding to its DNA target, p (dG) " and its RNA tar-get, poly (G) . The target-binding affinities, expressed in T"~ values, for this sulfamide-linked hexamer, referred to as s (mC) ~, are tabulated below, along with the cor-20 responding target-b-inding affinities for the analogous DNA oligomer, p (dC) ,.
T= value ( C. ) s (mC) 5/p (dG) 6 25 p (dC) 6/P (dG) 6 29 s (mC) 6/poly (G) 33 s (dC) 6/poly (G) 38 While specific embodiments, methods, and uses of the invention have been described, it will be appreciated that various changes and modifications of the invention 35 may be made without departing from the invention. In Wo 91/09073 PCI'/US90/07565 Z~6~9~6 particular, although preiierred polymer backbone struc-tures have been described and illustrated, it will be appreciated that other morpholino-based polymers may be constructed according to the backbone constraints and 5 requirementS dlscussed above.

Claims (19)

IT IS CLAIMED:
1. A polymer composition comprised of morpholino subunit structures of the form:
(A) where (i) the structures are linked together by un-charged, achiral linkages, one to three atoms long, joining the morpholino nitrogen of one subunit to the 5', exocyclic carbon of an adjacent subunit, and (ii) P? is a purine or pyrimidine base-pairing moiety effective to bind by base-specific hydrogen bonding to a base in a polynucleotide.
2. The composition of claim 1, wherein P? is selec-ted from the group consisting of:
1. 2. 3.
4. 5. 6.
7. 8. 9.
X= H, CH3, F, C?, Br, I
3. The composition of claim 1, wherein the linked structures have a form selected from the group consisting of:
(A) (B) (C) (D) (E) (F) and (G)
4. The composition of claim 1, wherein the linkage is of the form:
where X is NH, NCH3, O, S, or CH2; and, P? is a purine or pyrimidine base-pairing moiety effective to bind by base-specific hydrogen bonding to a base in a polynucleotide.
5. The composition of claim 1, wherein the linkage is of the form:
where Y is O or S; and, P? is a purine or pyrimidine base-pairing moiety effective to bind by base-specific hydrogen bonding to a base in a polynucleotide.
6. The composition of claim 1, wherein the linkage is of the form:
where P? is a purine or pyrimidine base-pairing moiety effective to bind by base-specific hydrogen bonding to a base in a polynucleotide.
7. The composition of claim 1, wherein the linkage is of the form:
where R is H or CH3; and, Pj is a purine or pyrimidine base-pairing moiety effective to bind by base-specific hydrogen bonding to a base in a polynucleotide.
8. The composition of claim 1, which further includes a moiety at one or both termini which is effective to enhance the solubility of the polymer in aqueous medium.
9. The composition of claim 8, wherein the terminal moiety is polyethylene glycol.
10. The composition of claim 1, compound of at least 3 morpholino subunits.
11. The composition of claim 1, wherein at least one of the Pi is a 2,6-diaminopurine.
12. The composition of claim 1, wherein at least one of the P? is a 5-halouracil.
13. The composition of claim 1, wherein at least 70% of the Pi are 2-amine containing purines.
14. A method for detecting a nucleic acid in a sample, comprising contacting a polymer of claim 1 with the sample under hybridization conditions that allow the nucleic acid in the sample to anneal to the polymer, and detecting the polymer-nucleic acid complex.
15. A method of claim 14, where said polymer contains a reporter group, and where said detecting is accomplished by identification of the reporter group.
16. A method of claim 15, where said reporter group is a radioactive moiety or biotin.
17. A method of claim 15, where said polymer is linked to a solid support.
18. A polymer of claim 1 useful as a therapeutic agent.
19. A polymer of claim 18, for use as an antiviral, antibacterial or antitumor agent.
CA002069906A 1989-12-20 1990-12-20 Uncharged morpholino-based polymers having achiral intersubunit linkages Expired - Lifetime CA2069906C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/454,055 US5034506A (en) 1985-03-15 1989-12-20 Uncharged morpholino-based polymers having achiral intersubunit linkages
US454,055 1989-12-20

Publications (2)

Publication Number Publication Date
CA2069906A1 CA2069906A1 (en) 1991-06-21
CA2069906C true CA2069906C (en) 1996-11-26

Family

ID=23803109

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002069906A Expired - Lifetime CA2069906C (en) 1989-12-20 1990-12-20 Uncharged morpholino-based polymers having achiral intersubunit linkages

Country Status (9)

Country Link
US (1) US5034506A (en)
EP (1) EP0506845B1 (en)
JP (1) JP3172174B2 (en)
KR (1) KR0154317B1 (en)
AT (1) ATE164081T1 (en)
AU (1) AU654473B2 (en)
CA (1) CA2069906C (en)
DE (1) DE69032167T2 (en)
WO (1) WO1991009073A1 (en)

Families Citing this family (1835)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470974A (en) * 1985-03-15 1995-11-28 Neu-Gene Development Group Uncharged polynucleotide-binding polymers
US5217866A (en) * 1985-03-15 1993-06-08 Anti-Gene Development Group Polynucleotide assay reagent and method
US5521063A (en) * 1985-03-15 1996-05-28 Antivirals Inc. Polynucleotide reagent containing chiral subunits and methods of use
US5235033A (en) * 1985-03-15 1993-08-10 Anti-Gene Development Group Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5506337A (en) * 1985-03-15 1996-04-09 Antivirals Inc. Morpholino-subunit combinatorial library and method
US5185444A (en) * 1985-03-15 1993-02-09 Anti-Gene Deveopment Group Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
US5378841A (en) * 1989-12-20 1995-01-03 Antivirals Inc. Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5914396A (en) * 1990-01-11 1999-06-22 Isis Pharmaceuticals, Inc. 2'-O-modified nucleosides and phosphoramidites
US20040142899A1 (en) * 1990-01-11 2004-07-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US6399754B1 (en) * 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US5959096A (en) * 1992-03-16 1999-09-28 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5514788A (en) * 1993-05-17 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US6753423B1 (en) 1990-01-11 2004-06-22 Isis Pharmaceuticals, Inc. Compositions and methods for enhanced biostability and altered biodistribution of oligonucleotides in mammals
US5955589A (en) * 1991-12-24 1999-09-21 Isis Pharmaceuticals Inc. Gapped 2' modified oligonucleotides
US5591623A (en) * 1990-08-14 1997-01-07 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of cell adhesion
US6339066B1 (en) 1990-01-11 2002-01-15 Isis Pharmaceuticals, Inc. Antisense oligonucleotides which have phosphorothioate linkages of high chiral purity and which modulate βI, βII, γ, δ, Ε, ζ and η isoforms of human protein kinase C
US5623065A (en) * 1990-08-13 1997-04-22 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5514577A (en) * 1990-02-26 1996-05-07 Isis Pharmaceuticals, Inc. Oligonucleotide therapies for modulating the effects of herpes viruses
US5834607A (en) * 1990-07-27 1998-11-10 Isis Pharmaceuticals, Inc. Amines and methods of making and using the same
US5789573A (en) * 1990-08-14 1998-08-04 Isis Pharmaceuticals, Inc. Antisense inhibition of ICAM-1, E-selectin, and CMV IE1/IE2
US5595978A (en) * 1990-08-16 1997-01-21 Isis Pharmaceuticals, Inc. Composition and method for treatment of CMV retinites
US5442049A (en) * 1992-11-19 1995-08-15 Isis Pharmaceuticals, Inc. Oligonucleotides for modulating the effects of cytomegalovirus infections
US6153595A (en) * 1990-08-16 2000-11-28 Isis Pharmaceuticals Inc. Composition and method for treatment of CMV infections
WO1994008003A1 (en) * 1991-06-14 1994-04-14 Isis Pharmaceuticals, Inc. ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE
US7015315B1 (en) 1991-12-24 2006-03-21 Isis Pharmaceuticals, Inc. Gapped oligonucleotides
US5965722A (en) * 1991-05-21 1999-10-12 Isis Pharmaceuticals, Inc. Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US6414112B1 (en) 1991-05-24 2002-07-02 Ole Buchardt Peptide nucleic acids having 2,6-diaminopurine nucleobases
US5766855A (en) * 1991-05-24 1998-06-16 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity and sequence specificity
US6713602B1 (en) * 1991-05-24 2004-03-30 Ole Buchardt Synthetic procedures for peptide nucleic acids
US5719262A (en) * 1993-11-22 1998-02-17 Buchardt, Deceased; Ole Peptide nucleic acids having amino acid side chains
US6441130B1 (en) 1991-05-24 2002-08-27 Isis Pharmaceuticals, Inc. Linked peptide nucleic acids
US6451968B1 (en) * 1991-05-24 2002-09-17 Isis Pharmaceuticals, Inc. Peptide nucleic acids
US5714331A (en) * 1991-05-24 1998-02-03 Buchardt, Deceased; Ole Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
DK51092D0 (en) * 1991-05-24 1992-04-15 Ole Buchardt OLIGONUCLEOTIDE ANALOGUE DESCRIBED BY PEN, MONOMERIC SYNTHONES AND PROCEDURES FOR PREPARING THEREOF, AND APPLICATIONS THEREOF
BR9206156A (en) * 1991-06-14 1995-10-17 Isis Pharmaceuticals Inc Oligonucleotide or aligonucleotide analogue process of modulating the expression of the human H-RAS gene process of detecting the presence of the H-RAS gene in cells or tissues process of detecting activated H-RAS based on the differential affinity of particular oligonucleotides by activated H-RAS VS, like, process of treating conditions that arise from the activation of the H-RAS oncogene
US5747253A (en) * 1991-08-23 1998-05-05 Isis Pharmaceuticals, Inc. Combinatorial oligomer immunoabsorbant screening assay for transcription factors and other biomolecule binding
US6335434B1 (en) 1998-06-16 2002-01-01 Isis Pharmaceuticals, Inc., Nucleosidic and non-nucleosidic folate conjugates
US8153602B1 (en) 1991-11-19 2012-04-10 Isis Pharmaceuticals, Inc. Composition and methods for the pulmonary delivery of nucleic acids
US6235887B1 (en) * 1991-11-26 2001-05-22 Isis Pharmaceuticals, Inc. Enhanced triple-helix and double-helix formation directed by oligonucleotides containing modified pyrimidines
TW393513B (en) * 1991-11-26 2000-06-11 Isis Pharmaceuticals Inc Enhanced triple-helix and double-helix formation with oligomers containing modified pyrimidines
EP0616612A4 (en) 1991-12-12 1995-01-11 Gilead Sciences Inc Nuclease stable and binding competent oligomers and methods for their use.
US5359044A (en) * 1991-12-13 1994-10-25 Isis Pharmaceuticals Cyclobutyl oligonucleotide surrogates
JPH06511387A (en) * 1991-12-24 1994-12-22 アイシス・ファーマシューティカルス・インコーポレーテッド Compositions and methods for β-amyloid modulation
ATE515510T1 (en) 1991-12-24 2011-07-15 Isis Pharmaceuticals Inc OLIGONUCLEOTIDES MODIFIED BY DNA SECTIONS
US20060270624A1 (en) * 1991-12-24 2006-11-30 Isis Pharmaceuticals, Inc. Gapped 2' modified oligonucleotides
US5856455A (en) * 1991-12-24 1999-01-05 Isis Pharmaceuticals, Inc. Gapped 2'-modified oligonucleotides
US6153599A (en) * 1992-03-16 2000-11-28 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5681747A (en) * 1992-03-16 1997-10-28 Isis Pharmaceuticals, Inc. Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof
US6117847A (en) * 1992-03-16 2000-09-12 Isis Pharmaceuticals, Inc. Oligonucleotides for enhanced modulation of protein kinase C expression
WO1993019203A1 (en) * 1992-03-16 1993-09-30 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase c
US5916807A (en) * 1992-03-16 1999-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5922686A (en) * 1992-03-16 1999-07-13 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of protein kinase C
US6537973B1 (en) 1992-03-16 2003-03-25 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5882927A (en) * 1992-03-16 1999-03-16 Isis Pharmaceuticals, Inc. Oligonucleotide inhibition of protein kinase C
US5885970A (en) * 1992-03-16 1999-03-23 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against human protein kinase C
US5948898A (en) * 1992-03-16 1999-09-07 Isis Pharmaceuticals, Inc. Methoxyethoxy oligonucleotides for modulation of protein kinase C expression
US5643780A (en) * 1992-04-03 1997-07-01 Isis Pharmaceuticals, Inc. Compositions and methods for modulating RNA activity through modification of the 5' cap structure of RNA
WO1993020236A1 (en) 1992-04-03 1993-10-14 Applied Biosystems, Inc. Probe composition and method
US5817781A (en) 1992-06-01 1998-10-06 Gilead Sciences, Inc. Modified internucleoside linkages (II)
US5434257A (en) * 1992-06-01 1995-07-18 Gilead Sciences, Inc. Binding compentent oligomers containing unsaturated 3',5' and 2',5' linkages
DE69333698T2 (en) * 1992-07-20 2005-12-01 Isis Pharmaceutical, Inc., Carlsbad PSEUDO HALF NODES FORMING RNA BY HYBRIDIZING ANTISSESEOLIGON NUCLEOTIDES TO TARGETED RNA SECONDARY STRUCTURES
US20040049021A1 (en) * 1992-09-10 2004-03-11 Anderson Kevin P. Compositions and mehtods for treatment of Hepatitis C virus-associated diseases
US6174868B1 (en) 1992-09-10 2001-01-16 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6423489B1 (en) 1992-09-10 2002-07-23 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
US6391542B1 (en) 1992-09-10 2002-05-21 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus-associated diseases
WO1994005813A1 (en) * 1992-09-10 1994-03-17 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Compositions and methods for treatment of hepatitis c virus-associated diseases
US6433159B1 (en) 1992-09-10 2002-08-13 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of Hepatitis C virus associated diseases
US6995146B2 (en) 1992-09-10 2006-02-07 Isis Pharmaceuticals, Inc. Compositions and methods for treatment of hepatitis C virus-associated diseases
US6235886B1 (en) 1993-09-03 2001-05-22 Isis Pharmaceuticals, Inc. Methods of synthesis and use
AU4848793A (en) 1992-09-11 1994-04-12 Isis Pharmaceuticals, Inc. Oligonucleotide and nucleotide amine analogs, methods of synthesis and use
US5523389A (en) * 1992-09-29 1996-06-04 Isis Pharmaceuticals, Inc. Inhibitors of human immunodeficiency virus
US20030013670A1 (en) * 1992-10-05 2003-01-16 Monia Brett P. Antisense oligonucleotide inhibition of ras
US5872242A (en) * 1992-10-05 1999-02-16 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
US6784290B1 (en) 1992-10-05 2004-08-31 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of ras
EP0670897A4 (en) * 1992-10-05 1997-08-06 Isis Pharmaceuticals Inc ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE.
AU679566B2 (en) 1993-09-03 1997-07-03 Isis Pharmaceuticals, Inc. Amine-derivatized nucleosides and oligonucleosides
US5801154A (en) * 1993-10-18 1998-09-01 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of multidrug resistance-associated protein
US5510239A (en) * 1993-10-18 1996-04-23 Isis Pharmaceuticals, Inc. Oligonucleotide modulation of multidrug resistance-associated protein
US6399376B1 (en) 1993-11-05 2002-06-04 Isis Pharmaceuticals, Inc. Modulation of vascular cell adhesive molecule expression through oligonucleotide interactions
US6710164B1 (en) 1993-11-22 2004-03-23 Peter E. Nielsen Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility
US20060142236A1 (en) * 1994-05-31 2006-06-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6410518B1 (en) 1994-05-31 2002-06-25 Isis Pharmaceuticals, Inc. Antisense oligonucleotide inhibition of raf gene expression
US6391636B1 (en) 1994-05-31 2002-05-21 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US6090626A (en) * 1994-05-31 2000-07-18 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of raf gene expression
US5656612A (en) * 1994-05-31 1997-08-12 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
US20030119769A1 (en) * 1994-05-31 2003-06-26 Monia Brett P Antisense oligonucleotide modulation of raf gene expression
US5981731A (en) * 1994-05-31 1999-11-09 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of B-raf gene expression
US5563255A (en) * 1994-05-31 1996-10-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of raf gene expression
KR100211178B1 (en) * 1994-05-31 1999-07-15 파샬 비. 린네 Antisense oligonucleotide modulation of raf gene expression
AU3143695A (en) * 1994-07-25 1996-02-22 Hybridon, Inc. Improved methods of detritylation for oligonucleotide synthesis
US5665873A (en) * 1995-02-09 1997-09-09 Dana Farber Cancer Institute Glucocorticoid response elements
US6420549B1 (en) 1995-06-06 2002-07-16 Isis Pharmaceuticals, Inc. Oligonucleotide analogs having modified dimers
DE69629702T2 (en) * 1995-08-01 2004-06-17 Isis Pharmaceuticals, Inc., Carlsbad LIPOSOMAL OLIGONUCLEOTIDE COMPOSITIONS
US5854033A (en) 1995-11-21 1998-12-29 Yale University Rolling circle replication reporter systems
US7244622B2 (en) * 1996-04-03 2007-07-17 Applera Corporation Device and method for multiple analyte detection
US7812149B2 (en) 1996-06-06 2010-10-12 Isis Pharmaceuticals, Inc. 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations
US20050032068A1 (en) * 2002-11-05 2005-02-10 Prakash Thazha P. Sugar and backbone-surrogate-containing oligomeric compounds and compositions for use in gene modulation
US20070275921A1 (en) * 1996-06-06 2007-11-29 Isis Pharmaceuticals, Inc. Oligomeric Compounds That Facilitate Risc Loading
US7875733B2 (en) * 2003-09-18 2011-01-25 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising 4′-thionucleosides for use in gene modulation
US20040266706A1 (en) * 2002-11-05 2004-12-30 Muthiah Manoharan Cross-linked oligomeric compounds and their use in gene modulation
US20040171030A1 (en) * 1996-06-06 2004-09-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to cytosine and uracil or thymine and their use in gene modulation
US20050118605A9 (en) * 1996-06-06 2005-06-02 Baker Brenda F. Oligomeric compounds having modified bases for binding to adenine and guanine and their use in gene modulation
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20030044941A1 (en) 1996-06-06 2003-03-06 Crooke Stanley T. Human RNase III and compositions and uses thereof
US9096636B2 (en) * 1996-06-06 2015-08-04 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US6593305B1 (en) * 1996-08-02 2003-07-15 Genesense Technologies Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
US5948681A (en) * 1996-08-14 1999-09-07 Children's Hospital Of Philadelphia Non-viral vehicles for use in gene transfer
US6111085A (en) 1996-09-13 2000-08-29 Isis Pharmaceuticals, Inc. Carbamate-derivatized nucleosides and oligonucleosides
KR20000048820A (en) 1996-10-01 2000-07-25 게론 코포레이션 Telomerase reverse transcriptase
US6001991A (en) * 1996-10-04 1999-12-14 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of MDR P-glycoprotein gene expression
US5919638A (en) * 1996-10-08 1999-07-06 Abbott Laboratories Reagents and methods useful for detecting prostate tumors
US20030165971A1 (en) * 1996-10-31 2003-09-04 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
US20050202499A1 (en) * 1996-10-31 2005-09-15 Billing-Medel Patricia A. Reagents and methods useful for detecting diseases of the breast
US7235653B2 (en) * 1996-12-31 2007-06-26 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6319906B1 (en) 1996-12-31 2001-11-20 Isis Pharmaceuticals Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US6077833A (en) * 1996-12-31 2000-06-20 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20040023917A1 (en) * 1996-12-31 2004-02-05 Bennett C. Frank Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
JP2001509167A (en) * 1997-01-24 2001-07-10 エイブイアイ バイオファーマ,インコーポレイテッド H. Methods and conjugates for treating pylori infection
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
US6576752B1 (en) 1997-02-14 2003-06-10 Isis Pharmaceuticals, Inc. Aminooxy functionalized oligomers
US6172209B1 (en) 1997-02-14 2001-01-09 Isis Pharmaceuticals Inc. Aminooxy-modified oligonucleotides and methods for making same
US20020137904A1 (en) * 1998-03-27 2002-09-26 Patricia A. Billing-Medel Reagents and methods useful for detecting diseases of the gastrointestinal tract
US6716625B1 (en) 1997-04-16 2004-04-06 Claude Selitrennikoff Histidine kinases of Aspergillus and other fungal species, related compositions, and methods of use
US20050208567A1 (en) * 1997-04-25 2005-09-22 Billing-Medel Patricia A Reagents and methods useful for detecting diseases of the prostate
US6528271B1 (en) * 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
US7541151B2 (en) 1997-06-05 2009-06-02 Duke University Single-cell biosensor for the measurement of GPCR ligands in a test sample
US5891646A (en) * 1997-06-05 1999-04-06 Duke University Methods of assaying receptor activity and constructs useful in such methods
US5962665A (en) 1997-06-16 1999-10-05 Abbott Laboratories Nucleic acid primers and probes for detecting HIV-1 and HIV-2
AU731909B2 (en) 1997-07-01 2001-04-05 Isis Pharmaceuticals, Inc. Compositions and methods for the delivery of oligonucleotides via the alimentary canal
WO1999001139A1 (en) 1997-07-03 1999-01-14 Thomas Jefferson University An improved method for design and selection of efficacious antisense oligonucleotides
US7105496B2 (en) 1998-07-23 2006-09-12 Northwestern University Methods and compositions for inhibiting angiogenesis
US6797691B1 (en) 1997-07-23 2004-09-28 Northwestern University Methods and compositions for inhibiting angiogenesis
US5877309A (en) * 1997-08-13 1999-03-02 Isis Pharmaceuticals, Inc. Antisense oligonucleotides against JNK
US20070149472A1 (en) * 1997-08-13 2007-06-28 Mckay Robert Antisense oligonucleotide compositions and methods for the modulation of jnk proteins
US6809193B2 (en) 1997-08-13 2004-10-26 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6133246A (en) * 1997-08-13 2000-10-17 Isis Pharmaceuticals Inc. Antisense oligonucleotide compositions and methods for the modulation of JNK proteins
US6383808B1 (en) 2000-09-11 2002-05-07 Isis Pharmaceuticals, Inc. Antisense inhibition of clusterin expression
US7252950B1 (en) 1997-09-04 2007-08-07 The Regents Of The University Of California Assays for detecting modulators of cytoskeletal function
US7115884B1 (en) 1997-10-06 2006-10-03 Trustees Of Tufts College Self-encoding fiber optic sensor
US20040171564A1 (en) * 1997-11-20 2004-09-02 Honkanen Richard E. Antisense oligonucleotide modulation of human serine/threonine protein phosphatase gene expression
US5948902A (en) 1997-11-20 1999-09-07 South Alabama Medical Science Foundation Antisense oligonucleotides to human serine/threonine protein phosphatase genes
EP1049475A4 (en) 1998-01-08 2003-06-04 Univ California KINESIN MOTOR MODULATORS DERIVED FROM THE MARINE SPONGE $i(ADOCIA)
US7189703B2 (en) * 1998-01-09 2007-03-13 Intracell, Llc Treatment and diagnosis of alzheimer's disease
US6764830B1 (en) 1998-01-23 2004-07-20 The Regents Of The University Of California Thermomyces lanuginosus kinesin motor protein and methods of screening for modulators of kinesin proteins
US6326479B1 (en) 1998-01-27 2001-12-04 Boston Probes, Inc. Synthetic polymers and methods, kits or compositions for modulating the solubility of same
BR9907990A (en) 1998-01-30 2000-10-24 Genesense Technologies Inc Sequence of oligonucleotides complementary to the thioredoxin or thioredoxin reductase genes and methods of using them to modulate cell growth
WO2000018885A1 (en) * 1998-09-29 2000-04-06 Gamida Cell Ltd. Methods of controlling proliferation and differentiation of stem and progenitor cells
US5968748A (en) * 1998-03-26 1999-10-19 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of human HER-2 expression
US20040186071A1 (en) 1998-04-13 2004-09-23 Bennett C. Frank Antisense modulation of CD40 expression
US7321828B2 (en) 1998-04-13 2008-01-22 Isis Pharmaceuticals, Inc. System of components for preparing oligonucleotides
US6417169B1 (en) * 1998-04-23 2002-07-09 Genesense Technologies Inc. Insulin-like growth factor II antisense oligonucleotide sequences and methods of using same to inhibit cell growth
CA2329252A1 (en) 1998-05-21 1999-11-25 Isis Pharmaceuticals Inc. Compositions and methods for topical delivery of oligonucleotides
AU745880B2 (en) 1998-05-21 2002-04-11 Isis Pharmaceuticals, Inc. Compositions and methods for non-parenteral delivery of oligonucleotides
US6586192B1 (en) 1998-05-29 2003-07-01 Thomas Jefferson University Compositions and methods for use in affecting hematopoietic stem cell populations in mammals
ATE423314T1 (en) 1998-06-24 2009-03-15 Illumina Inc DECODING OF MATRIXED SENSORS BY MICROPARTICLES
US6242589B1 (en) 1998-07-14 2001-06-05 Isis Pharmaceuticals, Inc. Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en) 1998-07-14 2005-03-15 Isis Pharmaceuticals, Inc. Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US7002003B1 (en) 1998-07-30 2006-02-21 University Of South Florida Method for the inhibition of function of STAT transcription factors
US6043352A (en) 1998-08-07 2000-03-28 Isis Pharmaceuticals, Inc. 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides
US20040009938A1 (en) * 1998-08-07 2004-01-15 Muthiah Manoharan Methods of enhancing renal uptake of oligonucleotides
US6673912B1 (en) 1998-08-07 2004-01-06 Isis Pharmaceuticals, Inc. 2′-O-aminoethyloxyethyl-modified oligonucleotides
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
US6175004B1 (en) 1998-09-01 2001-01-16 Isis Pharmaceuticals, Inc. Process for the synthesis of oligonucleotides incorporating 2-aminoadenosine
US6225293B1 (en) 1998-09-02 2001-05-01 Isis Pharmaceuticals, Inc. Methods and compounds for tracking the biodistribution of macromolecule-carrier combinations
US6077709A (en) 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6335194B1 (en) 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6069243A (en) * 1998-10-06 2000-05-30 Isis Pharmaceuticals, Inc. Process for oligonucleotide synthesis
US6214986B1 (en) * 1998-10-07 2001-04-10 Isis Pharmaceuticals, Inc. Antisense modulation of bcl-x expression
US6172216B1 (en) * 1998-10-07 2001-01-09 Isis Pharmaceuticals Inc. Antisense modulation of BCL-X expression
US20020138856A1 (en) * 1998-10-23 2002-09-26 Northwestern University Compositions and methods useful for treatment of depressive disorder based on an animal model
US6429027B1 (en) 1998-12-28 2002-08-06 Illumina, Inc. Composite arrays utilizing microspheres
US6300320B1 (en) 1999-01-05 2001-10-09 Isis Pharmaceuticals, Inc. Modulation of c-jun using inhibitors of protein kinase C
US6395029B1 (en) 1999-01-19 2002-05-28 The Children's Hospital Of Philadelphia Sustained delivery of polyionic bioactive agents
WO2000041731A1 (en) 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Reverse gene therapy
WO2000041732A1 (en) 1999-01-19 2000-07-20 The Children's Hospital Of Philadelphia Hydrogel compositions for controlled delivery of virus vectors and methods of use thereof
US7282489B2 (en) * 2000-01-19 2007-10-16 The Children's Hospital Of Philadelphia Compositions and methods for performing reverse gene therapy
US6127124A (en) * 1999-01-20 2000-10-03 Isis Pharmaceuticals, Inc. Fluorescence based nuclease assay
JP2002535015A (en) * 1999-01-29 2002-10-22 エイブイアイ バイオファーマ, インコーポレイテッド Non-invasive method for detecting target RNA
US6121000A (en) * 1999-02-11 2000-09-19 Genesense Technologies, Inc. Antitumor antisense sequences directed against R1 and R2 components of ribonucleotide reductase
ES2296613T3 (en) * 1999-03-18 2008-05-01 Queen Mary And Westfield College INHIBITORS OF ENDOTHELINE SYNTHESIS-1.
US6235891B1 (en) 1999-03-31 2001-05-22 South Alabama Medical Science Foundation Glucocorticoid receptor agonist and decreased PP5
CA2364305A1 (en) 1999-03-31 2000-10-05 The University Of North Carolina At Chapel Hill Isolated dna encoding cullin regulators roc1 and roc2, isolated proteins encoded by the same, and methods utilizing the same
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US20060275782A1 (en) 1999-04-20 2006-12-07 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
AU4476900A (en) 1999-04-20 2000-11-02 Illumina, Inc. Detection of nucleic acid reactions on bead arrays
US20030215821A1 (en) * 1999-04-20 2003-11-20 Kevin Gunderson Detection of nucleic acid reactions on bead arrays
US6331618B1 (en) 1999-05-13 2001-12-18 Pe Corporation (Ny) Compositions of solvents and high concentrations of nucleic acid analogs
WO2000075373A2 (en) 1999-05-20 2000-12-14 Illumina, Inc. Combinatorial decoding of random nucleic acid arrays
US8481268B2 (en) 1999-05-21 2013-07-09 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
US8080380B2 (en) * 1999-05-21 2011-12-20 Illumina, Inc. Use of microfluidic systems in the detection of target analytes using microsphere arrays
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US6656730B1 (en) 1999-06-15 2003-12-02 Isis Pharmaceuticals, Inc. Oligonucleotides conjugated to protein-binding drugs
US6593466B1 (en) 1999-07-07 2003-07-15 Isis Pharmaceuticals, Inc. Guanidinium functionalized nucleotides and precursors thereof
US6147200A (en) * 1999-08-19 2000-11-14 Isis Pharmaceuticals, Inc. 2'-O-acetamido modified monomers and oligomers
US7332275B2 (en) 1999-10-13 2008-02-19 Sequenom, Inc. Methods for detecting methylated nucleotides
US20020165188A1 (en) * 1999-10-14 2002-11-07 Meenhard Herlyn Methods for inhibition of tumorigenic properties of melanoma cells
AU2698301A (en) * 1999-12-30 2001-07-16 K.U. Leuven Research And Development Cyclohexene nucleic acids
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
EP1257668B1 (en) 2000-02-16 2008-10-29 Illumina, Inc. Parallel genotyping of multiple patient samples
US6846486B1 (en) 2000-02-24 2005-01-25 Advanced Biotherapy Concepts, Inc. Method of treating allergy by administering an anti-histamine antibody
WO2001074845A2 (en) * 2000-03-31 2001-10-11 Aventis Pasteur Limited Immunogenic peptides derived from prostate-specific membrane antigen (psma) and uses thereof
AU5340801A (en) * 2000-04-13 2001-10-30 Thomas N Wight Therapeutic compounds and methods
AU5345901A (en) * 2000-04-13 2001-10-30 Univ Rockefeller Enhancement of antibody-mediated immune responses
KR20020097241A (en) 2000-05-04 2002-12-31 에이브이아이 바이오파마 인코포레이티드 Splice-region antisense composition and method
US6680172B1 (en) 2000-05-16 2004-01-20 Regents Of The University Of Michigan Treatments and markers for cancers of the central nervous system
US6656700B2 (en) * 2000-05-26 2003-12-02 Amersham Plc Isoforms of human pregnancy-associated protein-E
US6686188B2 (en) * 2000-05-26 2004-02-03 Amersham Plc Polynucleotide encoding a human myosin-like polypeptide expressed predominantly in heart and muscle
CA2410950A1 (en) * 2000-05-30 2001-12-06 Hans-Michael Wenz Methods for detecting target nucleic acids using coupled ligation and amplification
US20060166227A1 (en) * 2000-06-20 2006-07-27 Stephen Kingsmore Protein expression profiling
EP3020804A1 (en) 2000-07-06 2016-05-18 Sarepta Therapeutics, Inc. Transforming growth factor beta (tgf- ) blocking agent-treated stem cell composition and method
FR2811323B1 (en) * 2000-07-07 2006-10-06 Fuma Tech Gmbh HYBRID MATERIAL, USE OF SAID HYBRID MATERIAL, AND METHOD OF MANUFACTURING THE SAME
US6958214B2 (en) * 2000-07-10 2005-10-25 Sequenom, Inc. Polymorphic kinase anchor proteins and nucleic acids encoding the same
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
US7105962B2 (en) * 2000-08-03 2006-09-12 Matsushita Electric Industrial Co., Ltd. Brushless motor for partable electronic equipment with wire treatment technique of coils
US20080194022A1 (en) * 2000-08-03 2008-08-14 Clarke Michael F Isolation and use of solid tumor stem cells
US6984522B2 (en) * 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8568766B2 (en) 2000-08-24 2013-10-29 Gattadahalli M. Anantharamaiah Peptides and peptide mimetics to treat pathologies associated with eye disease
US7264925B2 (en) * 2000-08-30 2007-09-04 Avi Biopharma, Inc. Method for analysis of oligonucleotide analogs
AU2001290629A1 (en) * 2000-09-07 2002-03-22 Boehringer Ingelheim International G.M.B.H Heat shock response and virus replication
ES2291362T3 (en) * 2000-09-14 2008-03-01 Mount Sinai School Of Medicine SCREENING PROCEDURES TO IDENTIFY G PROTEINS AND OTHER COMPOUNDS THAT MODULATE PHOSPHODESTERASE ACTIVITY (PDE).
EP1191097A1 (en) * 2000-09-21 2002-03-27 Leids Universitair Medisch Centrum Induction of exon skipping in eukaryotic cells
US20030044803A1 (en) * 2000-09-22 2003-03-06 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of JAK1
US20020164576A1 (en) * 2000-09-22 2002-11-07 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Nrf2
US20020115058A1 (en) * 2000-09-22 2002-08-22 Pedersen Finn Skou Methods for diagnosis and treatment of diseases associated with altered expression of Pik3r1
US20020123474A1 (en) * 2000-10-04 2002-09-05 Shannon Mark E. Human GTP-Rho binding protein2
EP2336166A1 (en) 2000-10-12 2011-06-22 University Of Rochester Compositions that inhibit proliferation of cancer cells
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
EP1736760A3 (en) 2000-12-11 2008-06-18 President And Fellows Of Harvard College Nanosensors
US7645441B2 (en) * 2000-12-22 2010-01-12 Sagres Discovery Inc. Compositions and methods in cancer associated with altered expression of PRLR
US7700274B2 (en) * 2000-12-22 2010-04-20 Sagres Discovery, Inc. Compositions and methods in cancer associated with altered expression of KCNJ9
US20030099963A1 (en) * 2000-12-22 2003-05-29 Morris David W. Novel compositions and methods in cancer associated with altered expression of TBX21
US7820447B2 (en) * 2000-12-22 2010-10-26 Sagres Discovery Inc. Compositions and methods for cancer
US20030087252A1 (en) * 2000-12-22 2003-05-08 Morris David W. Novel compositions and methods in cancer associated with altered expression of PRDM11
US20030232334A1 (en) * 2000-12-22 2003-12-18 Morris David W. Novel compositions and methods for cancer
US7892730B2 (en) 2000-12-22 2011-02-22 Sagres Discovery, Inc. Compositions and methods for cancer
US20030165878A1 (en) * 2000-12-22 2003-09-04 Morris David W. Novel compositions and methods in cancer associated with altered expression of MCM3AP
US7767802B2 (en) 2001-01-09 2010-08-03 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of anti-apoptotic genes
US7279324B2 (en) * 2001-01-23 2007-10-09 Duke University Nucleic acid encoding G-protein coupled receptor with modified DRY motif
US20030036854A1 (en) * 2001-02-06 2003-02-20 The Penn State Research Foundation Apparatus and method for designing proteins and protein libraries
US6573051B2 (en) * 2001-03-09 2003-06-03 Molecular Staging, Inc. Open circle probes with intramolecular stem structures
US7208279B2 (en) * 2001-03-14 2007-04-24 Caden Biosciences, Inc. Method for identifying inhibitors of G protein coupled receptor signaling
US7294472B2 (en) * 2001-03-14 2007-11-13 Caden Biosciences Method for identifying modulators of G protein coupled receptor signaling
ATE434936T1 (en) 2001-03-14 2009-07-15 Myriad Genetics Inc TSG101-GAG INTERACTION AND THEIR USE
US7803982B2 (en) 2001-04-20 2010-09-28 The Mount Sinai School Of Medicine Of New York University T1R3 transgenic animals, cells and related methods
US20040219632A1 (en) * 2001-04-20 2004-11-04 Robert Margolskee T1r3 a novel taste receptor
EP1470245A4 (en) * 2001-04-24 2005-08-31 Pharmacia & Upjohn Co Llc Single nucleotide polymorphisms diagnostic for schizophrenia
EP1392272B1 (en) 2001-05-11 2014-08-06 Merrion Research III Limited Permeation enhancers
EP1992643A3 (en) 2001-06-20 2008-12-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US7803915B2 (en) 2001-06-20 2010-09-28 Genentech, Inc. Antibody compositions for the diagnosis and treatment of tumor
CA2790034A1 (en) 2001-06-21 2003-01-03 Isis Pharmaceuticals, Inc. Antisense modulation of superoxide dismutase 1, soluble expression
EP1925672A1 (en) 2001-06-22 2008-05-28 Syngeta Participations AG Abiotic stress responsive polynucleotides and polypeptides
WO2003004610A2 (en) * 2001-07-06 2003-01-16 Regents Of The University Of Minnesota Hsst and angiogenesis
WO2003067210A2 (en) 2001-07-10 2003-08-14 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for detecting the activation state of the multiple proteins in single cells
US7393656B2 (en) 2001-07-10 2008-07-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for risk stratification
US7381535B2 (en) 2002-07-10 2008-06-03 The Board Of Trustees Of The Leland Stanford Junior Methods and compositions for detecting receptor-ligand interactions in single cells
EP1481076A4 (en) 2001-07-12 2005-05-11 Illumina Inc Multiplex nucleic acid reactions
US7425545B2 (en) 2001-07-25 2008-09-16 Isis Pharmaceuticals, Inc. Modulation of C-reactive protein expression
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7229774B2 (en) 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
WO2003013437A2 (en) * 2001-08-07 2003-02-20 University Of Delaware Compositions and methods for the prevention and treatment of huntington's disease
US20040096880A1 (en) * 2001-08-07 2004-05-20 Kmiec Eric B. Compositions and methods for the treatment of diseases exhibiting protein misassembly and aggregation
JP2005515468A (en) * 2001-08-20 2005-05-26 リジェネシス バイオリメディエイション プロダクツ Biosensors for analytes of small molecules
US20040115699A1 (en) * 2001-08-28 2004-06-17 Kaytes Paul S. Single nucleotide polymorphisms diagnostic for schizophrenia
EP1423536A2 (en) * 2001-08-28 2004-06-02 PHARMACIA &amp; UPJOHN COMPANY Single nucleotide polymorphisms diagnostic for schizophrenia
US6852491B2 (en) 2001-09-04 2005-02-08 Abbott Laboratories Amplification and detection reagents for HIV-1
US7214428B2 (en) * 2001-09-17 2007-05-08 Invitrogen Corporation Highly luminescent functionalized semiconductor nanocrystals for biological and physical applications
JP2005513471A (en) 2001-09-17 2005-05-12 バイオクリスタル・リミテッド Nanocrystal
EP1721977A3 (en) 2001-09-17 2008-10-15 PDL BioPharma, Inc. Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer
US7205048B2 (en) 2001-09-17 2007-04-17 Invitrogen Corporation Functionalized fluorescent nanocrystal compositions and methods of making
WO2003024392A2 (en) 2001-09-18 2003-03-27 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20070098728A1 (en) * 2001-09-24 2007-05-03 Pedersen Finn S Novel compositions and methods in cancer
CA2495529C (en) 2001-10-01 2009-05-19 Mount Sinai School Of Medicine Of New York University Noonan syndrome gene
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
NZ566396A (en) 2001-10-09 2009-07-31 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expressions
CN105131104B (en) 2001-10-10 2018-11-16 诺和诺德公司 The reconstruct and sugar conjugation of peptide
NZ532027A (en) 2001-10-10 2008-09-26 Neose Technologies Inc Remodeling and glycoconjugation of peptides
US8323903B2 (en) * 2001-10-12 2012-12-04 Life Technologies Corporation Antibody complexes and methods for immunolabeling
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
WO2003088808A2 (en) 2002-04-16 2003-10-30 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20040126762A1 (en) * 2002-12-17 2004-07-01 Morris David W. Novel compositions and methods in cancer
US20040166490A1 (en) * 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20030124592A1 (en) * 2001-10-24 2003-07-03 Bioprofile, Llc Methods for detecting genetic haplotypes by interaction with probes
WO2003054143A2 (en) * 2001-10-25 2003-07-03 Neurogenetics, Inc. Genes and polymorphisms on chromosome 10 associated with alzheimer's disease and other neurodegenerative diseases
US20030224380A1 (en) * 2001-10-25 2003-12-04 The General Hospital Corporation Genes and polymorphisms on chromosome 10 associated with Alzheimer's disease and other neurodegenerative diseases
US20030170678A1 (en) * 2001-10-25 2003-09-11 Neurogenetics, Inc. Genetic markers for Alzheimer's disease and methods using the same
EP1444246B1 (en) * 2001-10-26 2015-12-30 Danisco US Inc. Trichoderma reesei phytase enzymes, nucleic acids encoding such phytase enzymes, vectors and host cells incorporating same and methods of making and using same
AU2002356855A1 (en) 2001-10-26 2003-05-12 Genencor International, Inc. Phytase enzymes, nucleic acid sequences encoding phytase enzymes and vectors and host cells incorporating same
AU2002360349A1 (en) * 2001-11-09 2003-05-26 Pharmacia And Upjohn Company Single nucleotide polymorphisms in gh-1
US20060040262A1 (en) * 2002-12-27 2006-02-23 Morris David W Novel compositions and methods in cancer
US20040180344A1 (en) * 2003-03-14 2004-09-16 Morris David W. Novel therapeutic targets in cancer
US20040197778A1 (en) * 2002-12-26 2004-10-07 Sagres Discovery, Inc. Novel compositions and methods in cancer
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1575571A4 (en) 2002-01-02 2008-06-25 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor
WO2003057916A2 (en) 2002-01-09 2003-07-17 Riken Cancer profiles
IL152904A0 (en) 2002-01-24 2003-06-24 Gamida Cell Ltd Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
WO2003062404A1 (en) * 2002-01-25 2003-07-31 Gamida-Cell Ltd. Methods of expanding stem and progenitor cells and expanded cell populations obtained thereby
US7553619B2 (en) 2002-02-08 2009-06-30 Qiagen Gmbh Detection method using dissociated rolling circle amplification
US7499806B2 (en) * 2002-02-14 2009-03-03 Illumina, Inc. Image processing in microsphere arrays
US20030191075A1 (en) * 2002-02-22 2003-10-09 Cook Phillip Dan Method of using modified oligonucleotides for hepatic delivery
EP2110434A1 (en) 2002-02-25 2009-10-21 Genentech, Inc. Type-1 cytokine receptor GLM-R
US20030182669A1 (en) * 2002-03-19 2003-09-25 Rockman Howard A. Phosphoinositide 3-kinase mediated inhibition of GPCRs
US20030180712A1 (en) 2002-03-20 2003-09-25 Biostratum Ab Inhibition of the beta3 subunit of L-type Ca2+ channels
JP2005520543A (en) 2002-03-21 2005-07-14 サイグレス ディスカバリー, インコーポレイテッド Novel compositions and methods in cancer
US7332585B2 (en) 2002-04-05 2008-02-19 The Regents Of The California University Bispecific single chain Fv antibody molecules and methods of use thereof
US7026120B2 (en) 2002-04-15 2006-04-11 Abbott Laboratories Probes for detecting tumor cells
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
US7297484B2 (en) 2002-04-26 2007-11-20 Idaho Technology Characterization of single stranded nucleic acids by melting analysis of secondary structure using double strand-specific nucleic acid dye
AU2003221575B2 (en) 2002-05-02 2010-06-10 Dalia Barsyte Teneurin C-terminal associated peptides (TCAP) and uses thereof
US7015317B2 (en) * 2002-05-02 2006-03-21 Abbott Laboratories Polynucleotides for the detection and quantification of hepatitis B virus nucleic acids
WO2003093296A2 (en) 2002-05-03 2003-11-13 Sequenom, Inc. Kinase anchor protein muteins, peptides thereof, and related methods
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
US7176181B2 (en) * 2002-05-21 2007-02-13 Yeda Research And Development Co. Ltd. Compositions and methods of using galectin-8 as an inhibitor of tumor cell growth
US7199107B2 (en) 2002-05-23 2007-04-03 Isis Pharmaceuticals, Inc. Antisense modulation of kinesin-like 1 expression
JP4646625B2 (en) 2002-05-30 2011-03-09 メモリアル スローン−ケタリング キャンサー センター Ras inactivated kinase suppressor for the treatment of Ras mediated tumorigenesis
US7290215B2 (en) * 2002-06-03 2007-10-30 Microsoft Corporation Dynamic wizard interface system and method
AU2003231912A1 (en) * 2002-06-12 2003-12-31 Tel Aviv Medical Center Research Development Fund Methods of detecting and treating prostate cancer
WO2003105780A2 (en) * 2002-06-18 2003-12-24 Epigenesis Pharmaceuticals, Inc. A dry powder oligonucleotide formulation, preparation and its uses
AU2003257181A1 (en) 2002-08-05 2004-02-23 University Of Rochester Protein transducing domain/deaminase chimeric proteins, related compounds, and uses thereof
AU2003258157A1 (en) * 2002-08-12 2004-02-25 Genencor International, Inc. Mutant e. coli appa phytase enzymes
CA2498928A1 (en) * 2002-09-12 2004-03-25 Massachusetts Institute Of Technology Rb pathway and chromatin remodeling genes that antagonize let-60 ras signaling
EP1537208A1 (en) 2002-09-13 2005-06-08 Replicor, Inc. Non-sequence complementary antiviral oligonucleotides
CA2499770A1 (en) * 2002-09-20 2004-04-01 Yale University Riboswitches, methods for their use, and compositions for use with riboswitches.
WO2004031350A2 (en) 2002-09-26 2004-04-15 Amgen, Inc. Modulation of forkhead box o1a expression
US20040235005A1 (en) * 2002-10-23 2004-11-25 Ernest Friedlander Methods and composition for detecting targets
AU2003291753B2 (en) * 2002-11-05 2010-07-08 Isis Pharmaceuticals, Inc. Polycyclic sugar surrogate-containing oligomeric compounds and compositions for use in gene modulation
CA2504720C (en) 2002-11-05 2013-12-24 Isis Pharmaceuticals, Inc. Chimeric oligomeric compounds and their use in gene modulation
US9150606B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2'-modified nucleosides for use in gene modulation
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
WO2004044139A2 (en) * 2002-11-05 2004-05-27 Isis Parmaceuticals, Inc. Modified oligonucleotides for use in rna interference
US7807802B2 (en) 2002-11-12 2010-10-05 Abbott Lab Polynucleotides for the amplification and detection of Chlamydia trachomatis and Neisseria gonorrhoeae
CA2505801A1 (en) 2002-11-13 2004-05-27 Rosanne Crooke Antisense modulation of apolipoprotein b expression
DK1569695T3 (en) 2002-11-13 2013-08-05 Genzyme Corp ANTISENSE MODULATION OF APOLIPOPROTEIN-B EXPRESSION
US20060009378A1 (en) * 2002-11-14 2006-01-12 Itshak Golan Novel galectin sequences and compositions and methods utilizing same for treating or diagnosing arthritis and other chronic inflammatory diseases
EP2292259A3 (en) 2002-11-15 2011-03-23 MUSC Foundation For Research Development Complement receptor 2 targeted complement modulators
WO2004046330A2 (en) 2002-11-15 2004-06-03 Morphotek, Inc. Methods of generating high-production of antibodies from hybridomas created by in vitro immunization
US20040166514A1 (en) * 2002-11-19 2004-08-26 Singulex, Inc. Detection of target molecules through interaction with probes
AU2003294462C1 (en) 2002-11-21 2011-06-30 University Of Utah Research Foundation Purinergic modulation of smell
US7144999B2 (en) 2002-11-23 2006-12-05 Isis Pharmaceuticals, Inc. Modulation of hypoxia-inducible factor 1 alpha expression
WO2004056868A2 (en) * 2002-12-19 2004-07-08 Endocube Sas Nf-hev compositions and methods of use
CA2510587A1 (en) 2002-12-20 2004-07-15 Qiagen Gmbh Nucleic acid amplification
US9487823B2 (en) 2002-12-20 2016-11-08 Qiagen Gmbh Nucleic acid amplification
US6977153B2 (en) * 2002-12-31 2005-12-20 Qiagen Gmbh Rolling circle amplification of RNA
JP4177123B2 (en) * 2003-01-10 2008-11-05 富士通株式会社 Wiring pattern verification method, program and apparatus
US9169516B2 (en) 2003-01-24 2015-10-27 University Of Utah Research Foundation Methods of predicting mortality risk by determining telomere length
NZ541637A (en) 2003-02-11 2008-07-31 Antisense Therapeutics Pty Ltd Modulation of insulin like growth factor I receptor
US7002006B2 (en) * 2003-02-12 2006-02-21 Isis Pharmaceuticals, Inc. Protection of nucleosides
US20040170982A1 (en) 2003-02-14 2004-09-02 Morris David W. Novel therapeutic targets in cancer
US7767387B2 (en) * 2003-06-13 2010-08-03 Sagres Discovery, Inc. Therapeutic targets in cancer
CA2516138A1 (en) 2003-02-14 2004-09-02 Sagres Discovery, Inc. Therapeutic gpcr targets in cancer
US6943768B2 (en) 2003-02-21 2005-09-13 Xtellus Inc. Thermal control system for liquid crystal cell
AU2004215133B2 (en) 2003-02-27 2010-10-14 Yeda Research And Development Co. Ltd. Nucleic acid molecules, polypeptides, antibodies and compositions containing same useful for treating and detecting influenza virus infection
US7803781B2 (en) 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
CA2524255C (en) 2003-03-21 2014-02-11 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mrna by interfering with the secondary rna structure
US20040185559A1 (en) 2003-03-21 2004-09-23 Isis Pharmaceuticals Inc. Modulation of diacylglycerol acyltransferase 1 expression
US8043834B2 (en) 2003-03-31 2011-10-25 Qiagen Gmbh Universal reagents for rolling circle amplification and methods of use
AU2003237792A1 (en) 2003-04-01 2004-11-23 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
US20070026485A1 (en) 2003-04-09 2007-02-01 Neose Technologies, Inc. Glycopegylation methods and proteins/peptides produced by the methods
EP1618199A2 (en) * 2003-04-10 2006-01-25 Aristex Affinity purification system using troponin molecules as affinity ligands
US7598227B2 (en) 2003-04-16 2009-10-06 Isis Pharmaceuticals Inc. Modulation of apolipoprotein C-III expression
US7399853B2 (en) 2003-04-28 2008-07-15 Isis Pharmaceuticals Modulation of glucagon receptor expression
CA2523672C (en) 2003-04-29 2012-07-17 Avi Biopharma, Inc. Compositions for enhancing transport of molecules into cells
US20040219533A1 (en) * 2003-04-29 2004-11-04 Jim Davis Biological bar code
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
US20050025763A1 (en) 2003-05-08 2005-02-03 Protein Design Laboratories, Inc. Therapeutic use of anti-CS1 antibodies
EP1624936B1 (en) * 2003-05-16 2009-10-28 Universite Laval Cns chloride modulation and uses thereof
US7960355B2 (en) * 2003-05-23 2011-06-14 Isis Pharmaceuticals, Inc. Compositions and methods for the modulation of the expression of B7 protein
US7897582B2 (en) * 2003-05-23 2011-03-01 Isis Pharmaceuticals, Inc. Oligonucleotide compositions and methods for the modulation of the expression of B7 protein
US20060286545A1 (en) * 2003-05-23 2006-12-21 Mount Sinai School Of Medicine Of New York University Viral vectors with improved properties
US7276599B2 (en) * 2003-06-02 2007-10-02 Isis Pharmaceuticals, Inc. Oligonucleotide synthesis with alternative solvents
CN1984921B (en) 2003-06-03 2010-06-16 Isis药物公司 Modulation of survivin expression
WO2005001129A2 (en) * 2003-06-06 2005-01-06 Applera Corporation Mobility cassettes
EP1639090A4 (en) 2003-06-09 2008-04-16 Univ Michigan Compositions and methods for treating and diagnosing cancer
DK3604537T3 (en) 2003-06-13 2022-02-28 Alnylam Europe Ag Double-stranded ribonucleic acid with increased efficiency in an organism
US20040259100A1 (en) 2003-06-20 2004-12-23 Illumina, Inc. Methods and compositions for whole genome amplification and genotyping
WO2005017109A2 (en) * 2003-06-30 2005-02-24 Massachusetts Institute Of Technology Nucleic acids and polypeptides required for cell survival in the absence of rb
US7572581B2 (en) 2003-06-30 2009-08-11 Roche Molecular Systems, Inc. 2′-terminator nucleotide-related methods and systems
US7947817B2 (en) * 2003-06-30 2011-05-24 Roche Molecular Systems, Inc. Synthesis and compositions of 2'-terminator nucleotides
CA2533701A1 (en) 2003-07-31 2005-02-17 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for use in modulation of small non-coding rnas
US20090088982A1 (en) * 2003-07-31 2009-04-02 Fukushima Noelle H Co-detection of single polypeptide and polynucleotide molecules
WO2005012526A1 (en) 2003-08-04 2005-02-10 The Hospital For Sick Children Lafora's disease gene
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
ES2388138T3 (en) 2003-08-27 2012-10-09 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
US20050053981A1 (en) * 2003-09-09 2005-03-10 Swayze Eric E. Gapped oligomeric compounds having linked bicyclic sugar moieties at the termini
US20070123480A1 (en) * 2003-09-11 2007-05-31 Replicor Inc. Oligonucleotides targeting prion diseases
EP1668130A2 (en) 2003-09-18 2006-06-14 Isis Pharmaceuticals, Inc. Modulation of eif4e expression
US7125945B2 (en) * 2003-09-19 2006-10-24 Varian, Inc. Functionalized polymer for oligonucleotide purification
US20050222068A1 (en) * 2003-10-23 2005-10-06 Mourich Dan V Method and antisense composition for selective inhibition of HIV infection in hematopoietic cells
US20070281896A1 (en) * 2003-09-30 2007-12-06 Morris David W Novel compositions and methods in cancer
ES2437491T3 (en) 2003-10-10 2014-01-10 Alchemia Oncology Pty Limited Modulation of the synthesis and degradation of hyaluronan in the treatment of disease
US20050191653A1 (en) 2003-11-03 2005-09-01 Freier Susan M. Modulation of SGLT2 expression
EP1689432B1 (en) 2003-11-17 2009-12-30 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
DK1699924T3 (en) 2003-12-03 2019-10-21 Ocunexus Therapeutics Inc Connexin 43 Targeted Inhibitory Compounds and Methods for Using Them in the Treatment of Corneal Trauma
US7259258B2 (en) * 2003-12-17 2007-08-21 Illumina, Inc. Methods of attaching biological compounds to solid supports using triazine
WO2005060675A2 (en) * 2003-12-19 2005-07-07 Philadelphia Health And Education Corporation(D/B/A Drexel University College Of Medicine (Ducom)) Novel spliced 5-ht1a receptors and methods, kits, and uses relating thereto
US20050136414A1 (en) * 2003-12-23 2005-06-23 Kevin Gunderson Methods and compositions for making locus-specific arrays
WO2005067646A2 (en) 2004-01-07 2005-07-28 Hitachi Chemical Research Center, Inc. Primers and probes for the detection of hiv
WO2005065719A1 (en) * 2004-01-12 2005-07-21 Genesense Technologies Inc. Antisense oligonucleotides directed to ribonucleotide reductase r2 and uses thereof in combination therapies for the treatment of cancer
WO2006054296A2 (en) 2004-11-17 2006-05-26 Spectrum Dynamics Llc Methods of detecting prostate cancer
EP2363480A3 (en) 2004-01-20 2015-10-07 Isis Pharmaceuticals, Inc. Modulation of glucocorticoid receptor expression
US8778900B2 (en) * 2004-01-22 2014-07-15 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP1 expression
US7468431B2 (en) 2004-01-22 2008-12-23 Isis Pharmaceuticals, Inc. Modulation of eIF4E-BP2 expression
WO2005072527A2 (en) * 2004-01-23 2005-08-11 Avi Biopharma, Inc. Antisense oligomers and methods for inducing immune tolerance and immunosuppression
US7842459B2 (en) * 2004-01-27 2010-11-30 Compugen Ltd. Nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
US20060147946A1 (en) * 2004-01-27 2006-07-06 Pinchas Akiva Novel calcium channel variants and methods of use thereof
WO2005074633A2 (en) * 2004-02-03 2005-08-18 The Regents Of The University Of Michigan Compositions and methods for characterizing, regulating, diagnosing, and treating cancer
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
US20050266432A1 (en) * 2004-02-26 2005-12-01 Illumina, Inc. Haplotype markers for diagnosing susceptibility to immunological conditions
US8569474B2 (en) 2004-03-09 2013-10-29 Isis Pharmaceuticals, Inc. Double stranded constructs comprising one or more short strands hybridized to a longer strand
WO2005089268A2 (en) 2004-03-15 2005-09-29 Isis Pharmaceuticals, Inc. Compositions and methods for optimizing cleavage of rna by rnase h
US20050244869A1 (en) 2004-04-05 2005-11-03 Brown-Driver Vickie L Modulation of transthyretin expression
EP1737878A2 (en) 2004-04-05 2007-01-03 Alnylam Pharmaceuticals Inc. Process and reagents for oligonucleotide synthesis and purification
US20050260755A1 (en) * 2004-04-06 2005-11-24 Isis Pharmaceuticals, Inc. Sequential delivery of oligomeric compounds
US20050260652A1 (en) * 2004-04-15 2005-11-24 The General Hospital Corporation Compositions and methods that modulate RNA interference
EP1750776A2 (en) 2004-04-30 2007-02-14 Alnylam Pharmaceuticals Inc. Oligonucleotides comprising a c5-modified pyrimidine
EP2325331A1 (en) 2004-05-14 2011-05-25 Rosetta Genomics Ltd MicroRNAs and Uses Thereof
JP2007537167A (en) * 2004-05-14 2007-12-20 ユニヴェルシテ ラヴァル Regulation of phospholipase C gamma and thereby regulation of pain and nociception
EP1784501B1 (en) 2004-05-14 2015-11-18 Rosetta Genomics Ltd VIRAL AND VIRUS ASSOCIATED MicroRNAS AND USES THEREOF
JP2007538236A (en) 2004-05-21 2007-12-27 アトノミックス アクティーゼルスカブ Surface acoustic wave sensor containing hydrogel
NZ550772A (en) 2004-05-21 2009-10-30 Uab Research Foundation Variable lymphocyte receptors, related polypeptides and nucleic acids, and uses thereof
DE602005016402D1 (en) 2004-05-24 2009-10-15 Genvault Corp STABLE STORAGE OF PROTEIN AND STABLE STORAGE OF NUCLEIC ACID IN RECYCLABLE FORM
US20050287667A1 (en) 2004-06-01 2005-12-29 Pronai Therapeutics, Inc. Methods and compositions for the inhibition of gene expression
US8394947B2 (en) 2004-06-03 2013-03-12 Isis Pharmaceuticals, Inc. Positionally modified siRNA constructs
US20090048192A1 (en) * 2004-06-03 2009-02-19 Isis Pharmaceuticals, Inc. Double Strand Compositions Comprising Differentially Modified Strands for Use in Gene Modulation
US7858323B2 (en) 2004-06-09 2010-12-28 The Regents Of The University Of Michigan Phage microarray profiling of the humoral response to disease
US7700272B2 (en) * 2004-06-09 2010-04-20 Mcgill University Polynucleotides encoding acetylcholine-gated chloride channel subunits of Caenorhabditis elegans
EP4272748A3 (en) 2004-06-28 2024-03-27 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
US7745125B2 (en) * 2004-06-28 2010-06-29 Roche Molecular Systems, Inc. 2′-terminator related pyrophosphorolysis activated polymerization
USRE48960E1 (en) 2004-06-28 2022-03-08 The University Of Western Australia Antisense oligonucleotides for inducing exon skipping and methods of use thereof
DK1766012T3 (en) 2004-07-02 2011-09-19 Avi Biopharma Inc Antisense antibacterial method and compound
US20060024677A1 (en) 2004-07-20 2006-02-02 Morris David W Novel therapeutic targets in cancer
WO2006033732A1 (en) * 2004-08-17 2006-03-30 Invitrogen Corporation Synthesis of highly luminescent colloidal particles
US7427675B2 (en) * 2004-08-23 2008-09-23 Isis Pharmaceuticals, Inc. Compounds and methods for the characterization of oligonucleotides
US7884086B2 (en) 2004-09-08 2011-02-08 Isis Pharmaceuticals, Inc. Conjugates for use in hepatocyte free uptake assays
US8129352B2 (en) * 2004-09-16 2012-03-06 Avi Biopharma, Inc. Antisense antiviral compound and method for treating ssRNA viral infection
EP1799812A4 (en) 2004-09-16 2009-09-09 Gamida Cell Ltd Methods of ex vivo progenitor and stem cell expansion by co-culture with mesenchymal cells
ES2729826T3 (en) * 2004-09-23 2019-11-06 Arc Medical Devices Inc Pharmaceutical compositions and related methods to inhibit fibrous adhesions or inflammatory disease using low sulfate fucans
US20090281025A1 (en) * 2004-10-18 2009-11-12 Mount Sinai School Of Medicine Of New York University Inhibition of tumor growth and metastasis by atf2-derived peptides
EP1809720B1 (en) * 2004-10-29 2012-05-02 Life Technologies Corporation Functionalized fluorescent nanocrystals, and methods for their preparation and use
US7524829B2 (en) * 2004-11-01 2009-04-28 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US20090118132A1 (en) * 2004-11-04 2009-05-07 Roche Molecular Systems, Inc. Classification of Acute Myeloid Leukemia
US8440610B2 (en) 2004-11-12 2013-05-14 Massachusetts Institute Of Technology Mapkap kinase-2 as a specific target for blocking proliferation of P53-defective cells
WO2006050999A2 (en) * 2004-11-15 2006-05-18 Obe Therapy Biotechnology S.A.S Methods of reducing body fat
US7842794B2 (en) 2004-12-17 2010-11-30 Roche Molecular Systems, Inc. Reagents and methods for detecting Neisseria gonorrhoeae
DE102004063599B4 (en) * 2004-12-30 2007-07-12 Bayer Innovation Gmbh Shortened wound healing processes by means of novel fiber fleeces
AU2005321543A1 (en) * 2004-12-30 2006-07-06 Cinvention Ag Combination comprising an agent providing a signal, an implant material and a drug
WO2006076650A2 (en) * 2005-01-12 2006-07-20 Applera Corporation Compositions, methods, and kits for selective amplification of nucleic acids
PT1836239E (en) * 2005-01-13 2009-02-02 Cinv Ag Composite materials containing carbon nanoparticles
WO2006077256A1 (en) * 2005-01-24 2006-07-27 Cinvention Ag Metal containing composite materials
KR20150004906A (en) 2005-02-03 2015-01-13 코다 테라퓨틱스 (엔지) 리미티드 Anti-connexin compounds and uses thereof
CA2596506C (en) 2005-02-09 2021-04-06 Avi Biopharma, Inc. Antisense composition and method for treating muscle atrophy
WO2006123246A2 (en) * 2005-02-11 2006-11-23 Aurelium Biopharma Inc. Methods for identifying chemotherapeutic resistance in non-hematopoietic tumors
CN101175769A (en) 2005-03-10 2008-05-07 健泰科生物技术公司 Methods and compositions for modulating vascular integrity
WO2006097503A2 (en) * 2005-03-18 2006-09-21 Cinvention Ag Process for the preparation of porous sintered metal materials
US20060256599A1 (en) * 2005-03-22 2006-11-16 Malin Patricia J Database of electronically profiled cells and methods for generating and using same
US7476733B2 (en) 2005-03-25 2009-01-13 The United States Of America As Represented By The Department Of Health And Human Services Development of a real-time PCR assay for detection of pneumococcal DNA and diagnosis of pneumococccal disease
US20060240032A1 (en) * 2005-03-31 2006-10-26 Hinrichs David J Immunomodulating compositions and methods for use in the treatment of human autoimmune diseases
EP1863908B1 (en) 2005-04-01 2010-11-17 Qiagen GmbH Reverse transcription and amplification of rna with simultaneous degradation of dna
AU2006237727B2 (en) * 2005-04-22 2012-06-28 Academisch Ziekenhuis Leiden Modulation of exon recognition in pre-mRNA by interfering with the binding of SR proteins and by interfering with secondary RNA structure.
US7838502B2 (en) * 2005-05-06 2010-11-23 University Of Massachusetts Medical School Compositions and methods to modulate H. influenzae pathogenesis
US9505867B2 (en) 2005-05-31 2016-11-29 Ecole Polytechmique Fédérale De Lausanne Triblock copolymers for cytoplasmic delivery of gene-based drugs
WO2006133022A2 (en) 2005-06-03 2006-12-14 The Johns Hopkins University Compositions and methods for decreasing microrna expression for the treatment of neoplasia
AU2006259583A1 (en) * 2005-06-13 2006-12-28 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US8252756B2 (en) 2005-06-14 2012-08-28 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
JP5331476B2 (en) 2005-06-15 2013-10-30 カリダ・ジェノミックス・インコーポレイテッド Single molecule array for genetic and chemical analysis
US7919242B2 (en) 2005-06-30 2011-04-05 Roche Molecular Systems, Inc. Light emission modifiers and their uses in nucleic acid detection, amplification and analysis
JP2009500054A (en) * 2005-07-01 2009-01-08 シンベンション アーゲー Medical device containing reticulated composite material
JP2008545026A (en) * 2005-07-01 2008-12-11 シンベンション アーゲー Process for the preparation of porous reticulated composites
WO2007007317A1 (en) 2005-07-07 2007-01-18 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating h19, and methods of using same
US8067571B2 (en) 2005-07-13 2011-11-29 Avi Biopharma, Inc. Antibacterial antisense oligonucleotide and method
AU2006267051B2 (en) 2005-07-13 2013-03-07 Sarepta Therapeutics, Inc. Antisense antibacterial method and compound
US7790694B2 (en) * 2005-07-13 2010-09-07 Avi Biopharma Inc. Antisense antibacterial method and compound
US7776532B2 (en) 2005-08-11 2010-08-17 Synthetic Genomics, Inc. Method for in vitro recombination
AU2006281569A1 (en) 2005-08-17 2007-02-22 Medexis S.A. Composition and method for determination of CK19 expression
JP5523705B2 (en) 2005-08-29 2014-06-18 レグルス・セラピューティクス・インコーポレイテッド Method of using to modulate MIR-122A
EP1937278B1 (en) 2005-09-08 2012-07-25 AVI BioPharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
WO2007030691A2 (en) * 2005-09-08 2007-03-15 Avi Biopharma, Inc. Antisense antiviral compound and method for treating picornavirus infection
EP1762627A1 (en) 2005-09-09 2007-03-14 Qiagen GmbH Method for the activation of a nucleic acid for performing a polymerase reaction
JP5512125B2 (en) 2005-09-12 2014-06-04 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Recurrent gene fusion in prostate cancer
US8906609B1 (en) 2005-09-26 2014-12-09 Arrowhead Center, Inc. Label-free biomolecule sensor based on surface charge modulated ionic conductance
IL172297A (en) 2005-10-03 2016-03-31 Compugen Ltd Soluble vegfr-1 variants for diagnosis of preeclamsia
EP1943348B1 (en) 2005-10-03 2013-01-02 Life Technologies Corporation Compositions, methods, and kits for amplifying nucleic acids
EP2189522A1 (en) 2005-10-14 2010-05-26 MUSC Foundation For Research Development Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
US8652467B2 (en) * 2005-10-14 2014-02-18 The Regents Of The University Of Michigan Dek protein compositions and methods of using the same
US8080534B2 (en) 2005-10-14 2011-12-20 Phigenix, Inc Targeting PAX2 for the treatment of breast cancer
WO2007045616A1 (en) * 2005-10-18 2007-04-26 Cinvention Ag Thermoset particles and methods for production thereof
US7794951B2 (en) * 2005-10-18 2010-09-14 University Of Massachusetts Medical School SREBP2gc transcription factors and uses thereof
ES2775049T3 (en) 2005-10-21 2020-07-23 Univ California SHP-2 gene mutations in melanomas
CN101365801B (en) 2005-10-28 2013-03-27 阿尔尼拉姆医药品有限公司 Compositions and methods for inhibiting expression of huntingtin gene
JP5129149B2 (en) * 2005-10-31 2013-01-23 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Compositions and methods for treating and diagnosing cancer
JP2009513708A (en) 2005-10-31 2009-04-02 オンコメッド ファーマシューティカルズ インコーポレイテッド Compositions and methods for diagnosis and treatment of cancer
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
WO2007056326A2 (en) * 2005-11-04 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of nav1.8 gene
US8501704B2 (en) 2005-11-08 2013-08-06 Sarepta Therapeutics, Inc. Immunosuppression compound and treatment method
CA2626690A1 (en) 2005-11-09 2007-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of factor v leiden mutant gene
WO2007062380A2 (en) 2005-11-21 2007-05-31 Isis Pharmaceuticals, Inc. Modulation of eif4e-bp2 expression
US8846393B2 (en) 2005-11-29 2014-09-30 Gamida-Cell Ltd. Methods of improving stem cell homing and engraftment
EP1971371B1 (en) 2005-12-01 2015-08-05 Pronai Therapeutics, Inc. Cancer therapies and pharmaceutical compositions used therein
EP1969506A1 (en) * 2005-12-13 2008-09-17 Erasmus University Medical Center Rotterdam Genetic brain tumor markers
ES2698600T3 (en) 2005-12-13 2019-02-05 Univ Pennsylvania Methods for transfecting nucleic acids in living cells
US10647960B2 (en) 2005-12-13 2020-05-12 The Trustees Of The University Of Pennsylvania Transcriptome transfer produces cellular phenotype conversion
US9157066B2 (en) 2005-12-13 2015-10-13 The Trustees Of The University Of Pennsylvania Transcriptome transfer produces cellular phenotype conversion
US8313901B2 (en) * 2005-12-21 2012-11-20 Yale University Methods and compositions related to the modulation of riboswitches
CN101437933B (en) 2005-12-28 2013-11-06 斯克里普斯研究所 Natural antisense and non-coding RNA transcripts as drug targets
EP2216339A1 (en) 2006-01-16 2010-08-11 Compugen Ltd. Novel nucleotide and amino acid sequences, and methods of use thereof for diagnosis
EP1991274A4 (en) 2006-01-20 2009-06-10 Women S And Children S Health Method of treatment, prophylaxis and diagnosis of pathologies of the bone
EP3210633B1 (en) 2006-01-26 2019-06-19 Ionis Pharmaceuticals, Inc. Compositions and their uses directed to huntingtin
US7569686B1 (en) 2006-01-27 2009-08-04 Isis Pharmaceuticals, Inc. Compounds and methods for synthesis of bicyclic nucleic acid analogs
KR20130042043A (en) 2006-01-27 2013-04-25 아이시스 파마수티컬즈 인코포레이티드 6-modified bicyclic nucleic acid analogs
US8129515B2 (en) 2006-01-27 2012-03-06 Isis Pharmaceuticals, Inc. Oligomeric compounds and compositions for the use in modulation of microRNAs
US8229398B2 (en) * 2006-01-30 2012-07-24 Qualcomm Incorporated GSM authentication in a CDMA network
US20080019961A1 (en) * 2006-02-21 2008-01-24 Regents Of The University Of Michigan Hedgehog signaling pathway antagonist cancer treatment
EP2010677A4 (en) * 2006-02-24 2010-04-14 Investigen Inc Methods and compositions for detecting polynucleotides
EP1994180A4 (en) 2006-02-24 2009-11-25 Callida Genomics Inc High throughput genome sequencing on dna arrays
SG10201405158QA (en) * 2006-02-24 2014-10-30 Callida Genomics Inc High throughput genome sequencing on dna arrays
ATE467688T1 (en) * 2006-03-07 2010-05-15 Avi Biopharma Inc ANTIVIRAL ANTISENSE COMPOUND AND METHOD FOR TREATING ARENAVIRUS INFECTION
PL2596807T3 (en) 2006-03-08 2016-06-30 Archemix Llc Complement binding aptamers and anti-C5 agents useful in the treatment of ocular disorders
NZ571568A (en) 2006-03-31 2010-11-26 Alnylam Pharmaceuticals Inc Double-stranded RNA molecule compositions and methods for inhibiting expression of Eg5 gene
US7914988B1 (en) * 2006-03-31 2011-03-29 Illumina, Inc. Gene expression profiles to predict relapse of prostate cancer
US8007790B2 (en) 2006-04-03 2011-08-30 Stowers Institute For Medical Research Methods for treating polycystic kidney disease (PKD) or other cyst forming diseases
CN101460634A (en) 2006-04-13 2009-06-17 康乃尔研究基金会有限公司 Methods and compositions for targeting C-REL
WO2007123391A1 (en) * 2006-04-20 2007-11-01 Academisch Ziekenhuis Leiden Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene.
WO2007125173A2 (en) 2006-05-03 2007-11-08 Baltic Technology Development, Ltd. Antisense agents combining strongly bound base - modified oligonucleotide and artificial nuclease
US20090326042A1 (en) 2006-05-05 2009-12-31 Isis Pharmaceuticals, Inc Compounds and methods for modulating expression of crp
JP2010505741A (en) * 2006-05-10 2010-02-25 エイブイアイ バイオファーマ, インコーポレイテッド Oligonucleotide analogues with cationic intersubunit linkages
US8785407B2 (en) * 2006-05-10 2014-07-22 Sarepta Therapeutics, Inc. Antisense antiviral agent and method for treating ssRNA viral infection
CA2651815A1 (en) 2006-05-10 2007-11-22 Dxterity Diagnostics Detection of nucleic acid targets using chemically reactive oligonucleotide probes
US7666854B2 (en) * 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
CN103614375A (en) 2006-05-11 2014-03-05 阿尔尼拉姆医药品有限公司 Composition and method for inhibiting expression of PCSK9 gene
US20070265215A1 (en) * 2006-05-11 2007-11-15 Iversen Patrick L Antisense restenosis composition and method
DK2066684T3 (en) * 2006-05-11 2012-10-22 Isis Pharmaceuticals Inc 5'-Modified Bicyclic Nucleic Acid Analogs
EP1857548A1 (en) * 2006-05-19 2007-11-21 Academisch Ziekenhuis Leiden Means and method for inducing exon-skipping
CA2652770A1 (en) 2006-05-19 2007-11-29 Alnylam Pharmaceuticals, Inc. Rnai modulation of aha and therapeutic uses thereof
WO2007137220A2 (en) 2006-05-22 2007-11-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of ikk-b gene
EP2023938A4 (en) * 2006-05-23 2010-11-10 Isis Pharmaceuticals Inc Modulation of chrebp expression
WO2007143669A2 (en) 2006-06-05 2007-12-13 California Institute Of Technology Real time micro arrays
US8637436B2 (en) 2006-08-24 2014-01-28 California Institute Of Technology Integrated semiconductor bioarray
US11001881B2 (en) 2006-08-24 2021-05-11 California Institute Of Technology Methods for detecting analytes
US9115389B2 (en) * 2006-06-30 2015-08-25 Rosetta Genomics Ltd. Method for detecting a target nucleic acid comprising two portions using probes having a first portion complementary to the first portion of the target nucleic acid and a second portion substantially complementary to the second portion of the target nucleic acid
WO2008011473A2 (en) 2006-07-19 2008-01-24 Isis Pharmaceuticals, Inc. Compositions and their uses directed to hbxip
US11525156B2 (en) 2006-07-28 2022-12-13 California Institute Of Technology Multiplex Q-PCR arrays
US20100105610A1 (en) 2006-07-28 2010-04-29 Children's Memorial Hospital Methods of Inhibiting Tumor Cell Aggressiveness Using the Microenvironment of Human Embryonic Stem Cells
US8048626B2 (en) 2006-07-28 2011-11-01 California Institute Of Technology Multiplex Q-PCR arrays
DK2049664T3 (en) 2006-08-11 2012-01-02 Prosensa Technologies Bv Single-stranded oligonucleotides, complementary to repetitive elements, for the treatment of DNA repetitive instability-associated disorders
US11560588B2 (en) 2006-08-24 2023-01-24 California Institute Of Technology Multiplex Q-PCR arrays
US20080261216A1 (en) * 2006-09-08 2008-10-23 The Regents Of The University Of Michigan HERV Group II Viruses In Lymphoma And Cancer
WO2008033866A2 (en) * 2006-09-11 2008-03-20 Yale University Methods and compositions for the use of lysine riboswitches
CN101679473B (en) 2006-09-14 2014-12-10 加利福尼亚大学董事会 Nanoplasmonic molecular ruler for nuclease activity and DNA footprinting
AU2007299629C1 (en) 2006-09-21 2012-05-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the HAMP gene
DK2068886T3 (en) 2006-10-03 2013-11-18 Tekmira Pharmaceuticals Corp Lipid-containing preparations
US20100166743A1 (en) 2006-10-06 2010-07-01 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
EP1914303A1 (en) * 2006-10-09 2008-04-23 Qiagen GmbH Thermus eggertssonii DNA polymerases
US20080096193A1 (en) * 2006-10-24 2008-04-24 Charles Robert Bupp Methods and compositions for detecting polynucleotides
US7910302B2 (en) * 2006-10-27 2011-03-22 Complete Genomics, Inc. Efficient arrays of amplified polynucleotides
US8791084B2 (en) 2006-10-27 2014-07-29 Robarts Research Institute Inhibition of SOX9 function in the treatment of proteoglycan-associated pathophysiological conditions
WO2008136852A2 (en) 2006-11-01 2008-11-13 University Of Rochester Methods and compositions related to the structure and function of apobec3g
US20090111705A1 (en) 2006-11-09 2009-04-30 Complete Genomics, Inc. Selection of dna adaptor orientation by hybrid capture
KR20150072458A (en) * 2006-11-15 2015-06-29 코다 테라퓨틱스, 인크. Improved methods and compositions for wound healing
US20080242560A1 (en) * 2006-11-21 2008-10-02 Gunderson Kevin L Methods for generating amplified nucleic acid arrays
AU2006351377A1 (en) * 2006-11-30 2008-06-05 University Of British Columbia Poxviridae treatment comprising TAP-1 and/or TAP-2 as a molecular adjuvant
US8481506B2 (en) * 2006-12-05 2013-07-09 Rosetta Genomics, Ltd. Nucleic acids involved in viral infection
JP2010512327A (en) 2006-12-11 2010-04-22 ユニヴァーシティー オブ ユタ リサーチ ファウンデーション Compositions and methods for the treatment of pathological angiogenesis and vascular permeability
US9938641B2 (en) * 2006-12-18 2018-04-10 Fluidigm Corporation Selection of aptamers based on geometry
US7858772B2 (en) * 2006-12-22 2010-12-28 Roche Molecular Systems, Inc. Compounds and methods for synthesis and purification of oligonucleotides
EP2097448A4 (en) 2006-12-22 2010-07-21 Univ Utah Res Found Method of detecting ocular diseases and pathologic conditions and treatment of same
US7820389B2 (en) * 2007-01-10 2010-10-26 Geneohm Sciences, Inc. Inhibition of mismatch hybridization by a universal competitor DNA
WO2008086529A2 (en) * 2007-01-11 2008-07-17 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US7928083B2 (en) * 2007-01-16 2011-04-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem H19 silencing nucleic acid agents for treating rheumatoid arthritis
AU2008206953A1 (en) * 2007-01-19 2008-07-24 Cinvention Ag Porous, non-degradable implant made by powder molding
WO2008092002A2 (en) 2007-01-24 2008-07-31 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
EP2124967A4 (en) * 2007-01-26 2011-01-05 Rosetta Genomics Ltd Compositions and methods for treating hematopoietic malignancies
US20100196403A1 (en) * 2007-01-29 2010-08-05 Jacob Hochman Antibody conjugates for circumventing multi-drug resistance
WO2009045469A2 (en) 2007-10-02 2009-04-09 Amgen Inc. Increasing erythropoietin using nucleic acids hybridizable to micro-rna and precursors thereof
MX2009008470A (en) 2007-02-09 2009-11-26 Univ Northwestern Particles for detecting intracellular targets.
WO2008103702A2 (en) * 2007-02-23 2008-08-28 Investigen, Inc. Methods and compositions for rapid light-activated isolation and detection of analytes
WO2008104974A2 (en) * 2007-02-27 2008-09-04 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
US9006206B2 (en) 2007-02-27 2015-04-14 Rosetta Genomics Ltd. Composition and methods for modulating cell proliferation and cell death
JP2010520749A (en) * 2007-02-27 2010-06-17 ノースウェスタン ユニバーシティ Binding molecules to nanoparticles
CN101646764A (en) * 2007-02-28 2010-02-10 金文申有限公司 High surface cultivation system
US20080206862A1 (en) * 2007-02-28 2008-08-28 Cinvention Ag High surface cultivation system bag
US20120064520A1 (en) 2007-03-01 2012-03-15 Ranit Aharonov Diagnosis and prognosis of various types of cancers
JP2010521977A (en) 2007-03-22 2010-07-01 イェール ユニバーシティー Methods and compositions for riboswitches that regulate alternative splicing
PE20090064A1 (en) 2007-03-26 2009-03-02 Novartis Ag DOUBLE-CHAIN RIBONUCLEIC ACID TO INHIBIT THE EXPRESSION OF THE HUMAN E6AP GENE AND THE PHARMACEUTICAL COMPOSITION THAT INCLUDES IT
US20100273172A1 (en) 2007-03-27 2010-10-28 Rosetta Genomics Ltd. Micrornas expression signature for determination of tumors origin
AP3018A (en) 2007-03-29 2014-10-31 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expressionof a gene from the ebola
KR101461659B1 (en) 2007-05-11 2014-11-17 토마스 제퍼슨 유니버시티 Methods of treatment and prevention of neurodegenerative diseases and disorders
EP2162552A4 (en) 2007-05-11 2010-06-30 Univ Johns Hopkins Biomarkers for melanoma
WO2008141176A1 (en) * 2007-05-11 2008-11-20 The Trustees Of The University Of Pennsylvania Methods of treatment of skin ulcers
WO2008147526A1 (en) 2007-05-23 2008-12-04 The Trustees Of The University Of Pennsylvania Targeted carriers for intracellular drug delivery
JP2010528617A (en) 2007-05-29 2010-08-26 イェール ユニバーシティー Riboswitches and methods and compositions for using riboswitches and for use with riboswitches
JP2010528616A (en) * 2007-05-29 2010-08-26 イェール ユニバーシティー Methods and compositions related to riboswitches that regulate alternative splicing and RNA splicing
AU2008259907B2 (en) 2007-05-30 2014-12-04 Northwestern University Nucleic acid functionalized nanoparticles for therapeutic applications
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
US7807372B2 (en) * 2007-06-04 2010-10-05 Northwestern University Screening sequence selectivity of oligonucleotide-binding molecules using nanoparticle based colorimetric assay
ES2798758T3 (en) * 2007-06-06 2020-12-14 Sarepta Therapeutics Inc Soluble her2 and her3 splice variant proteins, splice exchange oligonucleotides and their use in the treatment of disease
WO2008154401A2 (en) 2007-06-08 2008-12-18 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
US20090324596A1 (en) 2008-06-30 2009-12-31 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
US10745701B2 (en) 2007-06-28 2020-08-18 The Trustees Of Princeton University Methods of identifying and treating poor-prognosis cancers
ES2694726T3 (en) 2007-06-29 2018-12-26 Sarepta Therapeutics, Inc. Tissue specific peptide conjugates and methods
WO2009006478A2 (en) * 2007-07-05 2009-01-08 Isis Pharmaceuticals, Inc. 6-disubstituted bicyclic nucleic acid analogs
US20100184823A1 (en) 2007-07-05 2010-07-22 Mark Aron Labow dsRNA For Treating Viral Infection
EP3018216B1 (en) 2007-07-06 2018-09-12 The Regents Of The University Of Michigan Recurrent gene fusions in prostate cancer
JP5706157B2 (en) * 2007-07-12 2015-04-22 プロセンサ テクノロジーズ ビー.ブイ.Prosensa Technologies B.V. Molecules for targeting compounds to various selected organs or tissues
JP2010533170A (en) * 2007-07-12 2010-10-21 プロセンサ テクノロジーズ ビー.ブイ. Molecules for targeting compounds to various selected organs, tissues or tumor cells
EP2188298B1 (en) * 2007-08-15 2013-09-18 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
EP2179037A4 (en) 2007-08-21 2010-12-22 Nodality Inc Methods for diagnosis, prognosis and methods of treatment
WO2009032693A2 (en) 2007-08-28 2009-03-12 Uab Research Foundation Synthetic apolipoprotein e mimicking polypeptides and methods of use
JP2010537638A (en) 2007-08-28 2010-12-09 ユーエービー リサーチ ファウンデーション Synthetic apolipoprotein E mimetic polypeptides and methods of use
US8415455B2 (en) 2007-09-04 2013-04-09 Compugen Ltd Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
US8138318B2 (en) 2007-09-13 2012-03-20 Abbott Laboratories Hepatitis B pre-S2 nucleic acid
CA2699394C (en) 2007-09-17 2020-03-24 The Regents Of The University Of California Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
US8445217B2 (en) 2007-09-20 2013-05-21 Vanderbilt University Free solution measurement of molecular interactions by backscattering interferometry
WO2009039442A1 (en) * 2007-09-21 2009-03-26 California Institute Of Technology Nfia in glial fate determination, glioma therapy and astrocytoma treatment
EP2203173B1 (en) 2007-10-26 2015-12-23 Academisch Ziekenhuis Leiden Means and methods for counteracting muscle disorders
USRE48468E1 (en) 2007-10-26 2021-03-16 Biomarin Technologies B.V. Means and methods for counteracting muscle disorders
US7820391B2 (en) 2007-11-06 2010-10-26 Osmetech Molecular Diagnostics Baseless nucleotide analogues and uses thereof
US8097712B2 (en) 2007-11-07 2012-01-17 Beelogics Inc. Compositions for conferring tolerance to viral disease in social insects, and the use thereof
ES2641290T3 (en) 2007-11-20 2017-11-08 Ionis Pharmaceuticals, Inc CD40 expression modulation
US8546556B2 (en) * 2007-11-21 2013-10-01 Isis Pharmaceuticals, Inc Carbocyclic alpha-L-bicyclic nucleic acid analogs
DK2565279T3 (en) 2007-12-05 2015-02-16 Complete Genomics Inc Efficient base determination in sequencing reactions
EP2245159A2 (en) 2007-12-10 2010-11-03 Alnylam Pharmaceuticals Inc. Compositions and methods for inhibiting expression of factor vii gene
WO2009074325A1 (en) 2007-12-13 2009-06-18 Philip Morris Products S.A. Transgenic plants modified for reduced cadmium transport, derivative products, and related methods
WO2009085270A2 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions
EP2252689A2 (en) * 2007-12-21 2010-11-24 Coda Therapeutics, Inc. Use of anti-connexin polynucleotides for the treatment of surgical adhesions
AU2008343756A1 (en) * 2007-12-21 2009-07-09 Coda Therapeutics, Inc. Use of anti-connexin polypeptide agent in combination with anti-connexin polynucleotide agent for the treatment of fibrotic conditions
AU2008345033B2 (en) * 2007-12-28 2014-04-03 Sarepta Therapeutics, Inc. Immunomodulatory agents and methods of use
JP5749494B2 (en) 2008-01-02 2015-07-15 テクミラ ファーマシューティカルズ コーポレイション Improved compositions and methods for delivery of nucleic acids
US20110038920A1 (en) * 2008-01-07 2011-02-17 Ryoichi Mori Wound healing compositions and treatments
AU2009208035B2 (en) 2008-01-22 2014-04-03 Dogenes Inc. Compositions and methods for detecting Juvenile Renal Dysplasia or calcium oxalate stones in dogs
AU2009207291B2 (en) 2008-01-27 2014-11-06 Mor Research Applications Methods and compositions for diagnosing complications of pregnancy
EP2245055A2 (en) * 2008-01-31 2010-11-03 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof as a drug target for producing drugs and biologics
EP2265627A2 (en) * 2008-02-07 2010-12-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexitol nucleic acid analogs
WO2009099326A1 (en) * 2008-02-08 2009-08-13 Prosensa Holding Bv Methods and means for treating dna repeat instability associated genetic disorders
CA2716793A1 (en) 2008-03-05 2009-09-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of eg5 and vegf genes
EP2282744B1 (en) 2008-03-21 2018-01-17 Ionis Pharmaceuticals, Inc. Oligomeric compounds comprising tricyclic nucleosides and methods for their use
EP2285819B1 (en) * 2008-04-04 2013-10-16 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising neutrally linked terminal bicyclic nucleosides
WO2009125401A2 (en) 2008-04-10 2009-10-15 Rosetta Genomics Ltd. Compositions and methods for enhancing oil content in plants
EP2982753B1 (en) 2008-04-18 2018-06-06 Baxter International Inc. Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
US10150990B2 (en) 2008-04-21 2018-12-11 Roche Molecular Systems, Inc. Ribonucleotide tag nucleic acid detection
WO2009134917A2 (en) * 2008-04-29 2009-11-05 Wyeth Methods for treating inflammation
EP2119783A1 (en) 2008-05-14 2009-11-18 Prosensa Technologies B.V. Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means
US8082730B2 (en) * 2008-05-20 2011-12-27 Caterpillar Inc. Engine system having particulate reduction device and method
CN102099687A (en) 2008-05-21 2011-06-15 金尼医疗公司 Compositions and methods of treatment using modulators of motoneuron diseases
CA2635187A1 (en) 2008-06-05 2009-12-05 The Royal Institution For The Advancement Of Learning/Mcgill University Oligonucleotide duplexes and uses thereof
WO2009155612A2 (en) * 2008-06-20 2009-12-23 Genvault Corporation Sample collection and storage devices and methods of use thereof
JP2011527893A (en) * 2008-07-15 2011-11-10 エフ.ホフマン−ラ ロシュ アーゲー Compositions and methods for inhibiting expression of TGF-β receptor gene
US8329647B2 (en) 2008-07-17 2012-12-11 Ikfe Institut Fur Klinische Forschung Und Entwicklung Gmbh Method of treating a subject according to biomarkers for insulin resistance
AU2009272369B2 (en) 2008-07-17 2016-04-14 Ikfe Institut Fur Klinische Forschung Und Entwicklung Gmbh Biomarkers for cardiodiabetes
EP2324044A4 (en) 2008-08-04 2012-04-25 Univ Miami Sting (stimulator of interferon genes), a regulator of innate immune responses
EP3081648A1 (en) 2008-08-25 2016-10-19 Excaliard Pharmaceuticals, Inc. Antisense oligonucleotides directed against connective tissue growth factor and uses thereof
EP3208337A1 (en) 2008-09-02 2017-08-23 Alnylam Pharmaceuticals, Inc. Compositions for combined inhibition of mutant egfr and il-6 expression
JP5822726B2 (en) 2008-09-03 2015-11-24 クワンタムディーエックス・グループ・リミテッド Design, synthesis and use of synthetic nucleotides containing charge tags
ES2574137T3 (en) 2008-09-03 2016-06-15 Quantumdx Group Limited Strategies and methods for detecting nucleic acids by biosensors
WO2010031007A2 (en) 2008-09-12 2010-03-18 Genvault Corporation Matrices and media for storage and stabilization of biomolecules
EP2346883B1 (en) 2008-09-23 2016-03-23 Scott G. Petersen Self delivering bio-labile phosphate protected pro-oligos for oligonucleotide based therapeutics and mediating rna interference
US9127312B2 (en) 2011-02-09 2015-09-08 Bio-Rad Laboratories, Inc. Analysis of nucleic acids
US8604192B2 (en) * 2008-09-24 2013-12-10 Isis Pharmaceuticals, Inc. Cyclohexenyl nucleic acids analogs
WO2010036698A1 (en) 2008-09-24 2010-04-01 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
JP5529142B2 (en) 2008-09-25 2014-06-25 アルナイラム ファーマシューティカルズ, インコーポレイテッド Lipid formulation composition and method for inhibiting expression of serum amyloid A gene
AU2009296246B2 (en) 2008-09-26 2015-07-30 Oncomed Pharmaceuticals, Inc. Frizzled-binding agents and uses thereof
US9290556B2 (en) 2008-09-29 2016-03-22 The Trustees Of The University Of Pennsylvania Tumor vascular marker-targeted vaccines
KR101770435B1 (en) 2008-10-03 2017-09-05 큐알엔에이, 인크. Treatment of apolipoprotein-a1 related diseases by inhibition of natural antisense transcript to apolipoproteina1
AU2009303345B2 (en) 2008-10-09 2015-08-20 Arbutus Biopharma Corporation Improved amino lipids and methods for the delivery of nucleic acids
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
CA2966011C (en) 2008-10-15 2021-10-19 Ionis Pharmaceuticals, Inc. Modulation of factor 11 expression
US8168775B2 (en) 2008-10-20 2012-05-01 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of transthyretin
CN102264374B (en) 2008-10-24 2015-01-07 Isis制药公司 5' and 2' bis-substituted nucleosides and oligomeric compounds prepared therefrom
US8987435B2 (en) 2008-10-24 2015-03-24 Isis Pharmaceuticals, Inc. Oligomeric compounds and methods
JP5864257B2 (en) 2008-10-24 2016-02-17 サレプタ セラピューティクス, インコーポレイテッド Multiple exon skipping compositions for DMD
US8309306B2 (en) * 2008-11-12 2012-11-13 Nodality, Inc. Detection composition
AU2009315665A1 (en) * 2008-11-17 2010-05-20 Arrowhead Research Corporation Compositions and methods for inhibiting expression of factor VII genes
AU2009316286B2 (en) 2008-11-24 2016-05-26 Northwestern University Polyvalent RNA-nanoparticle compositions
WO2010061393A1 (en) 2008-11-30 2010-06-03 Compugen Ltd. He4 variant nucleotide and amino acid sequences, and methods of use thereof
WO2010065671A2 (en) 2008-12-04 2010-06-10 Curna, Inc. Treatment of vascular endothelial growth factor (vegf) related diseases by inhibition of natural antisense transcript to vegf
US20110294870A1 (en) 2008-12-04 2011-12-01 Opko Curna, Llc Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene
CN102307997B (en) 2008-12-04 2018-03-30 库尔纳公司 By suppressing to treat the related disease of Sirtuin 1 (SIRT1) for the natural antisense transcript of Sirtuin 1
US20100256196A1 (en) 2008-12-04 2010-10-07 Ikfe Biomarkers for Atherosclerosis
ES2629630T3 (en) 2008-12-04 2017-08-11 Curna, Inc. Treatment of diseases related to erythropoietin (EPO) by inhibiting the natural antisense transcript to EPO
EP2633854B1 (en) 2008-12-05 2015-09-16 Yeda Research And Development Co. Ltd. miRNA-9 or miRNA-9* for use in treating ALS
AU2009324534B2 (en) 2008-12-10 2015-07-30 Alnylam Pharmaceuticals, Inc. GNAQ targeted dsRNA compositions and methods for inhibiting expression
US20110118134A1 (en) 2008-12-11 2011-05-19 Ikfe Gmbh Biomarkers for insulin sensitizer drug response
CA2746508A1 (en) * 2008-12-17 2010-07-15 Avi Biopharma, Inc. Antisense compositions and methods for modulating contact hypersensitivity or contact dermatitis
JP5840950B2 (en) 2008-12-22 2016-01-06 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデイション Monochromatic multiplex quantitative PCR
US8645115B2 (en) 2008-12-22 2014-02-04 Trustees Of Boston University Modular nucleic acid-based circuits for counters, binary operations, memory and logic
WO2010076655A1 (en) 2008-12-30 2010-07-08 Ikfe Gmbh Biomarkers for adipose tissue activity
US8206929B2 (en) 2009-01-07 2012-06-26 Roche Molecular Systems, Inc. Nucleic acid amplification with allele-specific suppression of sequence variants
EP2382475A2 (en) 2009-01-07 2011-11-02 IKFE GmbH Biomarkers for appetite regulation
US20100233270A1 (en) 2009-01-08 2010-09-16 Northwestern University Delivery of Oligonucleotide-Functionalized Nanoparticles
US20100294952A1 (en) * 2009-01-15 2010-11-25 Northwestern University Controlled agent release and sequestration
US20120101148A1 (en) 2009-01-29 2012-04-26 Alnylam Pharmaceuticals, Inc. lipid formulation
CA2750459A1 (en) 2009-02-03 2010-08-12 F. Hoffmann-La Roche Ag Compositions and methods for inhibiting expression of ptp1b genes
US9745574B2 (en) 2009-02-04 2017-08-29 Rxi Pharmaceuticals Corporation RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality
WO2010090969A1 (en) 2009-02-06 2010-08-12 Isis Pharmaceuticals, Inc. Tetrahydropyran nucleic acid analogs
US20100233733A1 (en) * 2009-02-10 2010-09-16 Nodality, Inc., A Delaware Corporation Multiple mechanisms for modulation of the pi3 kinase pathway
CN102439149B (en) 2009-02-12 2018-01-02 库尔纳公司 By suppressing to treat the related diseases of GDNF for the natural antisense transcript of the glial derived neurotrophic factor (GDNF)
ES2762610T3 (en) 2009-02-12 2020-05-25 Curna Inc Treatment of diseases related to brain-derived neurotrophic factor (BDNF) by inhibition of natural antisense transcript for BDNF
US7964355B2 (en) * 2009-02-17 2011-06-21 Investigen, Inc. Assays based on detection of photobleaching reaction products from dye catalytic complex
WO2010099341A1 (en) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of mig-12 gene
AU2010221419B2 (en) 2009-03-02 2015-10-01 Alnylam Pharmaceuticals, Inc. Nucleic acid chemical modifications
ES2845644T3 (en) 2009-03-04 2021-07-27 Curna Inc Treatment of sirtuin1-related diseases (SIRT1) by inhibition of the natural antisense transcript to sirtuin 1
US20100267806A1 (en) 2009-03-12 2010-10-21 David Bumcrot LIPID FORMULATED COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF Eg5 AND VEGF GENES
MX2011009751A (en) 2009-03-16 2011-09-29 Opko Curna Llc Treatment of nuclear factor (erythroid-derived 2)-like 2 (nrf2) related diseases by inhibition of natural antisense transcript to nrf2.
WO2010107740A2 (en) 2009-03-17 2010-09-23 Curna, Inc. Treatment of delta-like 1 homolog (dlk1) related diseases by inhibition of natural antisense transcript to dlk1
US8309356B2 (en) * 2009-04-01 2012-11-13 Yale University Pseudocomplementary oligonucleotides for targeted gene therapy
WO2010114599A1 (en) * 2009-04-01 2010-10-07 Dx Terity Diagnostics Inc. Chemical ligation dependent probe amplification (clpa)
KR20170072367A (en) 2009-04-15 2017-06-26 노오쓰웨스턴 유니버시티 Delivery of oligonucleotide-functionalized nanoparticles
EP3524275A1 (en) 2009-04-22 2019-08-14 Massachusetts Institute Of Technology Innate immune supression enables repeated delivery of long rna molecules
US20120046342A1 (en) 2009-04-24 2012-02-23 Prosensa Technologies B.V. Oligonucleotide comprising an inosine for treating dmd
US8871494B2 (en) 2009-04-24 2014-10-28 Wisconsin Alumni Research Foundation Over-production of secondary metabolites by over-expression of the VEA gene
US20100279882A1 (en) * 2009-05-01 2010-11-04 Mostafa Ronaghi Sequencing methods
EP2424987B1 (en) 2009-05-01 2017-11-15 CuRNA, Inc. Treatment of hemoglobin (hbf/hbg) related diseases by inhibition of natural antisense transcript to hbf/hbg
JP5769701B2 (en) 2009-05-05 2015-08-26 テクミラ ファーマシューティカルズ コーポレイションTekmira Pharmaceuticals Corporation Lipid composition
AU2010245933B2 (en) 2009-05-05 2016-06-16 Arbutus Biopharma Corporation Methods of delivering oligonucleotides to immune cells
CN102459596B (en) 2009-05-06 2016-09-07 库尔纳公司 By suppression therapy lipid transfer and the metabolic gene relevant disease of the natural antisense transcript for lipid transfer and metabolic gene
JP6250930B2 (en) 2009-05-06 2017-12-20 クルナ・インコーポレーテッド Treatment of TTP-related diseases by suppression of natural antisense transcripts against tristetraproline (TTP)
KR101742334B1 (en) 2009-05-08 2017-06-01 큐알엔에이, 인크. Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
US20120107331A1 (en) 2009-05-15 2012-05-03 Yale University Gemm riboswitches, structure-based compound design with gemm riboswitches, and methods and compositions for use of and with gemm riboswitches
SG176099A1 (en) * 2009-05-15 2011-12-29 Hoffmann La Roche Compositions and methods for inhibiting expression of glucocorticoid receptor (gcr) genes
CN102575251B (en) 2009-05-18 2018-12-04 库尔纳公司 The relevant disease of the reprogramming factor is treated by inhibiting the natural antisense transcript for the reprogramming factor
CA2682429A1 (en) * 2009-05-20 2010-11-20 Gary Levy An assay for measuring plasma fgl-2 and methods and uses thereof
KR101703695B1 (en) 2009-05-22 2017-02-08 큐알엔에이, 인크. Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
CN103221541B (en) 2009-05-28 2017-03-01 库尔纳公司 Antiviral gene relevant disease is treated by the natural antisense transcript suppressing antiviral gene
WO2010141511A2 (en) 2009-06-01 2010-12-09 Halo-Bio Rnai Therapeutics, Inc. Polynucleotides for multivalent rna interference, compositions and methods of use thereof
DK2440183T3 (en) 2009-06-10 2018-10-01 Arbutus Biopharma Corp Improved lipid formulation
DK2977455T3 (en) 2009-06-15 2020-07-13 Complete Genomics Inc PROGRESS FOR LONG-FRAGMENT READING SEQUENCE
WO2010148050A2 (en) 2009-06-16 2010-12-23 Curna, Inc. Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
KR101702689B1 (en) 2009-06-16 2017-02-06 큐알엔에이, 인크. Treatment of paraoxonase 1 (pon1) related diseases by inhibition of natural antisense transcript to pon1
CA2765889A1 (en) 2009-06-24 2010-12-29 Opko Curna, Llc Treatment of tumor necrosis factor receptor 2 (tnfr2) related diseases by inhibition of natural antisense transcript to tnfr2
CA2765815A1 (en) 2009-06-26 2010-12-29 Opko Curna, Llc Treatment of down syndrome gene related diseases by inhibition of natural antisense transcript to a down syndrome gene
US9512164B2 (en) 2009-07-07 2016-12-06 Alnylam Pharmaceuticals, Inc. Oligonucleotide end caps
WO2011005860A2 (en) 2009-07-07 2011-01-13 Alnylam Pharmaceuticals, Inc. 5' phosphate mimics
CA2768947C (en) 2009-07-24 2018-06-19 Opko Curna, Llc Treatment of sirtuin (sirt) related diseases by inhibition of natural antisense transcript to a sirtuin (sirt)
GB0913258D0 (en) 2009-07-29 2009-09-02 Dynex Technologies Inc Reagent dispenser
US9523701B2 (en) 2009-07-29 2016-12-20 Dynex Technologies, Inc. Sample plate systems and methods
US9234199B2 (en) 2009-08-05 2016-01-12 Curna, Inc. Treatment of insulin gene (INS) related diseases by inhibition of natural antisense transcript to an insulin gene (INS)
US9012421B2 (en) 2009-08-06 2015-04-21 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
EP2642291B1 (en) 2009-08-07 2015-10-07 Ohmx Corporation Enzyme triggered redox altering chemical elimination (E-trace) immunoassay
EP2464731B1 (en) 2009-08-11 2016-10-05 CuRNA, Inc. Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
US8409802B2 (en) 2009-08-14 2013-04-02 Roche Molecular Systems, Inc. Format of probes to detect nucleic acid differences
WO2011020023A2 (en) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of a gene from the ebola virus
WO2011022420A1 (en) 2009-08-17 2011-02-24 Yale University Methylation biomarkers and methods of use
WO2011022606A2 (en) 2009-08-21 2011-02-24 Curna, Inc. Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
CN102482671B (en) 2009-08-25 2017-12-01 库尔纳公司 IQGAP relevant diseases are treated by suppressing the natural antisense transcript of ' gtpase activating protein containing IQ die bodys ' (IQGAP)
US9321823B2 (en) 2009-09-02 2016-04-26 Genentech, Inc. Mutant smoothened and methods of using the same
US10174368B2 (en) 2009-09-10 2019-01-08 Centrillion Technology Holdings Corporation Methods and systems for sequencing long nucleic acids
CN102858995B (en) 2009-09-10 2016-10-26 森特瑞隆技术控股公司 Targeting sequence measurement
US9297796B2 (en) 2009-09-24 2016-03-29 President And Fellows Of Harvard College Bent nanowires and related probing of species
EP2480669B1 (en) 2009-09-25 2017-11-08 CuRNA, Inc. Treatment of filaggrin (flg) related diseases by modulation of flg expression and activity
CA2780741C (en) 2009-10-12 2023-04-04 Smith Holdings, Llc Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro
EP2488646B1 (en) 2009-10-14 2017-12-06 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Compositions for controlling varroa mites in bees
US8962584B2 (en) 2009-10-14 2015-02-24 Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd. Compositions for controlling Varroa mites in bees
BR112012009409A2 (en) 2009-10-22 2017-02-21 Genentech Inc method of identifying an inhibitory substance, antagonist molecule, isolated nucleic acid, vector, host cell, method of making the molecule, composition, article of manufacture, method of inhibiting a biological activity, method of treating a pathological condition, method for detect msp in a sample and method to detect hepsin in a sample
JP6147502B2 (en) 2009-10-27 2017-06-14 スウィフト バイオサイエンシーズ, インコーポレイテッド Polynucleotide primers and probes
WO2011053852A1 (en) 2009-10-30 2011-05-05 The Regents Of The University Of California Gna11 mutations in melanoma
CN102666879B (en) 2009-10-30 2016-02-24 西北大学 Templated nanometer conjugate
KR101965337B1 (en) 2009-11-02 2019-04-03 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US20110268810A1 (en) 2009-11-02 2011-11-03 Yale University Polymeric materials loaded with mutagenic and recombinagenic nucleic acids
EP2496716A1 (en) 2009-11-03 2012-09-12 University Of Virginia Patent Foundation Versatile, visible method for detecting polymeric analytes
US20110112176A1 (en) * 2009-11-09 2011-05-12 John Frederick Boylan Compositions and methods for inhibiting expression of kif10 genes
CN105838714B (en) 2009-11-12 2020-07-17 西澳大利亚大学 Antisense molecules and methods of treating diseases
WO2011058555A1 (en) 2009-11-12 2011-05-19 Yeda Research And Development Co. Ltd. A method of editing dna in a cell and constructs capable of same
EP3199634A1 (en) 2009-11-13 2017-08-02 Sarepta Therapeutics, Inc. Antisense antiviral compound and method for treating influenza viral infection
WO2011063403A1 (en) 2009-11-23 2011-05-26 Swift Biosciences, Inc. Devices to extend single stranded target molecules
AR079217A1 (en) 2009-11-30 2012-01-04 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TUMOR TREATMENT
US8614071B2 (en) 2009-12-11 2013-12-24 Roche Molecular Systems, Inc. Preferential amplification of mRNA over DNA using chemically modified primers
ES2661813T3 (en) 2009-12-16 2018-04-04 Curna, Inc. Treatment of diseases related to membrane transcription factor peptidase, site 1 (mbtps1) by inhibition of the natural antisense transcript to the mbtps1 gene
US20110152349A1 (en) 2009-12-18 2011-06-23 Anke Geick Compositions and methods for inhibiting expression of il-18 genes
CA2782373C (en) 2009-12-23 2019-03-26 Opko Curna, Llc Treatment of hepatocyte growth factor (hgf) related diseases by inhibition of natural antisense transcript to hgf
US9068183B2 (en) 2009-12-23 2015-06-30 Curna, Inc. Treatment of uncoupling protein 2 (UCP2) related diseases by inhibition of natural antisense transcript to UCP2
JP6141018B2 (en) 2009-12-24 2017-06-07 バイオマリン テクノロジーズ ベー.フェー. Molecules for treating inflammatory disorders
WO2011090740A2 (en) 2009-12-29 2011-07-28 Opko Curna, Llc Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
ES2585829T3 (en) 2009-12-29 2016-10-10 Curna, Inc. Treatment of diseases related to tumor protein 63 (p63) by inhibition of natural antisense transcription to p63
US20120289583A1 (en) 2009-12-31 2012-11-15 Curna, Inc. Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
KR101878501B1 (en) 2010-01-04 2018-08-07 큐알엔에이, 인크. Treatment of interferon regulatory factor 8 (irf8) related diseases by inhibition of natural antisense transcript to irf8
EP2521785B1 (en) 2010-01-06 2022-03-09 CuRNA, Inc. Inhibition of natural antisense transcript to a pancreatic developmental gene for use in a treatment of pancreatic developmental gene related diseases
US8779118B2 (en) 2010-01-11 2014-07-15 Isis Pharmaceuticals, Inc. Base modified bicyclic nucleosides and oligomeric compounds prepared therefrom
DK2524039T3 (en) 2010-01-11 2018-03-12 Curna Inc TREATMENT OF GENDER HORMON-BINDING GLOBULIN (SHBG) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENCE TRANSCRIPTS TO SHBG
SG182365A1 (en) 2010-01-12 2012-08-30 Univ Yale Structured rna motifs and compounds and methods for their use
TWI535445B (en) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Wnt antagonists and methods of treatment and screening
US8883739B2 (en) 2010-01-19 2014-11-11 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for male reproductive disorders
US9073033B2 (en) 2010-01-19 2015-07-07 Illumina, Inc. Methods and compositions for processing chemical reactions
CN102782135A (en) 2010-01-25 2012-11-14 库尔纳公司 Treatment of RNase H1 related diseases by inhibition of natural antisense transcript to RNase H1
WO2011097407A1 (en) 2010-02-04 2011-08-11 Ico Therapeutics Inc. Dosing regimens for treating and preventing ocular disorders using c-raf antisense
US20110196016A1 (en) 2010-02-05 2011-08-11 Anke Geick Compositions and Methods for Inhibiting Expression of IKK2 Genes
CN102844435B (en) 2010-02-22 2017-05-10 库尔纳公司 Treatment of pyrroline-5-carboxylate reductase 1 (pycr1) related diseases by inhibition of natural antisense transcript to pycr1
WO2011105901A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 9 (c9) and uses thereof
WO2011105902A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-beta (c8-beta) and uses thereof
MX2012009215A (en) 2010-02-23 2012-11-23 Genentech Inc Compositions and methods for the diagnosis and treatment of tumor.
WO2011105900A2 (en) 2010-02-23 2011-09-01 Academisch Ziekenhuis Bij De Universiteit Van Amsterdam Antagonists of complement component 8-alpha (c8-alpha) and uses thereof
AU2011219029B2 (en) 2010-02-26 2017-02-02 Columbia University Methods and compositions for the detection and treatment of cancer involving miRNAs and miRNA inhibitors and targets
EP2926821B1 (en) 2010-03-05 2019-12-25 Tissue Genesis, LLC Compositions to support tissue integration and inosculation of transplanted tissue and transplanted engineered penile tissue with adipose stromal cells
US9121022B2 (en) 2010-03-08 2015-09-01 Monsanto Technology Llc Method for controlling herbicide-resistant plants
WO2011112516A1 (en) 2010-03-08 2011-09-15 Ico Therapeutics Inc. Treating and preventing hepatitis c virus infection using c-raf kinase antisense oligonucleotides
EP2545173A2 (en) 2010-03-12 2013-01-16 Sarepta Therapeutics, Inc. Antisense modulation of nuclear hormone receptors
EP3210611B1 (en) 2010-03-12 2019-08-21 The Brigham and Women's Hospital, Inc. Methods of treating vascular inflammatory disorders
WO2011113054A2 (en) 2010-03-12 2011-09-15 Aurasense Llc Crosslinked polynucleotide structure
WO2011115818A1 (en) 2010-03-17 2011-09-22 Isis Pharmaceuticals, Inc. 5'-substituted bicyclic nucleosides and oligomeric compounds prepared therefrom
EP2548025A4 (en) 2010-03-17 2013-09-25 Univ Michigan Using phage epitopes to profile the immune response
US8889350B2 (en) 2010-03-26 2014-11-18 Swift Biosciences, Inc. Methods and compositions for isolating polynucleotides
ES2893199T3 (en) 2010-03-29 2022-02-08 Alnylam Pharmaceuticals Inc dsRNA therapy for transthyretin (TTR)-related ocular amyloidosis
WO2011123621A2 (en) 2010-04-01 2011-10-06 Alnylam Pharmaceuticals Inc. 2' and 5' modified monomers and oligonucleotides
CN102971337B (en) 2010-04-01 2016-09-21 昂考梅德药品有限公司 FZ combines medicament and application thereof
ES2657969T3 (en) 2010-04-02 2018-03-07 Curna, Inc. Treatment of diseases related to Colony Stimulating Factor 3 (CSF3) by inhibition of the natural antisense transcript to CSF3
RU2610661C2 (en) 2010-04-09 2017-02-14 Курна, Инк. Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
US20110269194A1 (en) 2010-04-20 2011-11-03 Swift Biosciences, Inc. Materials and methods for nucleic acid fractionation by solid phase entrapment and enzyme-mediated detachment
WO2011133802A1 (en) 2010-04-21 2011-10-27 Helix Therapeutics, Inc. Compositions and methods for treatment of lysosomal storage disorders
US20110262406A1 (en) 2010-04-21 2011-10-27 Yale University Compositions and methods for targeted inactivation of hiv cell surface receptors
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
AU2011248625B2 (en) 2010-04-26 2017-01-05 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of cysteinyl-tRNA synthetase
JP6294074B2 (en) 2010-04-27 2018-03-14 エータイアー ファーマ, インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of isoleucyl-tRNA synthetase
WO2011139853A2 (en) 2010-04-28 2011-11-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of alanyl trna synthetases
EP2601204B1 (en) 2010-04-28 2016-09-07 Ionis Pharmaceuticals, Inc. Modified nucleosides and oligomeric compounds prepared therefrom
EP3091027B1 (en) 2010-04-28 2018-01-17 Ionis Pharmaceuticals, Inc. 5' modified nucleosides and oligomeric compounds prepared therefrom
CA2797374C (en) 2010-04-29 2021-02-16 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of asparaginyl trna synthetases
CA2797393C (en) 2010-04-29 2020-03-10 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of valyl trna synthetases
WO2011139917A1 (en) 2010-04-29 2011-11-10 Isis Pharmaceuticals, Inc. Modulation of transthyretin expression
US9068177B2 (en) 2010-04-29 2015-06-30 Atyr Pharma, Inc Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glutaminyl-tRNA synthetases
CN103096925A (en) 2010-05-03 2013-05-08 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of arginyl-tRNA synthetases
MA34291B1 (en) 2010-05-03 2013-06-01 Genentech Inc COMPOSITIONS AND METHODS FOR DIAGNOSING AND TREATING A TUMOR
CN107988228B (en) 2010-05-03 2022-01-25 库尔纳公司 Treatment of Sirtuin (SIRT) related diseases by inhibition of natural antisense transcript to Sirtuin (SIRT)
CA2797978C (en) 2010-05-03 2019-12-03 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of methionyl-trna synthetases
CN103096912A (en) 2010-05-03 2013-05-08 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of phenylalanyl-alpha-tRNA synthetases
CN102985103A (en) 2010-05-04 2013-03-20 Atyr医药公司 Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of p38 multi-tRNA synthetase complex
CA2798123C (en) 2010-05-05 2020-06-23 The Governing Council Of The University Of Toronto Method of processing dried samples using digital microfluidic device
SG185481A1 (en) 2010-05-10 2012-12-28 Univ California Endoribonuclease compositions and methods of use thereof
JP5866106B2 (en) 2010-05-12 2016-02-17 コロンビア ユニヴァーシティ Method for producing enteroendocrine cells that produce and secrete insulin
US9050373B2 (en) 2010-05-13 2015-06-09 The Charlotte-Mecklenburg Hospital Authority Pharmaceutical compositions comprising antisense oligonucleotides and methods of using same
CA3090304A1 (en) 2010-05-13 2011-11-17 Sarepta Therapeutics, Inc. Antisense modulation of interleukins 17 and 23 signaling
JP6396656B2 (en) 2010-05-14 2018-09-26 エータイアー ファーマ, インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of phenylalanyl βtRNA synthetase
TWI531370B (en) 2010-05-14 2016-05-01 可娜公司 Treatment of par4 related diseases by inhibition of natural antisense transcript to par4
JP6027965B2 (en) 2010-05-17 2016-11-16 エータイアー ファーマ, インコーポレイテッド Innovative discovery of therapeutic, diagnostic and antibody compositions related to protein fragments of leucyl-tRNA synthetase
WO2011150226A1 (en) 2010-05-26 2011-12-01 Landers James P Method for detecting nucleic acids based on aggregate formation
CA2799596C (en) 2010-05-26 2020-09-22 Curna, Inc. Treatment of methionine sulfoxide reductase a (msra) related diseases by inhibition of natural antisense transcript to msra
US8895528B2 (en) 2010-05-26 2014-11-25 Curna, Inc. Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
AU2011257980B2 (en) 2010-05-28 2016-06-30 Sarepta Therapeutics, Inc. Oligonucleotide analogues having modified intersubunit linkages and/or terminal groups
WO2011153323A2 (en) 2010-06-02 2011-12-08 Alnylam Pharmaceuticals, Inc. Compositions and methods directed to treating liver fibrosis
US9228240B2 (en) 2010-06-03 2016-01-05 California Institute Of Technology Methods for detecting and quantifying viable bacterial endo-spores
US8957200B2 (en) 2010-06-07 2015-02-17 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
WO2011156713A1 (en) 2010-06-11 2011-12-15 Vanderbilt University Multiplexed interferometric detection system and method
KR102008708B1 (en) 2010-06-23 2019-08-08 큐알엔에이, 인크. Treatment of sodium channel voltage-gated, alpha subunit (scna) related diseases by inhibition of natural abtisense transcript to scna
WO2011163466A1 (en) 2010-06-23 2011-12-29 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Regulation of skin pigmentation by neuregulin-1 (nrg-1)
CN107441480A (en) 2010-06-30 2017-12-08 卡姆普根有限公司 Polypeptide and its purposes as the medicine for treating multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
CA2804416C (en) 2010-07-12 2020-04-28 Atyr Pharma, Inc. Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of glycyl-trna synthetases
CN103068982B (en) 2010-07-14 2017-06-09 库尔纳公司 DLG relevant diseases are treated by suppressing the natural antisense transcript of the big homologue of plate-like (DLG)
CA2805915C (en) 2010-07-22 2017-01-24 President And Fellows Of Harvard College Multiple input biologic classifier circuits for cells
US8198429B2 (en) 2010-08-09 2012-06-12 Avi Biopharma, Inc. Antisense antiviral compounds and methods for treating a filovirus infection
US20130143955A1 (en) 2010-08-09 2013-06-06 Yale University Cyclic di-GMP-II Riboswitches, Motifs, and Compounds, and Methods for Their Use
CN103228796B (en) 2010-08-11 2016-06-01 赛路拉公司 Gene typing DNA
AU2011293294B2 (en) 2010-08-25 2016-03-24 Pangu Biopharma Limited Innovative discovery of therapeutic, diagnostic, and antibody compositions related to protein fragments of Tyrosyl-tRNA synthetases
WO2012028697A1 (en) 2010-09-01 2012-03-08 Eth Zürich, Institute Of Molecular Biology And Biophysics Affinity purification system based on donor strand complementation
WO2012031243A2 (en) 2010-09-03 2012-03-08 Avi Biopharma, Inc. dsRNA MOLECULES COMPRISING OLIGONUCLEOTIDE ANALOGS HAVING MODIFIED INTERSUBUNIT LINKAGES AND/OR TERMINAL GROUPS
EP2614159B1 (en) 2010-09-10 2017-11-08 Bio-Rad Laboratories, Inc. Size selection of dna for chromatin analysis
US8483969B2 (en) 2010-09-17 2013-07-09 Illuminia, Inc. Variation analysis for multiple templates on a solid support
US20130210901A1 (en) 2010-09-20 2013-08-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Method of treating neurodegenerative diseases
WO2012047968A2 (en) 2010-10-05 2012-04-12 Genentech, Inc. Mutant smoothened and methods of using the same
EP2625274B1 (en) 2010-10-06 2017-07-19 CuRNA, Inc. Treatment of sialidase 4 (neu4) related diseases by inhibition of natural antisense transcript to neu4
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
WO2012052872A2 (en) 2010-10-17 2012-04-26 Yeda Research And Development Co. Ltd. Methods and compositions for the treatment of insulin-associated medical conditions
EP3434772A3 (en) 2010-10-18 2019-03-20 Arrowhead Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of rrm2 genes
US8648053B2 (en) 2010-10-20 2014-02-11 Rosalind Franklin University Of Medicine And Science Antisense oligonucleotides that target a cryptic splice site in Ush1c as a therapeutic for Usher syndrome
CA2815212A1 (en) 2010-10-22 2012-04-26 Curna, Inc. Treatment of alpha-l-iduronidase (idua) related diseases by inhibition of natural antisense transcript to idua
US8753816B2 (en) 2010-10-26 2014-06-17 Illumina, Inc. Sequencing methods
JP6073795B2 (en) 2010-10-27 2017-02-01 カッパーアールエヌエー,インコーポレイテッド Treatment of IFRD1-related diseases by inhibition of natural antisense transcripts to interferon-related developmental regulator 1 (IFRD1)
EP2633076B1 (en) 2010-10-28 2016-07-27 Life Technologies Corporation Chemically-enhanced primer compositions, methods and kits
EP2635679B1 (en) 2010-11-05 2017-04-19 Illumina, Inc. Linking sequence reads using paired code tags
CN103370054A (en) 2010-11-09 2013-10-23 阿尔尼拉姆医药品有限公司 Lipid formulated compositions and methods for inhibiting expression of EG5 and VEGF genes
CA2817090A1 (en) 2010-11-12 2012-05-18 Sarepta Therapeutics, Inc. Antisense antibacterial compounds and methods
AU2011325956B2 (en) 2010-11-12 2016-07-14 The General Hospital Corporation Polycomb-associated non-coding RNAs
WO2012068405A2 (en) 2010-11-17 2012-05-24 Isis Pharmaceuticals, Inc. Modulation of alpha synuclein expression
WO2012068340A2 (en) 2010-11-18 2012-05-24 Opko Curna Llc Antagonat compositions and methods of use
EP2643479B1 (en) 2010-11-22 2017-09-13 Rosetta Genomics Ltd Methods and materials for classification of tissue of origin of tumor samples
CN103459599B (en) 2010-11-23 2017-06-16 库尔纳公司 NANOG relevant diseases are treated by suppressing the natural antisense transcript of NANOG
US9150926B2 (en) 2010-12-06 2015-10-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Diagnosis and treatment of adrenocortical tumors using human microRNA-483
WO2012079046A2 (en) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
EP2649182A4 (en) 2010-12-10 2015-05-06 Alnylam Pharmaceuticals Inc Compositions and methods for increasing erythropoietin (epo) production
US9045749B2 (en) 2011-01-14 2015-06-02 The General Hospital Corporation Methods targeting miR-128 for regulating cholesterol/lipid metabolism
EP3733870A3 (en) 2011-01-14 2021-01-27 Life Technologies Corporation Methods for identification and quantification of mirnas
WO2012100078A1 (en) 2011-01-19 2012-07-26 Ohmx Corporation Enzyme triggered redox altering chemical elimination (e-trace) immmunoassay
DK3037536T3 (en) 2011-01-28 2020-01-13 Illumina Inc OLIGONUCLEOTID REPLACEMENT FOR DI-TAGGED AND DIRECTORY LIBRARIES
CN103403188B (en) 2011-01-31 2016-03-30 伊鲁米那股份有限公司 For reducing the method for nucleic acid damaging
DK2670404T3 (en) 2011-02-02 2018-11-19 Univ Princeton CIRCUIT MODULATORS AS VIRUS PRODUCTION MODULATORS
WO2012106508A1 (en) 2011-02-02 2012-08-09 Pfizer Inc. Method of treating keloids or hypertrophic scars using antisense compounds targeting connective tissue growth factor (ctgf)
US9365897B2 (en) 2011-02-08 2016-06-14 Illumina, Inc. Selective enrichment of nucleic acids
US9327037B2 (en) 2011-02-08 2016-05-03 The Johns Hopkins University Mucus penetrating gene carriers
JP2014507143A (en) 2011-02-08 2014-03-27 ザ シャーロット−メクレンバーグ ホスピタル オーソリティ ドゥーイング/ビジネス/アズ キャロライナズ ヘルスケア システム Antisense oligonucleotide
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
US20120208193A1 (en) 2011-02-15 2012-08-16 Bio-Rad Laboratories, Inc. Detecting methylation in a subpopulation of genomic dna
US9562853B2 (en) 2011-02-22 2017-02-07 Vanderbilt University Nonaqueous backscattering interferometric methods
EP2689028B1 (en) 2011-03-23 2017-08-30 Pacific Biosciences Of California, Inc. Isolation of polymerase-nucleic acid complexes and loading onto substrates
EP3406267A1 (en) 2011-03-25 2018-11-28 Children's Medical Center Corporation Lin28-mediated control of let-7 biogenesis
KR102481317B1 (en) 2011-03-29 2022-12-26 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for inhibiting expression of tmprss6 gene
EP2691101A2 (en) 2011-03-31 2014-02-05 Moderna Therapeutics, Inc. Delivery and formulation of engineered nucleic acids
US20120252682A1 (en) 2011-04-01 2012-10-04 Maples Corporate Services Limited Methods and systems for sequencing nucleic acids
EP2694660B1 (en) 2011-04-03 2018-08-08 The General Hospital Corporation Efficient protein expression in vivo using modified rna (mod-rna)
WO2012140627A1 (en) 2011-04-15 2012-10-18 Compugen Ltd. Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancer
EP3789498A1 (en) 2011-04-25 2021-03-10 Bio-rad Laboratories, Inc. Methods for nucleic acid analysis
WO2012149154A1 (en) 2011-04-26 2012-11-01 Swift Biosciences, Inc. Polynucleotide primers and probes
WO2012151289A2 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system to detect aggregate formation on a substrate
WO2012151268A1 (en) 2011-05-02 2012-11-08 University Of Virginia Patent Foundation Method and system for high throughput optical and label free detection of analytes
US9353371B2 (en) 2011-05-02 2016-05-31 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with usher syndrome
KR102339196B1 (en) 2011-05-05 2021-12-15 사렙타 쎄러퓨틱스, 인코퍼레이티드 Peptide Oligonucleotide Conjugates
CA2873204C (en) 2011-05-13 2021-10-19 The Regents Of The University Of California Photothermal substrates for selective transfection of cells
EP2710145B1 (en) 2011-05-17 2015-12-09 Dxterity Diagnostics Incorporated Methods and compositions for detecting target nucleic acids
WO2012160551A2 (en) 2011-05-24 2012-11-29 Rosetta Genomics Ltd Methods and compositions for determining heart failure or a risk of heart failure
WO2012170347A1 (en) 2011-06-09 2012-12-13 Isis Pharmaceuticals, Inc. Bicyclic nucleosides and oligomeric compounds prepared therefrom
JP6188686B2 (en) 2011-06-09 2017-08-30 カッパーアールエヌエー,インコーポレイテッド Treatment of FXN-related diseases by inhibition of natural antisense transcripts to frataxin (FXN)
EP2717923B1 (en) 2011-06-10 2017-09-27 Ionis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
MX345095B (en) 2011-06-21 2017-01-17 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (angptl3) irna compostions and methods of use thereof.
KR102540778B1 (en) 2011-06-21 2023-06-07 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for inhibition of expression of apolipoprotein c-iii(apoc3) genes
US9068184B2 (en) 2011-06-21 2015-06-30 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibition of expression of protein C (PROC) genes
EP3597750B1 (en) 2011-06-23 2022-05-04 Alnylam Pharmaceuticals, Inc. Serpina1 sirnas: compositions of matter and methods of treatment
CA2840614A1 (en) 2011-06-29 2013-01-03 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
SG194751A1 (en) 2011-06-30 2013-12-30 Arrowhead Res Corp Compositions and methods for inhibiting gene expression of hepatitis b virus
WO2013001372A2 (en) 2011-06-30 2013-01-03 University Of Oslo Methods and compositions for inhibition of activation of regulatory t cells
AU2012277376B2 (en) 2011-06-30 2016-11-24 Compugen Ltd. Polypeptides and uses thereof for treatment of autoimmune disorders and infection
WO2013006569A2 (en) 2011-07-01 2013-01-10 The Regents Of The University Of California Herpes virus vaccine and methods of use
AU2012284259A1 (en) 2011-07-15 2014-03-06 Sarepta Therapeutics, Inc. Methods and compositions for manipulating translation of protein isoforms from alternative initiation start sites
US20140328811A1 (en) 2011-08-01 2014-11-06 Alnylam Pharmaceuticals, Inc. Method for improving the success rate of hematopoietic stem cell transplants
CN107400711A (en) 2011-08-03 2017-11-28 伯乐实验室公司 Use the cell filtration small nucleic acids being permeabilized
ES2632212T3 (en) 2011-08-04 2017-09-11 Yeda Research And Development Co. Ltd. miR-135 and compositions comprising it for the treatment of medical conditions associated with serotonin
WO2013137922A2 (en) 2011-08-05 2013-09-19 Illumina, Inc. Functionalization and purification of molecules by reversible group exchange
CA2847811C (en) 2011-09-06 2019-10-22 Curna, Inc. Treatment of diseases related to alpha subunits of sodium channels, voltage-gated (scnxa) with small molecules
US10760086B2 (en) 2011-09-13 2020-09-01 Monsanto Technology Llc Methods and compositions for weed control
UA116090C2 (en) 2011-09-13 2018-02-12 Монсанто Текнолоджи Ллс Methods and compositions for weed control
AU2012308686B2 (en) 2011-09-13 2018-05-10 Monsanto Technology Llc Methods and compositions for weed control
AU2012308694B2 (en) 2011-09-13 2018-06-14 Monsanto Technology Llc Methods and compositions for weed control
US10829828B2 (en) 2011-09-13 2020-11-10 Monsanto Technology Llc Methods and compositions for weed control
AU2012308659B2 (en) 2011-09-13 2017-05-04 Monsanto Technology Llc Methods and compositions for weed control
US9840715B1 (en) 2011-09-13 2017-12-12 Monsanto Technology Llc Methods and compositions for delaying senescence and improving disease tolerance and yield in plants
US10806146B2 (en) 2011-09-13 2020-10-20 Monsanto Technology Llc Methods and compositions for weed control
CA2848753C (en) 2011-09-14 2022-07-26 Rana Therapeutics, Inc. Multimeric oligonucleotide compounds
US9920326B1 (en) 2011-09-14 2018-03-20 Monsanto Technology Llc Methods and compositions for increasing invertase activity in plants
AU2012308302A1 (en) 2011-09-14 2014-03-20 Northwestern University Nanoconjugates able to cross the blood-brain barrier
WO2013040552A2 (en) 2011-09-16 2013-03-21 Georgia Health Sciences University Methods of promoting immune tolerance
WO2013040548A2 (en) 2011-09-17 2013-03-21 Yale University Fluoride-responsive riboswitchs, fluoride transporters, and methods of use
US9801948B2 (en) 2011-09-21 2017-10-31 Yale University Antimicrobial compositions and methods of use thereof
CN107267615A (en) 2011-09-23 2017-10-20 霍夫曼-拉罗奇有限公司 G-shaped clamp is used for the purposes of improved ApoE gene
US20130085139A1 (en) 2011-10-04 2013-04-04 Royal Holloway And Bedford New College Oligomers
AU2012322788B2 (en) 2011-10-11 2018-01-04 The Brigham And Women's Hospital, Inc. Micrornas in neurodegenerative disorders
CN103998921B (en) 2011-10-14 2016-04-20 贝克顿·迪金森公司 Square wave thermal cycle
KR102102862B1 (en) 2011-10-14 2020-04-22 제넨테크, 인크. ANTI-HtrA1 ANTIBODIES AND METHODS OF USE
WO2013059293A1 (en) 2011-10-17 2013-04-25 Ohmx Corporation Single, direct detection of hemoglobin a1c percentage using enzyme triggered redox altering chemical elimination (e-trace) immunoassay
GB2497838A (en) 2011-10-19 2013-06-26 Nugen Technologies Inc Compositions and methods for directional nucleic acid amplification and sequencing
WO2013061328A2 (en) 2011-10-27 2013-05-02 Yeda Research And Development Co. Ltd. Method of treating cancer
CA2888915A1 (en) 2011-10-28 2013-05-02 The Regents Of The University Of California Flt3 mutations associated with drug resistance in aml patients having activating mutations in flt3
CA2853729A1 (en) 2011-10-28 2013-05-02 Board Of Regents, The University Of Texas System Novel compositions and methods for treating cancer
US10837879B2 (en) 2011-11-02 2020-11-17 Complete Genomics, Inc. Treatment for stabilizing nucleic acid arrays
CA2854459A1 (en) 2011-11-04 2013-05-10 Ohmx Corporation Novel chemistry used in biosensors
KR102271212B1 (en) 2011-11-18 2021-07-01 사렙타 쎄러퓨틱스, 인코퍼레이티드 Functionally-modified oligonucleotides and subunits thereof
AU2012345638C1 (en) 2011-11-30 2018-10-18 Sarepta Therapeutics, Inc. Induced exon inclusion in spinal muscle atrophy
WO2013082548A1 (en) 2011-11-30 2013-06-06 Sarepta Therapeutics, Inc. Oligonucleotides for treating expanded repeat diseases
WO2013082529A1 (en) 2011-12-02 2013-06-06 Yale University Enzymatic synthesis of poly(amine-co-esters) and methods of use thereof for gene delivery
US9895451B2 (en) 2011-12-02 2018-02-20 Yale University Formulations for targeted release of agents to low pH tissue environments or cellular compartments and methods of use thereof
US10465042B2 (en) 2011-12-02 2019-11-05 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
HUE038369T2 (en) 2011-12-08 2018-10-29 Sarepta Therapeutics Inc Oligonucleotide analogues targeting human lmna
EP2790736B1 (en) 2011-12-12 2018-01-31 Oncoimmunin, Inc. In vivo delivery of oligonucleotides
US20140329913A1 (en) 2011-12-14 2014-11-06 The Johns Hopkins University Nanoparticles with enhanced mucosal penetration or decreased inflammation
KR20140102759A (en) 2011-12-16 2014-08-22 모더나 세라퓨틱스, 인코포레이티드 Modified nucleoside, nucleotide, and nucleic acid compositions
AU2012354062B2 (en) 2011-12-16 2017-09-07 Targetgene Biotechnologies Ltd Compositions and methods for modifying a predetermined target nucleic acid sequence
WO2013096455A1 (en) 2011-12-20 2013-06-27 Dana-Farber Cancer Institute, Inc. Methods for diagnosing and treating oncogenic kras-associated cancer
US9115394B2 (en) 2011-12-22 2015-08-25 Roche Molecular Systems, Inc. Methods and reagents for reducing non-specific amplification
AU2012358238B2 (en) 2011-12-22 2017-12-07 C. Frank Bennett Methods for modulating Metastasis-Associated-in-Lung-Adenocarcinoma-Transcript-1(MALAT-1) expression
US20130217071A1 (en) 2011-12-30 2013-08-22 Luz Montesclaros Methods and compositions for performing nucleic acid amplification reactions
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
US9250203B2 (en) 2012-01-09 2016-02-02 Ohmx Corporation Enzyme cascade methods for E-TRACE assay signal amplification
ES2842938T3 (en) 2012-01-11 2021-07-15 Ionis Pharmaceuticals Inc Compositions and Methods for IKBKAP Splice Modulation
KR101811917B1 (en) 2012-01-19 2017-12-22 더 존스 홉킨스 유니버시티 Nanoparticles formulations with enhanced mucus penetration
CN105861487B (en) 2012-01-26 2020-05-05 纽亘技术公司 Compositions and methods for targeted nucleic acid sequence enrichment and efficient library generation
CN104203289B (en) 2012-01-27 2020-11-03 比奥马林技术公司 RNA-regulatory oligonucleotides with improved properties for the treatment of duchenne muscular dystrophy and becker muscular dystrophy
AU2013216320A1 (en) 2012-02-01 2014-04-03 Compugen Ltd. C10RF32 antibodies, and uses thereof for treatment of cancer
EP2812342B1 (en) 2012-02-08 2017-11-15 Ionis Pharmaceuticals, Inc. Modulation of rna by repeat targeting
WO2013119888A1 (en) 2012-02-09 2013-08-15 President And Fellows Of Harvard College Selective nucleic acid amplification from nucleic acid pools
BR112014020119A2 (en) 2012-02-13 2020-10-27 Gamida-Cell Ltd culture of mesenchymal stem cells
EP3222627B1 (en) 2012-02-15 2019-08-07 Pacific Biosciences of California, Inc. Polymerase enzyme substrates with protein shield
EP3401394A1 (en) 2012-02-22 2018-11-14 Exostem Biotec Ltd Generation of neural stem cells
JP6329911B2 (en) 2012-02-22 2018-05-23 ブレインステム バイオテック リミテッド MicroRNA for the production of astrocytes
CA2866625C (en) 2012-03-13 2020-12-08 Swift Biosciences, Inc. Methods and compositions for size-controlled homopolymer tailing of substrate polynucleotides by a nucleic acid polymerase
EP2639238A1 (en) 2012-03-15 2013-09-18 Universität Bern Tricyclic nucleosides and oligomeric compounds prepared therefrom
US20150031750A1 (en) 2012-03-15 2015-01-29 The Scripps Research Institute Treatment of brain derived neurotrophic factor (bdnf) related diseases by inhibition of natural antisense transcript to bdnf
WO2013138662A1 (en) 2012-03-16 2013-09-19 4S3 Bioscience, Inc. Antisense conjugates for decreasing expression of dmpk
WO2013142514A1 (en) 2012-03-19 2013-09-26 Isis Pharmaceuticals, Inc. Methods and compositions for modulating alpha-1-antitrypsin expression
NZ700399A (en) 2012-03-20 2016-07-29 Sarepta Therapeutics Inc Boronic acid conjugates of oligonucleotide analogues
US20150086584A1 (en) 2012-03-22 2015-03-26 University Of Miami Multi-specific binding agents
WO2013148260A1 (en) 2012-03-30 2013-10-03 Washington University Methods for modulating tau expression for reducing seizure and modifying a neurodegenerative syndrome
CA2868398A1 (en) 2012-04-02 2013-10-10 Moderna Therapeutics, Inc. Modified polynucleotides for the production of cosmetic proteins and peptides
AU2013243949A1 (en) 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of biologics and proteins associated with human disease
EP3563872A1 (en) 2012-04-05 2019-11-06 Massachusetts Institute Of Technology Immunostimulatory compositions and methods of use thereof
WO2013154799A1 (en) 2012-04-09 2013-10-17 Isis Pharmaceuticals, Inc. Tricyclic nucleosides and oligomeric compounds prepared therefrom
EP2850092B1 (en) 2012-04-09 2017-03-01 Ionis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
WO2013155439A1 (en) 2012-04-13 2013-10-17 Massachusetts Institute Of Technology Analog and mixed-signal computation and circuits in living cells
EP2839005B1 (en) 2012-04-20 2021-01-06 Aptamir Therapeutics, Inc. Mirna modulators of thermogenesis
US9127274B2 (en) 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
US9533068B2 (en) 2012-05-04 2017-01-03 The Johns Hopkins University Drug loaded microfiber sutures for ophthalmic application
CA2872519C (en) 2012-05-04 2017-09-05 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
US9273949B2 (en) 2012-05-11 2016-03-01 Vanderbilt University Backscattering interferometric methods
EA201492116A1 (en) 2012-05-16 2015-05-29 Рана Терапьютикс, Инк. COMPOSITIONS AND METHODS FOR MODULATING THE EXPRESSION OF MECP2
CA2873794A1 (en) 2012-05-16 2013-11-21 Rana Therapeutics Inc. Compositions and methods for modulating smn gene family expression
CN104583398A (en) 2012-05-16 2015-04-29 Rana医疗有限公司 Compositions and methods for modulating gene expression
US20160002624A1 (en) 2012-05-17 2016-01-07 Isis Pharmaceuticals, Inc. Antisense oligonucleotide compositions
US9574193B2 (en) 2012-05-17 2017-02-21 Ionis Pharmaceuticals, Inc. Methods and compositions for modulating apolipoprotein (a) expression
US9518261B2 (en) 2012-05-22 2016-12-13 Ionis Pharmaceuticals, Inc. Modulation of enhancer RNA mediated gene expression
CA2874521A1 (en) 2012-05-24 2013-11-28 Dana-Farber Cancer Institute, Inc. Targeting the glutamine to pyruvate pathway for treatment of oncogenic kras-associated cancer
AR091143A1 (en) 2012-05-24 2015-01-14 Seeds Ltd Ab COMPOSITIONS AND METHODS TO SILENCE GENETIC EXPRESSION
EA038924B1 (en) 2012-05-25 2021-11-10 Те Риджентс Оф Те Юниверсити Оф Калифорния Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
US9487780B2 (en) 2012-06-01 2016-11-08 Ionis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
WO2013181665A1 (en) 2012-06-01 2013-12-05 Isis Pharmaceuticals, Inc. Antisense compounds targeting genes associated with fibronectin
WO2013184209A1 (en) 2012-06-04 2013-12-12 Ludwig Institute For Cancer Research Ltd. Mif for use in methods of treating subjects with a neurodegenerative disorder
CN104619894B (en) 2012-06-18 2017-06-06 纽亘技术公司 For the composition and method of the Solid phase of unexpected nucleotide sequence
ES2688831T3 (en) 2012-06-25 2018-11-07 Ionis Pharmaceuticals, Inc. UBE3A-ATS expression modulation
US20150011396A1 (en) 2012-07-09 2015-01-08 Benjamin G. Schroeder Methods for creating directional bisulfite-converted nucleic acid libraries for next generation sequencing
US20140038182A1 (en) 2012-07-17 2014-02-06 Dna Logix, Inc. Cooperative primers, probes, and applications thereof
US20150285802A1 (en) 2012-07-18 2015-10-08 Dana-Farber Cancer Institute, Inc. Methods for treating, preventing and predicting risk of developing breast cancer
DK2877494T3 (en) 2012-07-23 2020-09-21 La Jolla Inst Allergy & Immunology PTPRS and proteoglycans in autoimmune disease
US9175266B2 (en) 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
US9567569B2 (en) 2012-07-23 2017-02-14 Gamida Cell Ltd. Methods of culturing and expanding mesenchymal stem cells
ES2917400T3 (en) 2012-07-26 2022-07-08 Illumina Inc Compositions and methods for nucleic acid amplification
EP3693460A1 (en) 2012-07-27 2020-08-12 Ionis Pharmaceuticals, Inc. Modulation of renin-angiotensin system (ras) related diseases by angiotensinogen
US20150216892A1 (en) 2012-08-03 2015-08-06 Aptamir Therapeutics, Inc. Cell-specific delivery of mirna modulators for the treatment of obesity and related disorders
US8603470B1 (en) 2012-08-07 2013-12-10 National Cheng Kung University Use of IL-20 antagonists for treating liver diseases
KR102237882B1 (en) 2012-08-15 2021-04-07 아이오니스 파마수티컬즈, 인코포레이티드 Method of preparing oligomeric compounds using modified capping protocols
EP2885313A4 (en) 2012-08-20 2016-03-09 Univ California Polynucleotides having bioreversible groups
KR102240217B1 (en) 2012-09-25 2021-04-14 젠자임 코포레이션 Peptide-linked morpholino antisense oligonucleotides for treatment of myotonic dystrophy
US9175291B2 (en) 2012-10-11 2015-11-03 Isis Pharmaceuticals Inc. Modulation of androgen receptor expression
EP4052709A1 (en) 2012-10-11 2022-09-07 Ionis Pharmaceuticals, Inc. Methods of treating kennedy's disease
EP2906255B1 (en) 2012-10-12 2023-02-22 Ionis Pharmaceuticals, Inc. Antisense compounds and uses thereof
US20150275208A1 (en) 2012-10-12 2015-10-01 Isis Pharmaceuticals, Inc. Selective antisense compounds and uses thereof
US9029335B2 (en) 2012-10-16 2015-05-12 Isis Pharmaceuticals, Inc. Substituted 2′-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
MX364070B (en) 2012-10-18 2019-04-10 Monsanto Technology Llc Methods and compositions for plant pest control.
US10548962B2 (en) 2012-10-22 2020-02-04 The Board Of Regents For Oklahoma State University Use of the salmonella SPP type III secretion proteins as a protective vaccination
CA2887711A1 (en) 2012-10-23 2014-05-01 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
CA2889415C (en) 2012-10-24 2020-06-02 Genmark Diagnostics, Inc. Integrated multiplex target analysis
US20140322706A1 (en) 2012-10-24 2014-10-30 Jon Faiz Kayyem Integrated multipelx target analysis
JP2016509572A (en) 2012-11-05 2016-03-31 プロナイ セラピューティクス インコーポレイテッド Methods of using biomarkers for the treatment of cancer by modulating BCL2 expression
CA2890207A1 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel ntrk1 fusion molecules and uses thereof
JP6144355B2 (en) 2012-11-26 2017-06-07 モデルナティエックス インコーポレイテッドModernaTX,Inc. Chemically modified mRNA
US9486473B2 (en) 2012-12-13 2016-11-08 Ymir Genomics, Llc MicroRNAs and uses thereof
KR20200143739A (en) 2012-12-20 2020-12-24 사렙타 쎄러퓨틱스 인코퍼레이티드 Improved exon skipping compositions for treating muscular dystrophy
BR112015015975A2 (en) 2013-01-01 2018-11-06 A. B. Seeds Ltd. isolated dsrna molecules and methods of using them for silencing target molecules of interest.
US10683505B2 (en) 2013-01-01 2020-06-16 Monsanto Technology Llc Methods of introducing dsRNA to plant seeds for modulating gene expression
WO2014113540A1 (en) 2013-01-16 2014-07-24 Iowa State University Research Foundation, Inc. A deep intronic target for splicing correction on spinal muscular atrophy gene
CA2897941A1 (en) 2013-01-17 2014-07-24 Moderna Therapeutics, Inc. Signal-sensor polynucleotides for the alteration of cellular phenotypes
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
US9956294B2 (en) 2013-01-18 2018-05-01 H. Lee Moffitt Cancer Center And Research Institute, Inc. Targeted sensitization of non-del(5q) malignant cells
US10000767B2 (en) 2013-01-28 2018-06-19 Monsanto Technology Llc Methods and compositions for plant pest control
US9701708B2 (en) 2013-01-31 2017-07-11 Ionis Pharmaceuticals, Inc. Method of preparing oligomeric compounds using modified coupling protocols
CN105073195A (en) 2013-02-04 2015-11-18 昂科梅德制药有限公司 Methods and monitoring of treatment with a Wnt pathway inhibitor
US10568975B2 (en) 2013-02-05 2020-02-25 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
AU2014216137B2 (en) 2013-02-14 2018-05-10 Ionis Pharmaceuticals, Inc. Modulation of Apolipoprotein C-III (ApoCIII) expression in lipoprotein lipase deficient (LPLD) populations
US20150366890A1 (en) 2013-02-25 2015-12-24 Trustees Of Boston University Compositions and methods for treating fungal infections
KR102384693B1 (en) 2013-03-12 2022-04-07 유니버시티 오브 유타 리서치 파운데이션 Composition and methods for inducing apoptosis
US20160024181A1 (en) 2013-03-13 2016-01-28 Moderna Therapeutics, Inc. Long-lived polynucleotide molecules
AU2014249015B2 (en) 2013-03-13 2020-04-16 Monsanto Technology Llc Methods and compositions for weed control
UY35385A (en) 2013-03-13 2014-09-30 Monsanto Technology Llc ? METHODS AND COMPOSITIONS FOR WEED CONTROL ?.
EP2970951B1 (en) 2013-03-13 2019-02-20 Illumina, Inc. Methods for nucleic acid sequencing
AU2014235794A1 (en) 2013-03-14 2015-10-22 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
US20140283211A1 (en) 2013-03-14 2014-09-18 Monsanto Technology Llc Methods and Compositions for Plant Pest Control
DK2970964T3 (en) 2013-03-14 2019-04-01 Sarepta Therapeutics Inc EXON SKIPPING COMPOSITIONS FOR TREATMENT OF MUSCLE DYROPHY
EA035882B1 (en) 2013-03-14 2020-08-27 Сарепта Терапьютикс, Инк. Antisense oligonucleotides inducing exon skipping for treating muscular dystrophy
BR112015022156A2 (en) 2013-03-14 2017-11-14 Isis Pharmaceuticals Inc compositions and methods for modulating tau expression
KR102342916B1 (en) 2013-03-14 2021-12-24 알닐람 파마슈티칼스 인코포레이티드 Complement component c5 irna compositions and methods of use thereof
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
US10258698B2 (en) 2013-03-14 2019-04-16 Modernatx, Inc. Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions
US10568328B2 (en) 2013-03-15 2020-02-25 Monsanto Technology Llc Methods and compositions for weed control
WO2014152497A2 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for cognitive disorders
CA2942831A1 (en) 2013-03-15 2014-09-18 The Trustees Of Princeton University Methods and devices for high throughput purification
EP2971130A4 (en) 2013-03-15 2016-10-05 Nugen Technologies Inc Sequential sequencing
CA2901384A1 (en) 2013-03-15 2014-09-18 Intermune, Inc. Proteomic ipf markers
WO2014152054A1 (en) 2013-03-15 2014-09-25 Bio-Rad Laboratories, Inc. Digital assays for mutation detection
US10077439B2 (en) 2013-03-15 2018-09-18 Modernatx, Inc. Removal of DNA fragments in mRNA production process
AU2014232869A1 (en) 2013-03-15 2015-10-08 Patrizia Fanara Methods for monitoring the effects of an agent in sujects with motoneuron disease with dementia
CN110186835B (en) 2013-03-15 2022-05-31 Gpb科学有限公司 On-chip microfluidic processing of particles
BR112015022998A2 (en) 2013-03-15 2017-11-14 Sarepta Therapeutics Inc improved compositions for treating muscular dystrophy
KR102276405B1 (en) 2013-03-15 2021-07-12 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 Foot and mouth disease virus (fmdv) consensus proteins, coding sequences therefor and vaccines made therefrom
US8980864B2 (en) 2013-03-15 2015-03-17 Moderna Therapeutics, Inc. Compositions and methods of altering cholesterol levels
EP2969217A2 (en) 2013-03-15 2016-01-20 Genmark Diagnostics Inc. Systems, methods, and apparatus for manipulating deformable fluid vessels
CN115261411A (en) 2013-04-04 2022-11-01 哈佛学院校长同事会 Therapeutic uses of genome editing with CRISPR/Cas systems
WO2014172434A1 (en) 2013-04-16 2014-10-23 The Johns Hopkins University Diagnostic and prognostic test for sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (pwss)
AU2014259759B2 (en) 2013-05-01 2020-06-18 Ionis Pharmaceuticals, Inc. Compositions and methods
EP2994544B1 (en) 2013-05-06 2019-10-02 Pacific Biosciences Of California, Inc. Real-time electronic sequencing
AR096203A1 (en) 2013-05-06 2015-12-16 Alnylam Pharmaceuticals Inc DOSAGES AND METHODS FOR MANAGING NUCLEIC ACID MOLECULES FORMULATED IN LIPIDS
PT2999785T (en) 2013-05-22 2018-07-09 Alnylam Pharmaceuticals Inc Serpina1 irna compositions and methods of use thereof
EP3587578A1 (en) 2013-05-22 2020-01-01 Alnylam Pharmaceuticals, Inc. Tmprss6 irna compositions and methods of use thereof
AU2014268510A1 (en) 2013-05-22 2015-11-26 Telomere Diagnostics, Inc. Measures of short telomere abundance
WO2014197835A2 (en) 2013-06-06 2014-12-11 The General Hospital Corporation Methods and compositions for the treatment of cancer
CA2918787A1 (en) 2013-06-13 2014-12-18 George Tachas Combination therapy
WO2014203189A1 (en) 2013-06-18 2014-12-24 Rosetta Genomics Ltd. Nanocarrier system for micrornas and uses thereof
WO2014205449A2 (en) 2013-06-21 2014-12-24 Isis Pharmaceuticals, Inc. Compounds and methods for modulating apolipoprotein c-iii expression for improving a diabetic profile
RU2700244C2 (en) 2013-07-02 2019-09-13 Ионис Фармасьютикалз, Инк. Modulators of growth hormone receptor
DK3019619T3 (en) 2013-07-11 2021-10-11 Modernatx Inc COMPOSITIONS INCLUDING SYNTHETIC POLYNUCLEOTIDES CODING CRISPR-RELATED PROTEINS, SYNTHETIC SGRNAs, AND USES OF USE
JP6617702B2 (en) 2013-07-15 2019-12-11 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア FTY720 azacyclic constraint analog
RU2703498C2 (en) 2013-07-19 2019-10-17 Монсанто Текнолоджи Ллс Compositions and methods for controlling leptinotarsa
TWI657819B (en) 2013-07-19 2019-05-01 美商Ionis製藥公司 Compositions for modulating tau expression
US9850496B2 (en) 2013-07-19 2017-12-26 Monsanto Technology Llc Compositions and methods for controlling Leptinotarsa
US9944998B2 (en) 2013-07-25 2018-04-17 Bio-Rad Laboratories, Inc. Genetic assays
AU2014306271A1 (en) 2013-08-08 2016-03-24 The Scripps Research Institute A method for the site-specific enzymatic labelling of nucleic acids in vitro by incorporation of unnatural nucleotides
TW201536329A (en) 2013-08-09 2015-10-01 Isis Pharmaceuticals Inc Compounds and methods for modulation of dystrophia myotonica-protein kinase (DMPK) expression
US10782295B2 (en) 2013-08-13 2020-09-22 The Scripps Research Institute Cysteine-reactive ligand discovery in proteomes
JP6652922B2 (en) 2013-08-28 2020-02-26 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. Regulation of prekallikrein (PKK) expression
CA2922698C (en) 2013-08-29 2023-01-03 City Of Hope Cell penetrating conjugates comprising non-cell penetrating antibodies covalently attached to one or more phosphorothioate nucleic acids
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
WO2015034928A1 (en) 2013-09-03 2015-03-12 Moderna Therapeutics, Inc. Chimeric polynucleotides
US20150197534A1 (en) 2013-09-05 2015-07-16 Sarepta Therapeutics, Inc. Antisense-induced exon2 inclusion in acid alpha-glucosidase
EP3791862A1 (en) 2013-09-11 2021-03-17 Eagle Biologics, Inc. Liquid protein formulations containing viscosity-lowering agents
US10059947B2 (en) 2013-09-11 2018-08-28 Synthena Ag Nucleic acids and methods for the treatment of Pompe disease
PE20190354A1 (en) 2013-09-13 2019-03-07 Ionis Pharmaceuticals Inc COMPLEMENT B FACTOR MODULATORS
US9708360B2 (en) 2013-09-30 2017-07-18 Geron Corporation Phosphorodiamidate backbone linkage for oligonucleotides
US10385088B2 (en) 2013-10-02 2019-08-20 Modernatx, Inc. Polynucleotide molecules and uses thereof
WO2015050990A1 (en) 2013-10-02 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
JP2016538829A (en) 2013-10-03 2016-12-15 モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. Polynucleotide encoding low density lipoprotein receptor
CA3188691A1 (en) 2013-10-04 2015-04-09 Novartis Ag 3'end caps for rnai agents for use in rna interference
WO2015050871A2 (en) 2013-10-04 2015-04-09 Novartis Ag Organic compounds to treat hepatitis b virus
US10119143B2 (en) 2013-10-04 2018-11-06 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
EP3052627B1 (en) 2013-10-04 2018-08-22 Novartis AG Novel formats for organic compounds for use in rna interference
WO2015054451A1 (en) 2013-10-09 2015-04-16 The United States Of America As Represented By The Secretary Department Of Health And Human Services Detection of hepatitis delta virus (hdv) for the diagnosis and treatment of sjögren's syndrome and lymphoma
US11162096B2 (en) 2013-10-14 2021-11-02 Ionis Pharmaceuticals, Inc Methods for modulating expression of C9ORF72 antisense transcript
WO2015057998A1 (en) 2013-10-16 2015-04-23 The University Of British Columbia Device for formulating particles at small volumes
US9758546B2 (en) 2013-10-21 2017-09-12 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
CA2928779A1 (en) 2013-10-21 2015-04-30 The General Hospital Corporation Methods relating to circulating tumor cell clusters and the treatment of cancer
USD881409S1 (en) 2013-10-24 2020-04-14 Genmark Diagnostics, Inc. Biochip cartridge
US9498778B2 (en) 2014-11-11 2016-11-22 Genmark Diagnostics, Inc. Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system
MX367192B (en) 2013-10-30 2019-08-08 Green Life Biotech Llc Pathogenesis quantification systems and treatment methods for citrus greening blight.
WO2015066708A1 (en) 2013-11-04 2015-05-07 Northwestern University Quantification and spatio-temporal tracking of a target using a spherical nucleic acid (sna)
AU2014341879B2 (en) 2013-11-04 2020-07-23 Beeologics, Inc. Compositions and methods for controlling arthropod parasite and pest infestations
WO2015073711A1 (en) 2013-11-13 2015-05-21 Nugen Technologies, Inc. Compositions and methods for identification of a duplicate sequencing read
WO2015071474A2 (en) 2013-11-18 2015-05-21 Crispr Therapeutics Ag Crispr-cas system materials and methods
CN105934522B (en) 2013-11-26 2021-07-20 伊鲁米那股份有限公司 Compositions and methods for polynucleotide sequencing
DK3077510T3 (en) 2013-12-02 2020-06-08 Ionis Pharmaceuticals Inc ANTISENSE COMPOUNDS AND APPLICATIONS THEREOF
WO2015126502A2 (en) 2013-12-03 2015-08-27 Northwestern University Liposomal particles, methods of making same and uses thereof
EP3077430A4 (en) 2013-12-05 2017-08-16 Centrillion Technology Holdings Corporation Modified surfaces
US10597715B2 (en) 2013-12-05 2020-03-24 Centrillion Technology Holdings Methods for sequencing nucleic acids
US10391467B2 (en) 2013-12-05 2019-08-27 Centrillion Technology Holdings Corporation Fabrication of patterned arrays
US10385388B2 (en) 2013-12-06 2019-08-20 Swift Biosciences, Inc. Cleavable competitor polynucleotides
CA2844640A1 (en) 2013-12-06 2015-06-06 The University Of British Columbia Method for treatment of castration-resistant prostate cancer
UA119253C2 (en) 2013-12-10 2019-05-27 Біолоджикс, Інк. Compositions and methods for virus control in varroa mite and bees
EP3080302B1 (en) 2013-12-10 2020-09-16 Conexio Genomics Pty Ltd Methods and probes for identifying gene alleles
EP3080266B1 (en) 2013-12-12 2021-02-03 The Regents of The University of California Methods and compositions for modifying a single stranded target nucleic acid
CN105814205B (en) 2013-12-12 2019-11-19 阿尔尼拉姆医药品有限公司 Complement component iRNA composition and its application method
AU2014368912B2 (en) 2013-12-20 2020-04-30 Biomed Valley Discoveries, Inc. Cancer treatments using combinations of type 2 MEK and ERK inhibitors
JP6599334B2 (en) 2013-12-20 2019-10-30 ザ ジェネラル ホスピタル コーポレイション Methods and assays for circulating tumor cells in the blood
US9243289B2 (en) 2013-12-23 2016-01-26 Roche Molecular Systems, Inc. Method for screening reagents used in PCR assays
AU2014369900B2 (en) 2013-12-24 2021-05-20 Ionis Pharmaceuticals, Inc. Modulation of angiopoietin-like 3 expression
AU2015206585A1 (en) 2014-01-15 2016-07-21 Monsanto Technology Llc Methods and compositions for weed control using EPSPS polynucleotides
CN112322735A (en) 2014-01-16 2021-02-05 启迪公司 Gene expression panels for prognosis of prostate cancer recurrence
EP3812473A1 (en) 2014-01-31 2021-04-28 Temple University Of The Commonwealth System Of Higher Education Bag3 as target for therapy of heart failure
WO2015120075A2 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
WO2015118537A2 (en) 2014-02-05 2015-08-13 Yeda Research And Development Co. Ltd. Micro-rnas and compositions comprising same for the treatment and diagnosis of serotonin-, adrenalin-, noradrenalin-, glutamate-, and corticotropin-releasing hormone- associated medical conditions
EA201691587A1 (en) 2014-02-11 2017-01-30 Элнилэм Фармасьютикалз, Инк. COMPOSITIONS BASED ON iRNA FOR KETOGEXOKINASE (KHK) AND METHODS OF THEIR APPLICATION
WO2015127368A1 (en) 2014-02-23 2015-08-27 The Johns Hopkins University Hypotonic microbicidal formulations and methods of use
WO2015131107A1 (en) 2014-02-28 2015-09-03 Nugen Technologies, Inc. Reduced representation bisulfite sequencing with diversity adaptors
US10036019B2 (en) 2014-03-17 2018-07-31 Ionis Pharmaceuticals, Inc. Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
US10006027B2 (en) 2014-03-19 2018-06-26 Ionis Pharmaceuticals, Inc. Methods for modulating Ataxin 2 expression
DK3119888T3 (en) 2014-03-19 2021-09-06 Ionis Pharmaceuticals Inc COMPOSITIONS FOR MODULATING ATAXIN-2 EXPRESSION
WO2015149006A2 (en) 2014-03-27 2015-10-01 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating ncoa4-mediated autophagic targeting of ferritin
US11060139B2 (en) 2014-03-28 2021-07-13 Centrillion Technology Holdings Corporation Methods for sequencing nucleic acids
ES2868305T3 (en) 2014-03-28 2021-10-21 Univ Washington Through Its Center For Commercialization Vaccines against breast and ovarian cancer
JP6574239B2 (en) 2014-03-30 2019-09-11 セフィエド Modified thymine polynucleotide oligomers and methods
EP3757214B1 (en) 2014-04-01 2022-06-15 Biogen MA Inc. Compositions for modulating sod-1 expression
WO2015153339A2 (en) 2014-04-01 2015-10-08 Monsanto Technology Llc Compositions and methods for controlling insect pests
DK3129493T3 (en) 2014-04-09 2021-09-27 Scripps Research Inst Import of unnatural or modified nucleoside triphosphates into cells via nucleic acid triphosphate transporters
WO2015164693A1 (en) 2014-04-24 2015-10-29 Isis Pharmaceuticals, Inc. Oligomeric compounds comprising alpha-beta-constrained nucleic acid
JP6667453B2 (en) 2014-05-01 2020-03-18 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. Compositions and methods for modulating growth hormone receptor expression
EP3845547A1 (en) 2014-05-01 2021-07-07 Ionis Pharmaceuticals, Inc. Galnac3 conjugated modified oligonucleotide for modulating angiopoietin-like 3 expression
PL3608406T3 (en) 2014-05-01 2023-05-22 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating complement factor b expression
MX2016014140A (en) 2014-05-01 2017-09-15 Ionis Pharmaceuticals Inc Compositions and methods for modulating pkk expression.
WO2015168514A1 (en) 2014-05-01 2015-11-05 Isis Pharmaceuticals, Inc. Method for synthesis of reactive conjugate clusters
WO2015171918A2 (en) 2014-05-07 2015-11-12 Louisiana State University And Agricultural And Mechanical College Compositions and uses for treatment thereof
US11918695B2 (en) 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
EP3140269B1 (en) 2014-05-09 2023-11-29 Yale University Hyperbranched polyglycerol-coated particles and methods of making and using thereof
US9937270B2 (en) 2014-05-12 2018-04-10 The John Hopkins University Engineering synthethic brain penetrating gene vectors
WO2015175545A1 (en) 2014-05-12 2015-11-19 The Johns Hopkins University Highly stable biodegradable gene vector platforms for overcoming biological barriers
TW201607559A (en) 2014-05-12 2016-03-01 阿尼拉製藥公司 Methods and compositions for treating a SERPINC1-associated disorder
EP3143141B1 (en) 2014-05-16 2019-10-02 Oregon State University Antisense antibacterial compounds and methods
AU2015264449B2 (en) 2014-05-19 2022-05-05 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
KR20220087576A (en) 2014-05-22 2022-06-24 알닐람 파마슈티칼스 인코포레이티드 Angiotensinogen (agt) irna compositions and methods of use thereof
WO2015179693A1 (en) 2014-05-22 2015-11-26 Isis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US20170182189A1 (en) 2014-05-23 2017-06-29 Genzyme Corporation Inhibiting or downregulating glycogen synthase by creating premature stop codons using antisense oligonucleotides
WO2015187541A1 (en) 2014-06-02 2015-12-10 Children's Medical Center Corporation Methods and compositions for immunomodulation
CN106535876B (en) 2014-06-04 2020-09-11 埃克西奎雷股份有限公司 Multivalent delivery of immunomodulators through liposomal spherical nucleic acids for prophylactic or therapeutic applications
US11033620B2 (en) 2014-06-09 2021-06-15 Biomed Valley Discoveries, Inc. Combination therapies targeting tumor-associated stroma or tumor cells and microtubules
WO2015191568A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature
US10434174B2 (en) 2014-06-09 2019-10-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapies using platinum agents and agents that target tumor-associated stroma or tumor cells
US10758613B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Intstitutes Of Health Combination therapies using anti-metabolites and agents that target tumor-associated stroma or tumor cells
US10758526B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies using agents that target tumor-associated stroma or tumor cells and other pathways
US10758614B2 (en) 2014-06-09 2020-09-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services National Institutes Of Health Combination therapies targeting tumor-associated stroma or tumor cells and topoisomerase
WO2015191615A2 (en) 2014-06-09 2015-12-17 Biomed Valley Discoveries, Inc. Combination therapies using agents that target tumor-associated stroma or tumor cells and alkylating agents
WO2015190922A1 (en) 2014-06-10 2015-12-17 Erasmus University Medical Center Rotterdam Antisense oligonucleotides useful in treatment of pompe disease
AU2015274660B2 (en) 2014-06-10 2020-07-16 Dxterity Diagnostics Incorporated Devices and methods for collecting and stabilizing biological samples
TW201620526A (en) 2014-06-17 2016-06-16 愛羅海德研究公司 Compositions and methods for inhibiting gene expression of alpha-1 antitrypsin
AU2015280252A1 (en) 2014-06-23 2017-01-12 Monsanto Technology Llc Compositions and methods for regulating gene expression via RNA interference
US11807857B2 (en) 2014-06-25 2023-11-07 Monsanto Technology Llc Methods and compositions for delivering nucleic acids to plant cells and regulating gene expression
EP3161159B1 (en) 2014-06-25 2020-08-05 The General Hospital Corporation Targeting human satellite ii (hsatii)
HUE049261T2 (en) 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd Isolated polypeptides of cd44 and uses thereof
EP3169693B1 (en) 2014-07-16 2022-03-09 ModernaTX, Inc. Chimeric polynucleotides
US9951327B1 (en) 2014-07-17 2018-04-24 Integrated Dna Technologies, Inc. Efficient and rapid method for assembling and cloning double-stranded DNA fragments
EP3169699A4 (en) 2014-07-18 2018-06-20 The University of Washington Cancer vaccine compositions and methods of use thereof
EP3172321B2 (en) 2014-07-21 2023-01-04 Illumina, Inc. Polynucleotide enrichment using crispr-cas systems
EP3171895A1 (en) 2014-07-23 2017-05-31 Modernatx, Inc. Modified polynucleotides for the production of intrabodies
RU2697502C2 (en) 2014-07-24 2019-08-14 Эбботт Молекьюлар Инк. Compositions and methods for detecting and analyzing micobacterium tuberculosis
US11072681B2 (en) 2014-07-28 2021-07-27 The Regents Of The University Of California Compositions and methods of making polymerizing nucleic acids
RU2021123470A (en) 2014-07-29 2021-09-06 Монсанто Текнолоджи Ллс COMPOSITIONS AND METHODS FOR COMBATING PESTS
AU2015298263B2 (en) 2014-07-31 2020-05-14 Anji Pharmaceuticals, Inc. ApoE mimetic peptides and higher potency to clear plasma cholesterol
DK3174976T3 (en) 2014-08-01 2020-11-23 Gpb Scient Inc Particle processing methods and systems
WO2016022540A1 (en) 2014-08-04 2016-02-11 The Trustees Of The University Of Pennsylvania Transcriptome in vivo analysis ( tiva) and transcriptome in situ analysis (tisa)
US10980744B2 (en) 2014-08-08 2021-04-20 The Regents Of The University Of California High density peptide polymers
US20170232109A1 (en) 2014-08-19 2017-08-17 Northwestern University Protein/oligonucleotide core-shell nanoparticle therapeutics
EA201790434A1 (en) 2014-08-22 2017-07-31 Окленд Юнисервисиз Лимитед CHANNEL MODULATORS
WO2016030899A1 (en) 2014-08-28 2016-03-03 Yeda Research And Development Co. Ltd. Methods of treating amyotrophic lateral scleroses
PL3185957T3 (en) 2014-08-29 2022-11-14 Alnylam Pharmaceuticals, Inc. Patisiran for use in treating transthyretin mediated amyloidosis
CA2959386A1 (en) 2014-08-29 2016-03-03 Lee Adam Wheeler Methods and compositions for the treatment of cancer
WO2016033424A1 (en) 2014-08-29 2016-03-03 Genzyme Corporation Methods for the prevention and treatment of major adverse cardiovascular events using compounds that modulate apolipoprotein b
SI3189074T1 (en) 2014-09-05 2021-08-31 Rsem, Limited Partnership Compositions and methods for treating and preventing inflammation
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
US10913973B2 (en) 2014-09-17 2021-02-09 Board Of Regents, The University Texas System Methods and devices related to toehold-based strand displacement with loop-mediated isothermal amplification
US10556020B2 (en) 2014-09-26 2020-02-11 University Of Massachusetts RNA-modulating agents
CA2961954A1 (en) 2014-09-29 2016-04-07 The Jackson Laboratory High efficiency, high throughput generation of genetically modified mammals by electroporation
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
JOP20200115A1 (en) 2014-10-10 2017-06-16 Alnylam Pharmaceuticals Inc Compositions And Methods For Inhibition Of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) Gene Expression
CN107530399B (en) 2014-10-10 2022-03-18 马萨诸塞眼科耳科诊所 Effective delivery of therapeutic molecules in vitro and in vivo
EP3206751A4 (en) 2014-10-14 2018-06-13 The J. David Gladstone Institutes Compositions and methods for reactivating latent immunodeficiency virus
EP3207138B1 (en) 2014-10-17 2020-07-15 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting aminolevulinic acid synthase-1 (alas1) and uses thereof
US11370823B2 (en) 2014-10-29 2022-06-28 Massachusetts Eye And Ear Infirmary Efficient delivery of therapeutic molecules to cells of the inner ear
EP3212770B1 (en) 2014-10-29 2022-06-29 Massachusetts Eye & Ear Infirmary Methods for efficient delivery of therapeutic molecules in vitro and in vivo
EP3212794B1 (en) 2014-10-30 2021-04-07 Genzyme Corporation Polynucleotide agents targeting serpinc1 (at3) and methods of use thereof
JOP20200092A1 (en) 2014-11-10 2017-06-16 Alnylam Pharmaceuticals Inc HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US9598722B2 (en) 2014-11-11 2017-03-21 Genmark Diagnostics, Inc. Cartridge for performing assays in a closed sample preparation and reaction system
WO2016077364A2 (en) 2014-11-11 2016-05-19 Genmark Diagnostics, Inc. Instrument and cartridge for performing assays in a closed sample preparation and reaction system
US10005080B2 (en) 2014-11-11 2018-06-26 Genmark Diagnostics, Inc. Instrument and cartridge for performing assays in a closed sample preparation and reaction system employing electrowetting fluid manipulation
AU2015346514B2 (en) 2014-11-11 2021-04-08 Illumina, Inc. Polynucleotide amplification using CRISPR-Cas systems
EP3221451A1 (en) 2014-11-17 2017-09-27 Alnylam Pharmaceuticals, Inc. Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
WO2016081621A1 (en) 2014-11-18 2016-05-26 Yale University Formulations for targeted release of agents under low ph conditions and methods of use thereof
US10682422B2 (en) 2014-11-18 2020-06-16 Yale University Formulations for targeted release of agents under low pH conditions and methods of use thereof
WO2016081728A1 (en) 2014-11-19 2016-05-26 The Trustees Of Columbia University In The City Of New York Osteocalcin as a treatment for frailty associated with aging
JP2017537619A (en) 2014-11-21 2017-12-21 ノースウェスタン ユニバーシティ Sequence-specific intracellular uptake of spherical nucleic acid nanoparticle complexes
US10400243B2 (en) 2014-11-25 2019-09-03 Ionis Pharmaceuticals, Inc. Modulation of UBE3A-ATS expression
JP6997623B2 (en) 2014-12-12 2022-02-04 エム. ウルフ、トッド Compositions and Methods for Editing Intracellular Nucleic Acids Utilizing Oligonucleotides
US9909169B2 (en) 2014-12-17 2018-03-06 Roche Molecular Systems, Inc. Allele-specific amplification of nucleic acids using blocking oligonucleotides for wild type suppression
CA2971169A1 (en) 2014-12-30 2016-07-07 Telomere Diagnostics, Inc. Multiplex quantitative pcr
US9688707B2 (en) 2014-12-30 2017-06-27 Ionis Pharmaceuticals, Inc. Bicyclic morpholino compounds and oligomeric compounds prepared therefrom
CA2972653A1 (en) 2014-12-31 2016-07-07 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
WO2016112132A1 (en) 2015-01-06 2016-07-14 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
MX2017009272A (en) 2015-01-16 2018-04-11 Cell penetrating antibodies.
WO2016115490A1 (en) 2015-01-16 2016-07-21 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of dux4
US9434947B2 (en) 2015-01-20 2016-09-06 Oregon Health & Science University Modulation of KCNH2 isoform expression by oligonucleotides as a therapeutic approach for long QT syndrome
WO2016118762A1 (en) 2015-01-22 2016-07-28 Monsanto Technology Llc Compositions and methods for controlling leptinotarsa
EP3247988A4 (en) 2015-01-23 2018-12-19 Vanderbilt University A robust interferometer and methods of using same
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
JP6929791B2 (en) 2015-02-09 2021-09-01 デューク ユニバーシティ Compositions and methods for epigenome editing
RU2761432C2 (en) 2015-02-10 2021-12-08 Иллюмина, Инк. Method and composition for analysis of cellular components
JP2018510621A (en) 2015-02-13 2018-04-19 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain-containing 3 (PNPLA3) iRNA compositions and methods of use thereof
US10450342B2 (en) 2015-02-23 2019-10-22 Ionis Pharmaceuticals, Inc. Method for solution phase detritylation of oligomeric compounds
WO2016135559A2 (en) 2015-02-23 2016-09-01 Crispr Therapeutics Ag Materials and methods for treatment of human genetic diseases including hemoglobinopathies
PL3650459T3 (en) 2015-02-24 2024-02-26 City Of Hope Chemically encoded spatially addressed library screening platforms
AU2016222546B2 (en) 2015-02-26 2020-01-23 Ionis Pharmaceuticals, Inc. Allele specific modulators of P23H rhodopsin
US11129844B2 (en) 2015-03-03 2021-09-28 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating MECP2 expression
US10781445B2 (en) 2015-03-11 2020-09-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Decoy oligonucleotides for the treatment of diseases
MA41795A (en) 2015-03-18 2018-01-23 Sarepta Therapeutics Inc EXCLUSION OF AN EXON INDUCED BY ANTISENSE COMPOUNDS IN MYOSTATIN
US9708647B2 (en) 2015-03-23 2017-07-18 Insilixa, Inc. Multiplexed analysis of nucleic acid hybridization thermodynamics using integrated arrays
WO2016154345A1 (en) 2015-03-24 2016-09-29 Pacific Biosciences Of California, Inc. Methods and compositions for single molecule composition loading
US20180064748A1 (en) 2015-03-27 2018-03-08 Yeda Research And Development Co. Ltd. Methods of treating motor neuron diseases
EP3274712A4 (en) 2015-03-27 2019-01-23 The Scripps Research Institute Lipid probes and uses thereof
KR20180020125A (en) 2015-03-27 2018-02-27 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 Modified T cells and methods for their manufacture and use
DK3277368T3 (en) 2015-03-31 2020-07-27 Oncosec Medical Inc SYSTEMS FOR IMPROVED TISSUE REGISTRATION-BASED ELECTROPORATION
EP3283502A4 (en) 2015-04-07 2019-04-03 The General Hospital Corporation Methods for reactivating genes on the inactive x chromosome
US10745702B2 (en) 2015-04-08 2020-08-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the LECT2 gene
CN104845967B (en) 2015-04-15 2020-12-11 苏州新海生物科技股份有限公司 Oligonucleotide fragment, method for selectively amplifying target nucleic acid sequence variant by using same and application of oligonucleotide fragment
US20180126014A1 (en) 2015-04-15 2018-05-10 Yale University Compositions for enhancing delivery of agents across the blood brain barrier and methods of use thereof
WO2016167780A1 (en) 2015-04-16 2016-10-20 Ionis Pharmaceuticals, Inc. Compositions for modulating expression of c9orf72 antisense transcript
PL3283080T3 (en) 2015-04-16 2020-07-27 Ionis Pharmaceuticals, Inc. Compositions for modulating c9orf72 expression
US20180156807A1 (en) 2015-04-29 2018-06-07 New York University Method for treating high-grade gliomas
EP3291677A4 (en) 2015-05-04 2019-02-13 Monsanto Technology LLC Compositions and methods for controlling arthropod parasite and pest infestations
US20180161300A1 (en) 2015-05-11 2018-06-14 Yeda Research And Development Co., Ltd. Citrin inhibitors for the treatment of cancer
WO2016187425A1 (en) 2015-05-19 2016-11-24 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
US10787664B2 (en) 2015-05-26 2020-09-29 City Of Hope Compounds of chemically modified oligonucleotides and methods of use thereof
EP3851531A1 (en) 2015-06-01 2021-07-21 Sarepta Therapeutics, Inc. Antisense-induced exon exclusion in type vii collagen
DK3302709T3 (en) 2015-06-01 2021-08-23 Univ Temple METHODS AND COMPOSITIONS FOR THE RNA GUIDE TREATMENT OF HIV INFECTION
US10196701B2 (en) 2015-06-01 2019-02-05 The Penn State Research Foundation Hepatitis B virus capsid assembly
UY36703A (en) 2015-06-02 2016-12-30 Monsanto Technology Llc COMPOSITIONS AND METHODS FOR THE ADMINISTRATION OF A POLINUCLEOTIDE ON A PLANT
WO2016196782A1 (en) 2015-06-03 2016-12-08 Monsanto Technology Llc Methods and compositions for introducing nucleic acids into plants
US10392607B2 (en) 2015-06-03 2019-08-27 The Regents Of The University Of California Cas9 variants and methods of use thereof
US11020417B2 (en) 2015-06-04 2021-06-01 Sarepta Therapeutics, Inc Methods and compounds for treatment of lymphocyte-related diseases and conditions
US10464067B2 (en) 2015-06-05 2019-11-05 Miroculus Inc. Air-matrix digital microfluidics apparatuses and methods for limiting evaporation and surface fouling
EP3303548A4 (en) 2015-06-05 2019-01-02 Miroculus Inc. Evaporation management in digital microfluidic devices
WO2016201111A1 (en) 2015-06-09 2016-12-15 Centrillion Technology Holdings Corporation Methods for sequencing nucleic acids
WO2016201301A1 (en) 2015-06-12 2016-12-15 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
EP3310918B1 (en) 2015-06-18 2020-08-05 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, hao1) and methods of use thereof
WO2016209862A1 (en) 2015-06-23 2016-12-29 Alnylam Pharmaceuticals, Inc. Glucokinase (gck) irna compositions and methods of use thereof
EP3314250A4 (en) 2015-06-26 2018-12-05 Beth Israel Deaconess Medical Center, Inc. Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
WO2017004079A1 (en) 2015-06-29 2017-01-05 Biomed Valley Discoveries, Inc. Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment
JP2018519811A (en) 2015-06-29 2018-07-26 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
WO2017004243A1 (en) 2015-06-29 2017-01-05 Caris Science, Inc. Therapeutic oligonucleotides
US10494632B2 (en) 2015-07-10 2019-12-03 Alnylam Pharmaceuticals, Inc. Insulin-like growth factor binding protein, acid labile subunit (IGFALS) compositions and methods of use thereof
WO2017011276A1 (en) 2015-07-10 2017-01-19 Ionis Pharmaceuticals, Inc. Modulators of diacyglycerol acyltransferase 2 (dgat2)
CN108184327A (en) 2015-07-14 2018-06-19 雅培分子公司 For identifying the composition of drug resistant M and method
WO2017019918A1 (en) 2015-07-28 2017-02-02 Caris Science, Inc. Targeted oligonucleotides
US20180221393A1 (en) 2015-08-03 2018-08-09 Biokine Therapeutics Ltd. Cxcr4 binding agents for treatment of diseases
WO2017023861A1 (en) 2015-08-03 2017-02-09 The Regents Of The University Of California Compositions and methods for modulating abhd2 activity
WO2017021961A1 (en) 2015-08-04 2017-02-09 Yeda Research And Development Co. Ltd. Methods of screening for riboswitches and attenuators
JP7104462B2 (en) 2015-08-06 2022-07-21 シティ・オブ・ホープ Cell-permeable protein-antibody conjugate and usage
AU2016306275A1 (en) 2015-08-07 2018-02-08 Arrowhead Pharmaceuticals, Inc. RNAi therapy for Hepatitis B virus infection
EP3130681B1 (en) 2015-08-13 2019-11-13 Centrillion Technology Holdings Corporation Methods for synchronizing nucleic acid molecules
MX2018002090A (en) 2015-08-24 2018-09-12 Halo Bio Rnai Therapeutics Inc Polynucleotide nanoparticles for the modulation of gene expression and uses thereof.
WO2017040078A1 (en) 2015-09-02 2017-03-09 Alnylam Pharmaceuticals, Inc. PROGRAMMED CELL DEATH 1 LIGAND 1 (PD-L1) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP3859333A1 (en) 2015-09-10 2021-08-04 InSilixa, Inc. Systems for multiplex quantitative nucleic acid amplification
US9499861B1 (en) 2015-09-10 2016-11-22 Insilixa, Inc. Methods and systems for multiplex quantitative nucleic acid amplification
US11434486B2 (en) 2015-09-17 2022-09-06 Modernatx, Inc. Polynucleotides containing a morpholino linker
EP3353328A4 (en) 2015-09-24 2019-06-12 Ionis Pharmaceuticals, Inc. Modulators of kras expression
CA2998287A1 (en) 2015-09-24 2017-04-20 Crispr Therapeutics Ag Novel family of rna-programmable endonucleases and their uses in genome editing and other applications
CA2999177A1 (en) 2015-09-24 2017-03-30 The Regents Of The University Of California Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment
WO2017053781A1 (en) 2015-09-25 2017-03-30 Ionis Pharmaceuticals, Inc. Compositions and methods for modulating ataxin 3 expression
US20190054113A1 (en) 2015-09-30 2019-02-21 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
PE20181085A1 (en) 2015-10-08 2018-07-05 Ionis Pharmaceuticals Inc COMPOSITIONS AND METHODS TO MODULATE THE EXPRESSION OF ANGIOTENSINOGEN
JP2018530560A (en) 2015-10-09 2018-10-18 サレプタ セラピューティクス, インコーポレイテッド Compositions and methods for the treatment of Duchenne muscular dystrophy and related disorders
EP3362102A1 (en) 2015-10-14 2018-08-22 Life Technologies Corporation Ribonucleoprotein transfection agents
US10801026B2 (en) 2015-10-15 2020-10-13 City Of Hope Compounds and compositions including phosphorothioated oligodeoxynucleotide, and methods of use thereof
SK500652015A3 (en) 2015-10-15 2017-05-03 Ústav Polymérov Sav A method for altering the functional state of mRNA allowing its selective and specific recognition
WO2017075038A1 (en) 2015-10-26 2017-05-04 Rana Therapeutics, Inc. Nanoparticle formulations for delivery of nucleic acid complexes
JP2019507579A (en) 2015-10-28 2019-03-22 クリスパー セラピューティクス アーゲー Materials and methods for the treatment of Duchenne muscular dystrophy
HUE054093T2 (en) 2015-10-30 2021-08-30 Hoffmann La Roche Anti-htra1 antibodies and methods of use thereof
EP3370734B1 (en) 2015-11-05 2023-01-04 Children's Hospital Los Angeles Antisense oligo for use in treating acute myeloid leukemia
BR112018008971A2 (en) 2015-11-06 2018-11-27 Crispr Therapeutics Ag Materials and Methods for Treatment of Type 1a Glycogen Storage Disease
US20190046555A1 (en) 2015-11-06 2019-02-14 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds for use in therapy
US10557137B2 (en) 2015-11-06 2020-02-11 Ionis Pharmaceuticals, Inc. Modulating apolipoprotein (a) expression
WO2017081686A1 (en) 2015-11-10 2017-05-18 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Means and methods for reducing tumorigenicity of cancer stem cells
CA3005878A1 (en) 2015-11-19 2017-05-26 The Brigham And Women's Hospital, Inc. Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
CA3005968A1 (en) 2015-11-23 2017-06-01 The Regents Of The University Of California Tracking and manipulating cellular rna via nuclear delivery of crispr/cas9
CA3006759A1 (en) 2015-11-30 2017-06-08 The Regents Of The University Of California Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
WO2017093804A2 (en) 2015-12-01 2017-06-08 Crispr Therapeutics Ag Materials and methods for treatment of alpha-1 antitrypsin deficiency
EP3389670A4 (en) 2015-12-04 2020-01-08 Ionis Pharmaceuticals, Inc. Methods of treating breast cancer
WO2017099579A1 (en) 2015-12-07 2017-06-15 Erasmus University Medical Center Rotterdam Enzymatic replacement therapy and antisense therapy for pompe disease
CA3006748A1 (en) 2015-12-15 2017-06-22 Sarepta Therapeutics, Inc. Peptide oligonucleotide conjugates
AU2016369612B2 (en) 2015-12-17 2023-06-01 Modernatx, Inc. Polynucleotides encoding methylmalonyl-CoA mutase
US11761007B2 (en) 2015-12-18 2023-09-19 The Scripps Research Institute Production of unnatural nucleotides using a CRISPR/Cas9 system
AU2016379402B2 (en) 2015-12-23 2023-01-12 Board Of Regents, The University Of Texas System Antisense antibacterial compounds and methods
EP3394261A4 (en) 2015-12-23 2019-11-27 Oregon State University Antisense antibacterial compounds and methods
CA3009308A1 (en) 2015-12-23 2017-06-29 Chad Albert COWAN Materials and methods for treatment of amyotrophic lateral sclerosis and/or frontal temporal lobular degeneration
CA3006599A1 (en) 2016-01-05 2017-07-13 Ionis Pharmaceuticals, Inc. Methods for reducing lrrk2 expression
JP7349788B2 (en) 2016-01-06 2023-09-25 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア Branch mixer and its use and manufacturing method
JP2019501659A (en) 2016-01-15 2019-01-24 ザ ジャクソン ラボラトリー Genetically modified non-human mammal by multi-cycle electroporation of CAS9 protein
WO2017132483A1 (en) 2016-01-29 2017-08-03 Vanderbilt University Free-solution response function interferometry
US20190038771A1 (en) 2016-02-02 2019-02-07 Crispr Therapeutics Ag Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
CA3019952A1 (en) 2016-02-04 2017-08-10 Curis, Inc. Mutant smoothened and methods of using the same
CN109415728A (en) 2016-02-15 2019-03-01 天普大学-联邦高等教育系统 The excision of retroviral nucleic acid sequence
US11136597B2 (en) 2016-02-16 2021-10-05 Yale University Compositions for enhancing targeted gene editing and methods of use thereof
WO2017143061A1 (en) 2016-02-16 2017-08-24 Yale University Compositions and methods for treatment of cystic fibrosis
EP3416689B1 (en) 2016-02-18 2023-01-18 CRISPR Therapeutics AG Materials and methods for treatment of severe combined immunodeficiency (scid) or omenn syndrome
CN109312347A (en) 2016-02-19 2019-02-05 希望之城 Bispecific aptamer
US11234996B2 (en) 2016-02-25 2022-02-01 The Brigham And Women's Hospital, Inc. Treatment methods for fibrosis targeting SMOC2
JP7025340B2 (en) 2016-02-26 2022-02-24 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー Multiplexed single molecule RNA visualization using a two-probe proximity ligation system
CN109072240A (en) 2016-02-26 2018-12-21 耶鲁大学 Use the composition and method of piRNA diagnosing and treating cancer
US20210189062A1 (en) 2016-03-01 2021-06-24 Alexion Pharmaceuticals, Inc. Biodegradable activated polymers for therapeutic delivery
WO2017155858A1 (en) 2016-03-07 2017-09-14 Insilixa, Inc. Nucleic acid sequence identification using solid-phase cyclic single base extension
SG11201807729YA (en) 2016-03-08 2018-10-30 Kemyth Biotech Co Ltd Use of pneumolysin peptides as antagonists against toll-like receptor 4 and methods of treating toll-like receptor 4 related diseases
US11136577B2 (en) 2016-03-09 2021-10-05 Ionis Pharmaceuticals, Inc. Methods and compositions for inhibiting PMP22 expression
WO2017158422A1 (en) 2016-03-16 2017-09-21 Crispr Therapeutics Ag Materials and methods for treatment of hereditary haemochromatosis
WO2017161172A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Methods of modulating keap1
WO2017161168A1 (en) 2016-03-16 2017-09-21 Ionis Pharmaceuticals, Inc. Modulation of dyrk1b expression
EP4339288A2 (en) 2016-03-18 2024-03-20 Caris Science, Inc. Oligonucleotide probes and uses thereof
WO2017173247A1 (en) 2016-03-31 2017-10-05 City Of Hope Aptamer compositions and the use thereof
WO2017173453A1 (en) 2016-04-01 2017-10-05 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
EP3443094B1 (en) 2016-04-13 2022-10-19 Ionis Pharmaceuticals, Inc. Methods for reducing c9orf72 expression
WO2017181163A2 (en) 2016-04-16 2017-10-19 Oncocyte Corporation Methods and compositions for detection and diagnosis of breast cancer
US20200330609A1 (en) 2016-04-18 2020-10-22 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
KR102522059B1 (en) 2016-04-18 2023-04-14 사렙타 쎄러퓨틱스 인코퍼레이티드 Antisense oligomers and methods of their use to treat diseases associated with the acid alpha-glucosidase gene
MA45295A (en) 2016-04-19 2019-02-27 Alnylam Pharmaceuticals Inc HIGH DENSITY LIPOPROTEIN BINDING PROTEIN (HDLBP / VIGILINE) RNA COMPOSITION AND METHODS FOR USING THEM
KR102329187B1 (en) 2016-04-29 2021-11-22 사렙타 쎄러퓨틱스, 인코퍼레이티드 Oligonucleotide analogues targeting human LMNA
JP2019527065A (en) 2016-05-04 2019-09-26 アビリタ バイオ,インク. Methods and platforms for preparing multiple transmembrane proteins
WO2017191503A1 (en) 2016-05-05 2017-11-09 Crispr Therapeutics Ag Materials and methods for treatment of hemoglobinopathies
CA3022319A1 (en) 2016-05-06 2017-11-09 Tod M. Woolf Improved methods for genome editing with and without programmable nucleases
US11542544B2 (en) 2016-05-11 2023-01-03 Illumina, Inc. Polynucleotide enrichment and amplification using CRISPR-Cas or Argonaute systems
WO2017197128A1 (en) 2016-05-11 2017-11-16 Yale University Poly(amine-co-ester) nanoparticles and methods of use thereof
EP3458597B1 (en) 2016-05-18 2022-09-07 Roche Diagnostics GmbH Quantitative real time pcr amplification using an electrowetting-based device
CN109563114B (en) 2016-05-24 2022-08-12 萨勒普塔医疗公司 Process for preparing oligomers
WO2017205880A1 (en) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
MA45158A (en) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc PHARMACEUTICAL COMPOSITION CONSISTING OF ÉTEPLIRSEN
US11472824B2 (en) 2016-05-24 2022-10-18 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
WO2017205879A2 (en) 2016-05-24 2017-11-30 Sarepta Therapeutics, Inc. Processes for preparing phosphorodiamidate morpholino oligomers
CN109311920B (en) 2016-05-24 2021-11-09 萨勒普塔医疗公司 Process for preparing phosphoric acid diamide morpholino oligomer
MA45362A (en) 2016-05-24 2019-04-10 Sarepta Therapeutics Inc PROCESSES FOR THE PREPARATION OF MORPHOLINO OLIGOMERS OF PHOSPHORODIAMIDATE
AU2017271579B2 (en) 2016-05-25 2023-10-19 Caris Science, Inc. Oligonucleotide probes and uses thereof
US11828755B2 (en) 2016-06-09 2023-11-28 The Regents Of The University Of California Biomarker concentration and signal amplification for use in paper-based immunoassays and a single platform for extracting, concentrating, and amplifying DNA
WO2017222834A1 (en) 2016-06-10 2017-12-28 City Of Hope Compositions and methods for mitochondrial genome editing
EP3469083A1 (en) 2016-06-10 2019-04-17 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING PAROXYSMAL NOCTURNAL HEMOGLOBINURIA (PNH)
US10544457B2 (en) 2016-06-14 2020-01-28 Pacific Biosciences Of California, Inc. Methods and compositions for enriching compositions for polymerase enzyme complexes
US10925973B2 (en) 2016-06-15 2021-02-23 University Of Utah Research Foundation Compositions and methods for using albumin-based nanomedicines
US10337051B2 (en) 2016-06-16 2019-07-02 The Regents Of The University Of California Methods and compositions for detecting a target RNA
WO2017219017A1 (en) 2016-06-17 2017-12-21 Ionis Pharmaceuticals, Inc. Modulation of gys1 expression
ES2929047T3 (en) 2016-06-24 2022-11-24 Scripps Research Inst Novel nucleoside triphosphate transporter and uses thereof
US11174469B2 (en) 2016-06-29 2021-11-16 Crispr Therapeutics Ag Materials and methods for treatment of Amyotrophic Lateral Sclerosis (ALS) and other related disorders
CA3029119A1 (en) 2016-06-29 2018-01-04 Crispr Therapeutics Ag Materials and methods for treatment of friedreich ataxia and other related disorders
US11427838B2 (en) 2016-06-29 2022-08-30 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of myotonic dystrophy type 1 (DM1) and other related disorders
JP2019525742A (en) 2016-06-30 2019-09-12 サレプタ セラピューティクス, インコーポレイテッド Exon skipping oligomer for muscular dystrophy
JP2019520079A (en) 2016-07-06 2019-07-18 クリスパー セラピューティクス アクチェンゲゼルシャフト Substances and methods for treating pain related disorders
CA3029132A1 (en) 2016-07-06 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of pain related disorders
WO2018007871A1 (en) 2016-07-08 2018-01-11 Crispr Therapeutics Ag Materials and methods for treatment of transthyretin amyloidosis
WO2018013525A1 (en) 2016-07-11 2018-01-18 Translate Bio Ma, Inc. Nucleic acid conjugates and uses thereof
WO2018013558A1 (en) 2016-07-12 2018-01-18 Life Technologies Corporation Compositions and methods for detecting nucleic acid regions
LT3484524T (en) 2016-07-15 2022-12-27 Ionis Pharmaceuticals, Inc. Compounds and methods for modulation of smn2
KR20190031306A (en) 2016-07-21 2019-03-25 맥스시티 인코포레이티드 Methods and compositions for altering genomic DNA
US10711300B2 (en) 2016-07-22 2020-07-14 Pacific Biosciences Of California, Inc. Methods and compositions for delivery of molecules and complexes to reaction sites
WO2018020323A2 (en) 2016-07-25 2018-02-01 Crispr Therapeutics Ag Materials and methods for treatment of fatty acid disorders
CN109963564B (en) 2016-07-27 2022-08-12 利兰斯坦福初级大学董事会 Disaggregated cell-penetrating complexes for nucleic acid delivery
JOP20170161A1 (en) 2016-08-04 2019-01-30 Arrowhead Pharmaceuticals Inc RNAi Agents for Hepatitis B Virus Infection
NL2017294B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Natural cryptic exon removal by pairs of antisense oligonucleotides.
NL2017295B1 (en) 2016-08-05 2018-02-14 Univ Erasmus Med Ct Rotterdam Antisense oligomeric compound for Pompe disease
CA3034064A1 (en) 2016-08-22 2018-03-01 Miroculus Inc. Feedback system for parallel droplet control in a digital microfluidic device
US11364304B2 (en) 2016-08-25 2022-06-21 Northwestern University Crosslinked micellar spherical nucleic acids
EP4101859A1 (en) 2016-09-02 2022-12-14 Dicerna Pharmaceuticals, Inc. 4'-oxymethylphosphonate nucleotide analogs and oligonucleotides comprising the same
US11780895B2 (en) 2016-09-13 2023-10-10 The Jackson Laboratory Targeted DNA demethylation and methylation
US11090391B2 (en) 2016-09-16 2021-08-17 The Johns Hopkins University Protein nanocages with enhanced mucus penetration for targeted tissue and intracellular delivery
WO2018053501A1 (en) 2016-09-19 2018-03-22 Genmark Diagnostics, Inc. Instrument for processing cartridge for performing assays in a closed sample preparation and reaction system
CN116804031A (en) 2016-09-20 2023-09-26 科罗拉多州立大学董事会法人团体 Synthesis of backbone modified morpholino oligonucleotides and chimeras using phosphoramidite chemistry
JOP20190065A1 (en) 2016-09-29 2019-03-28 Ionis Pharmaceuticals Inc Compounds and methods for reducing tau expression
JP2019532644A (en) 2016-09-30 2019-11-14 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア RNA-induced nucleic acid modifying enzyme and method of using the same
WO2018067900A1 (en) 2016-10-06 2018-04-12 Ionis Pharmaceuticals, Inc. Method of conjugating oligomeric compounds
US11459568B2 (en) 2016-10-31 2022-10-04 University Of Massachusetts Targeting microRNA-101-3p in cancer therapy
JOP20190104A1 (en) 2016-11-10 2019-05-07 Ionis Pharmaceuticals Inc Compounds and methods for reducing atxn3 expression
US11434301B2 (en) 2016-11-11 2022-09-06 The Regents Of The University Of California Anti-CD46 antibodies and methods of use
US11008325B2 (en) 2016-11-14 2021-05-18 Virginia Commonwealth University Inhibitors of cancer invasion, attachment, and/or metastasis
TWI788312B (en) 2016-11-23 2023-01-01 美商阿尼拉製藥公司 SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
EP3330276A1 (en) 2016-11-30 2018-06-06 Universität Bern Novel bicyclic nucleosides and oligomers prepared therefrom
EP3548620A4 (en) 2016-12-02 2020-07-22 Cold Spring Harbor Laboratory Modulation of lnc05 expression
AU2017378153B2 (en) 2016-12-13 2024-03-28 Seattle Children's Hospital (dba Seattle Children's Research Institute) Methods of exogenous drug activation of chemical-induced signaling complexes expressed in engineered cells in vitro and in vivo
WO2018112470A1 (en) 2016-12-16 2018-06-21 The Brigham And Women's Hospital, Inc. Co-delivery of nucleic acids for simultaneous suppression and expression of target genes
SG10201913552UA (en) 2016-12-16 2020-03-30 Alnylam Pharmaceuticals Inc Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions
AU2017382773A1 (en) 2016-12-19 2019-08-01 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
BR112019012647A2 (en) 2016-12-19 2019-11-19 Sarepta Therapeutics Inc exon jump oligomer conjugates for muscular dystrophy
WO2018118627A1 (en) 2016-12-19 2018-06-28 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
JP2020515815A (en) 2016-12-28 2020-05-28 ミロキュラス インコーポレイテッド Digital microfluidic device and method
BR112019014282A2 (en) 2017-01-10 2020-03-03 Arrowhead Pharmaceuticals, Inc. ANTITHRIPSIN RNAI AGENTS (AAT) ALPHA-1, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE
US11535597B2 (en) 2017-01-18 2022-12-27 The Scripps Research Institute Photoreactive ligands and uses thereof
MX2019008675A (en) 2017-01-23 2019-09-18 Regeneron Pharma Hydroxysteroid 17-beta dehydrogenase 13 (hsd17b13) variants and uses thereof.
EP4253565A2 (en) 2017-01-24 2023-10-04 Vastogen, Inc. Methods for constructing copies of nucleic acid molecules
WO2018154439A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 1 (sca1) and other spinocerebellar ataxia type 1 protein (atxn1) gene related conditions or disorders
US20200216857A1 (en) 2017-02-22 2020-07-09 Crispr Therapeutics Ag Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
WO2018154459A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of primary hyperoxaluria type 1 (ph1) and other alanine-glyoxylate aminotransferase (agxt) gene related conditions or disorders
WO2018154418A1 (en) 2017-02-22 2018-08-30 Crispr Therapeutics Ag Materials and methods for treatment of early onset parkinson's disease (park1) and other synuclein, alpha (snca) gene related conditions or disorders
JP2020508056A (en) 2017-02-22 2020-03-19 クリスパー・セラピューティクス・アクチェンゲゼルシャフトCRISPR Therapeutics AG Compositions and methods for gene editing
EP3596099A4 (en) 2017-03-06 2020-12-09 Singular Genomics Systems, Inc. Nucleic acid sequencing-by-synthesis (sbs) methods that combine sbs cycle steps
US11180756B2 (en) 2017-03-09 2021-11-23 Ionis Pharmaceuticals Morpholino modified oligomeric compounds
WO2018169960A1 (en) 2017-03-17 2018-09-20 The Johns Hopkins University Nanoparticle formulations for enhanced drug delivery to the bladder
JOP20190215A1 (en) 2017-03-24 2019-09-19 Ionis Pharmaceuticals Inc Modulators of pcsk9 expression
US20180284123A1 (en) 2017-03-30 2018-10-04 California Institute Of Technology Barcoded rapid assay platform useful for efficient analysis of candidate molecules and methods of making and using the platform
US20200113821A1 (en) 2017-04-04 2020-04-16 Yale University Compositions and methods for in utero delivery
US11623219B2 (en) 2017-04-04 2023-04-11 Miroculus Inc. Digital microfluidics apparatuses and methods for manipulating and processing encapsulated droplets
CA3059446A1 (en) 2017-04-18 2018-10-25 Alnylam Pharmaceuticals, Inc. Methods for the treatment of subjects having a hepatitis b virus (hbv) infection
JP2020517638A (en) 2017-04-20 2020-06-18 エータイアー ファーマ, インコーポレイテッド Compositions and methods for treating lung inflammation
EP3612546B1 (en) 2017-04-20 2022-07-13 Synthena AG Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
WO2018193428A1 (en) 2017-04-20 2018-10-25 Synthena Ag Modified oligomeric compounds comprising tricyclo-dna nucleosides and uses thereof
KR20190135054A (en) 2017-04-21 2019-12-05 파이 테라퓨틱스, 인크. Acne treatment composition comprising propionibacterium acnes bacteriophage
EP3612232A1 (en) 2017-04-21 2020-02-26 The Broad Institute, Inc. Targeted delivery to beta cells
CA3061738A1 (en) 2017-04-28 2018-11-01 Auckland Uniservices Limited Methods of treatment and novel constructs
CA3062595A1 (en) 2017-05-10 2018-11-15 The Regents Of The University Of California Directed editing of cellular rna via nuclear delivery of crispr/cas9
WO2018209092A1 (en) 2017-05-10 2018-11-15 Board Of Regents, The University Of Texas System Methods and devices related to amplifying nucleic acid at a variety of temperatures
JP7356354B2 (en) 2017-05-12 2023-10-04 クリスパー セラピューティクス アクチェンゲゼルシャフト Materials and methods for the manipulation of cells and their use in immuno-oncology
WO2018212271A1 (en) 2017-05-18 2018-11-22 国立大学法人京都大学 Composition for prevention or treatment of spinocerebellar ataxia type 36
WO2019006371A1 (en) 2017-06-30 2019-01-03 City Of Hope Compositions and methods of modulating macrophage activity
JP7325341B2 (en) 2017-07-11 2023-08-14 シンソークス,インク. Incorporation of non-natural nucleotides and method thereof
AU2018301442A1 (en) 2017-07-13 2020-01-30 Massachusetts Institute Of Technology Targeting the HDAC2-Sp3 complex to enhance synaptic function
AU2018301477A1 (en) 2017-07-13 2020-02-27 Alnylam Pharmaceuticals Inc. Lactate dehydrogenase a (LDHA) iRNA compositions and methods of use thereof
CN111093710A (en) 2017-07-13 2020-05-01 希望之城 Phosphorothioate-conjugated peptides and methods of use thereof
KR20200028997A (en) 2017-07-13 2020-03-17 노오쓰웨스턴 유니버시티 General and direct method of preparing oligonucleotide-functionalized metal-organic framework nanoparticles
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
WO2019023133A1 (en) 2017-07-24 2019-01-31 Miroculus Inc. Digital microfluidics systems and methods with integrated plasma collection device
US11459306B2 (en) 2017-07-31 2022-10-04 The Trustees Of Columbia University In The City Of New York Compounds, compositions, and methods for treating T-cell acute lymphoblastic leukemia
NZ761430A (en) 2017-08-03 2024-03-22 Synthorx Inc Cytokine conjugates for the treatment of proliferative and infectious diseases
NL2019390B1 (en) 2017-08-04 2019-02-21 Univ Leiden Screening Method
WO2019032827A1 (en) 2017-08-09 2019-02-14 Massachusetts Institute Of Technology Albumin binding peptide conjugates and methods thereof
AU2018314236A1 (en) 2017-08-11 2020-03-19 Apterna Limited RNA aptamers against transferrin receptor (TfR)
WO2019036613A1 (en) 2017-08-18 2019-02-21 Ionis Pharmaceuticals, Inc. Modulation of the notch signaling pathway for treatment of respiratory disorders
US20190060482A1 (en) 2017-08-31 2019-02-28 Life Technologies Corporation Cationic lipid compositions for tissue-specific delivery
CN111587149B (en) 2017-09-01 2022-11-11 米罗库鲁斯公司 Digital microfluidic device and method of use thereof
US20200299729A1 (en) 2017-09-08 2020-09-24 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof
WO2019051237A1 (en) 2017-09-08 2019-03-14 Life Technologies Corporation Methods for improved homologous recombination and compositions thereof
WO2019051173A1 (en) 2017-09-08 2019-03-14 Ionis Pharmaceuticals, Inc. Modulators of smad7 expression
MA50267A (en) 2017-09-19 2020-07-29 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS OF TREATMENT OF TRANSTHYRETIN-MEDIA AMYLOSIS (TTR)
EA201991450A1 (en) 2017-09-22 2019-12-30 Сарепта Терапьютикс, Инк. OLIGOMER CONJUGATES FOR EXONISM SKIP IN MUSCULAR DYSTROPHY
EP3687519A1 (en) 2017-09-28 2020-08-05 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
JP2020536060A (en) 2017-09-28 2020-12-10 サレプタ セラピューティクス, インコーポレイテッド Combination therapy to treat muscular dystrophy
WO2019067981A1 (en) 2017-09-28 2019-04-04 Sarepta Therapeutics, Inc. Combination therapies for treating muscular dystrophy
US20220080055A9 (en) 2017-10-17 2022-03-17 Crispr Therapeutics Ag Compositions and methods for gene editing for hemophilia a
WO2019079637A2 (en) 2017-10-18 2019-04-25 Sarepta Therapeutics, Inc. Antisense oligomer compounds
US11099202B2 (en) 2017-10-20 2021-08-24 Tecan Genomics, Inc. Reagent delivery system
US20210180091A1 (en) 2017-10-26 2021-06-17 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
EP3704245A1 (en) 2017-11-01 2020-09-09 Novartis AG Synthetic rnas and methods of use
WO2019089922A1 (en) 2017-11-01 2019-05-09 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof
TWI809004B (en) 2017-11-09 2023-07-21 美商Ionis製藥公司 Compounds and methods for reducing snca expression
MA50579A (en) 2017-11-09 2020-09-16 Crispr Therapeutics Ag AUTO-INACTIVATION (INS) CRISPR / CAS OR CRISPR / CPF1 SYSTEMS AND THEIR USES
WO2019092269A1 (en) 2017-11-13 2019-05-16 F. Hoffmann-La Roche Ag Devices for sample analysis using epitachophoresis
US20200385719A1 (en) 2017-11-16 2020-12-10 Alnylam Pharmaceuticals, Inc. Kisspeptin 1 (kiss1) irna compositions and methods of use thereof
WO2019100039A1 (en) 2017-11-20 2019-05-23 Alnylam Pharmaceuticals, Inc. Serum amyloid p component (apcs) irna compositions and methods of use thereof
US10953036B2 (en) 2017-11-20 2021-03-23 University Of Georgia Research Foundation, Inc. Compositions and methods of modulating HIF-2A to improve muscle generation and repair
CA3082450A1 (en) 2017-11-21 2019-05-31 Crispr Therapeutics Ag Materials and methods for treatment of autosomal dominant retinitis pigmentosa
US11728007B2 (en) 2017-11-30 2023-08-15 Grail, Llc Methods and systems for analyzing nucleic acid sequences using mappability analysis and de novo sequence assembly
CN111629747A (en) 2017-12-05 2020-09-04 沃泰克斯药物股份有限公司 CRISPR-CAS9 modified CD34+ human pigment stem cells and progenitor cells and application thereof
CA3084825A1 (en) 2017-12-14 2019-06-20 Crispr Therapeutics Ag Novel rna-programmable endonuclease systems and their use in genome editing and other applications
EP3724206B1 (en) 2017-12-14 2023-06-28 Ionis Pharmaceuticals, Inc. Conjugated antisense compounds and their use
US20200308588A1 (en) 2017-12-18 2020-10-01 Alnylam Pharmaceuticals, Inc. High mobility group box-1 (hmgb1) irna compositions and methods of use thereof
WO2019126037A1 (en) 2017-12-19 2019-06-27 City Of Hope Modified tracrrnas grnas, and uses thereof
AU2018393050A1 (en) 2017-12-21 2020-06-18 Bayer Healthcare Llc Materials and methods for treatment of Usher Syndrome Type 2A
EP3728595A1 (en) 2017-12-21 2020-10-28 CRISPR Therapeutics AG Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp)
WO2019126641A2 (en) 2017-12-21 2019-06-27 Ionis Pharmaceuticals, Inc. Modulation of frataxin expression
US11242568B2 (en) 2017-12-29 2022-02-08 City Of Hope DNA methylation diagnostic test for breast cancer
CA3088180A1 (en) 2018-01-12 2019-07-18 Crispr Therapeutics Ag Compositions and methods for gene editing by targeting transferrin
US20200392510A1 (en) 2018-01-15 2020-12-17 Ionis Pharmaceuticals, Inc. Modulators of dnm2 expression
EP3740472A1 (en) 2018-01-19 2020-11-25 Synthena AG Tricyclo-dna nucleoside precursors and processes for preparing the same
WO2019147743A1 (en) 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
US11268077B2 (en) 2018-02-05 2022-03-08 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
EP3749767A1 (en) 2018-02-05 2020-12-16 Vertex Pharmaceuticals Incorporated Materials and methods for treatment of hemoglobinopathies
EP3749368A1 (en) 2018-02-08 2020-12-16 Yeda Research and Development Co. Ltd Methods of identifying and using agents for treating diseases associated with intestinal barrier dysfunction
US11332733B2 (en) 2018-02-12 2022-05-17 lonis Pharmaceuticals, Inc. Modified compounds and uses thereof
MA51869A (en) 2018-02-16 2020-12-23 Bayer Healthcare Llc COMPOSITIONS AND METHODS FOR TARGETING GENE EDITING OF FIBRINOGEN-ALPHA
JP2021514974A (en) 2018-02-26 2021-06-17 シンソークス, インコーポレイテッド IL-15 conjugate and its use
JP7239597B2 (en) 2018-03-02 2023-03-14 アイオーニス ファーマシューティカルズ, インコーポレーテッド Regulators of IRF4 expression
EP3759127A4 (en) 2018-03-02 2022-03-30 Ionis Pharmaceuticals, Inc. Compounds and methods for the modulation of amyloid-beta precursor protein
CN112105625A (en) 2018-03-07 2020-12-18 赛诺菲 Nucleotide precursors, nucleotide analogs, and oligomeric compounds containing the same
WO2019178248A1 (en) 2018-03-13 2019-09-19 The Regents Of The University Of California Inhibitors of integrin alpha 2 beta 1 and methods of use
AU2019239957A1 (en) 2018-03-19 2020-09-10 Bayer Healthcare Llc Novel RNA-programmable endonuclease systems and uses thereof
EP3768694A4 (en) 2018-03-22 2021-12-29 Ionis Pharmaceuticals, Inc. Methods for modulating fmr1 expression
EP4051799A2 (en) 2018-03-30 2022-09-07 Rheinische Friedrich-Wilhelms-Universität Bonn Aptamers for targeted activaton of t cell-mediated immunity
US20210155959A1 (en) 2018-04-06 2021-05-27 Children's Medical Center Corporation Compositions and methods for somatic cell reprogramming and modulating imprinting
JP7275164B2 (en) 2018-04-11 2023-05-17 アイオーニス ファーマシューティカルズ, インコーポレーテッド Regulators of EZH2 expression
WO2019204668A1 (en) 2018-04-18 2019-10-24 Casebia Therapeutics Limited Liability Partnership Compositions and methods for knockdown of apo(a) by gene editing for treatment of cardiovascular disease
US20210189460A1 (en) 2018-04-25 2021-06-24 Qiagen Sciences Llc Sequential paired-end sequencing
KR20210008497A (en) 2018-05-09 2021-01-22 아이오니스 파마수티컬즈, 인코포레이티드 Compounds and methods for reducing ATXN3 expression
BR112020020957B1 (en) 2018-05-09 2022-05-10 Ionis Pharmaceuticals, Inc Oligomeric compounds, population and pharmaceutical composition thereof and their uses
TW202016304A (en) 2018-05-14 2020-05-01 美商阿尼拉製藥公司 Angiotensinogen (agt) irna compositions and methods of use thereof
US10765760B2 (en) 2018-05-29 2020-09-08 Sarepta Therapeutics, Inc. Exon skipping oligomer conjugates for muscular dystrophy
AU2019278884A1 (en) 2018-05-30 2021-01-07 Novartis Ag Lipid-modified nucleic acid compounds and methods
US10987428B2 (en) 2018-06-01 2021-04-27 City Of Hope Phosphorothioate-conjugated miRNAs and methods of using the same
EP3806868A4 (en) 2018-06-13 2022-06-22 Sarepta Therapeutics, Inc. Exon skipping oligomers for muscular dystrophy
JP2021526823A (en) 2018-06-14 2021-10-11 アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. Compounds and methods for increasing STMN2 expression
JP7315594B2 (en) 2018-06-27 2023-07-26 アイオーニス ファーマシューティカルズ, インコーポレーテッド Compounds and methods for reducing LRRK2 expression
SG11202012499RA (en) 2018-06-28 2021-01-28 Crispr Therapeutics Ag Compositions and methods for genomic editing by insertion of donor polynucleotides
EP3826645A4 (en) 2018-07-25 2023-05-17 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing atxn2 expression
TW202020153A (en) 2018-07-27 2020-06-01 美商薩羅塔治療公司 Exon skipping oligomers for muscular dystrophy
US10857174B2 (en) 2018-07-27 2020-12-08 United States Government As Represented By The Department Of Veterans Affairs Morpholino oligonucleotides useful in cancer treatment
US11939593B2 (en) 2018-08-01 2024-03-26 University Of Georgia Research Foundation, Inc. Compositions and methods for improving embryo development
WO2020028729A1 (en) 2018-08-01 2020-02-06 Mammoth Biosciences, Inc. Programmable nuclease compositions and methods of use thereof
US20210189431A1 (en) 2018-08-10 2021-06-24 Yale University Compositions and methods for embryonic gene editing in vitro
JP2021533767A (en) 2018-08-13 2021-12-09 アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. Hepatitis B virus (HBV) dsRNA substance composition and its usage
US20210348162A1 (en) 2018-08-16 2021-11-11 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the lect2 gene
CN113329739A (en) 2018-08-20 2021-08-31 罗贡股份有限公司 Antisense oligonucleotides targeting SCN2A for the treatment of SCN1A encephalopathy
EP3843845A4 (en) 2018-08-29 2022-05-11 University Of Massachusetts Inhibition of protein kinases to treat friedreich ataxia
CN112912502A (en) 2018-08-31 2021-06-04 耶鲁大学 Compositions and methods for enhancing triplex and nuclease-based gene editing
CN112930399A (en) 2018-08-31 2021-06-08 耶鲁大学 Compositions and methods for enhancing donor oligonucleotide-based gene editing
WO2020051507A1 (en) 2018-09-06 2020-03-12 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
US10724052B2 (en) 2018-09-07 2020-07-28 Crispr Therapeutics Ag Universal donor cells
EP3620520A1 (en) 2018-09-10 2020-03-11 Universidad del Pais Vasco Novel target to treat a metabolic disease in an individual
EP3850110A4 (en) 2018-09-11 2022-06-08 Singular Genomics Systems, Inc. Modified archaeal family b polymerases
CN112912422A (en) 2018-09-14 2021-06-04 西北大学 Programming protein polymerization with DNA
CN112424355A (en) 2018-09-18 2021-02-26 阿尔尼拉姆医药品有限公司 Ketohexokinase (KHK) iRNA compositions and methods of use thereof
TW202023573A (en) 2018-09-19 2020-07-01 美商Ionis製藥公司 Modulators of pnpla3 expression
WO2020061381A1 (en) 2018-09-19 2020-03-26 La Jolla Institute For Immunology Ptprs and proteoglycans in rheumatoid arthritis
WO2020074742A1 (en) 2018-10-12 2020-04-16 F. Hoffmann-La Roche Ag Detection methods for epitachophoresis workflow automation
JP2022505173A (en) 2018-10-17 2022-01-14 クリスパー・セラピューティクス・アクチェンゲゼルシャフト Compositions and Methods for Delivering Transgenes
US20230028359A1 (en) 2018-10-25 2023-01-26 Singular Genomics Systems, Inc. Nucleotide analogues
US10913951B2 (en) 2018-10-31 2021-02-09 University of Pittsburgh—of the Commonwealth System of Higher Education Silencing of HNF4A-P2 isoforms with siRNA to improve hepatocyte function in liver failure
TW202028222A (en) 2018-11-14 2020-08-01 美商Ionis製藥公司 Modulators of foxp3 expression
BR112021008967A2 (en) 2018-11-15 2021-08-17 Ionis Pharmaceuticals, Inc. irf5 expression modulators
JP7455831B2 (en) 2018-11-21 2024-03-26 アイオーニス ファーマシューティカルズ, インコーポレーテッド Compounds and methods for reducing prion expression
NL2022043B1 (en) 2018-11-21 2020-06-03 Akershus Univ Hf Tagmentation-Associated Multiplex PCR Enrichment Sequencing
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
WO2020112195A1 (en) 2018-11-30 2020-06-04 Yale University Compositions, technologies and methods of using plerixafor to enhance gene editing
US20210332495A1 (en) 2018-12-06 2021-10-28 Northwestern University Protein Crystal Engineering Through DNA Hybridization Interactions
KR20210104759A (en) 2018-12-13 2021-08-25 사렙타 쎄러퓨틱스 인코퍼레이티드 Exon skipping oligomer conjugates for muscular dystrophy
KR20210103931A (en) 2018-12-14 2021-08-24 일루미나 케임브리지 리미티드 Reduced pacing by unlabeled nucleotides during sequencing
WO2020126593A1 (en) 2018-12-17 2020-06-25 Illumina Cambridge Limited Compositions for use in polyunucleotide sequencing
SG11202012758WA (en) 2018-12-17 2021-01-28 Illumina Cambridge Ltd Primer oligonucleotide for sequencing
CN113543791A (en) 2018-12-20 2021-10-22 维尔生物科技有限公司 Combination HBV therapy
CN113631709A (en) 2018-12-20 2021-11-09 普拉克西斯精密药物股份有限公司 Compositions and methods for treating KCNT 1-related disorders
EP3674702A1 (en) 2018-12-27 2020-07-01 Imec VZW Method for sequencing a polynucleotide using a biofet
EP3931313A2 (en) 2019-01-04 2022-01-05 Mammoth Biosciences, Inc. Programmable nuclease improvements and compositions and methods for nucleic acid amplification and detection
WO2020146397A1 (en) 2019-01-08 2020-07-16 Singular Genomics Systems, Inc. Nucleotide cleavable linkers and uses thereof
SG11202107669WA (en) 2019-01-16 2021-08-30 Genzyme Corp Serpinc1 irna compositions and methods of use thereof
MX2021008918A (en) 2019-01-31 2021-08-24 Ionis Pharmaceuticals Inc Modulators of yap1 expression.
EP3918069A1 (en) 2019-01-31 2021-12-08 Bar Ilan University Neoantigens created by aberrant-induced splicing and uses thereof in enhancing immunotherapy
WO2020160511A1 (en) 2019-02-01 2020-08-06 The Board Of Trustees Of The Leland Stanford Junior University Immolative cell-penetrating complexes for nucleic acid delivery to the lung
BR112021014415A2 (en) 2019-02-06 2021-09-21 Synthorx, Inc. IL-2 CONJUGATES AND METHODS OF USING THEM
WO2020163630A1 (en) 2019-02-06 2020-08-13 Singular Genomics Systems, Inc. Compositions and methods for nucleic acid sequencing
WO2020168362A1 (en) 2019-02-15 2020-08-20 Crispr Therapeutics Ag Gene editing for hemophilia a with improved factor viii expression
WO2020171889A1 (en) 2019-02-19 2020-08-27 University Of Rochester Blocking lipid accumulation or inflammation in thyroid eye disease
EP3927378A1 (en) 2019-02-21 2021-12-29 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Method for reduction drug-induced nephrotoxicity
US11504425B2 (en) 2019-02-26 2022-11-22 Wayne State University Amphiphilic oligodeoxynucleotide conjugates as adjuvant enhancers
EP3931328A4 (en) 2019-02-27 2023-09-13 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
US20220127661A1 (en) 2019-03-04 2022-04-28 King Abdullah University Of Science And Technology Compositions and methods of targeted nucleic acid enrichment by loop adapter protection and exonuclease digestion
MX2021010559A (en) 2019-03-07 2021-12-15 Univ California Crispr-cas effector polypeptides and methods of use thereof.
CA3133226A1 (en) 2019-03-11 2020-09-17 Sorrento Therapeutics, Inc. Improved process for integration of dna constructs using rna-guided endonucleases
US20220145274A1 (en) 2019-03-12 2022-05-12 Crispr Therapeutics Ag Novel high fidelity rna-programmable endonuclease systems and uses thereof
EP3937780A4 (en) 2019-03-14 2022-12-07 InSilixa, Inc. Methods and systems for time-gated fluorescent-based detection
WO2020198268A1 (en) 2019-03-28 2020-10-01 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy with casimersen
CA3198063A1 (en) 2019-03-29 2020-10-08 Mitsubishi Tanabe Pharma Corporation Compound, method and pharmaceutical composition for modulating expression of dux4
MX2021011928A (en) 2019-03-29 2022-01-04 Dicerna Pharmaceuticals Inc Compositions and methods for the treatment of kras associated diseases or disorders.
AU2020253821A1 (en) 2019-03-29 2021-10-28 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating UBE3A-ATS
CN114206499A (en) 2019-04-08 2022-03-18 米罗库鲁斯公司 Multi-cartridge digital microfluidic devices and methods of use
WO2020214763A1 (en) 2019-04-18 2020-10-22 Sarepta Therapeutics, Inc. Compositions for treating muscular dystrophy
US11814464B2 (en) 2019-04-29 2023-11-14 Yale University Poly(amine-co-ester) polymers and polyplexes with modified end groups and methods of use thereof
US20220177880A1 (en) 2019-05-03 2022-06-09 Dicerna Pharmaceuticals, Inc. Double-stranded nucleic acid inhibitor molecules with shortened sense strands
WO2020225606A1 (en) 2019-05-08 2020-11-12 Crispr Therapeutics Ag Crispr/cas all-in-two vector systems for treatment of dmd
SG11202112240VA (en) 2019-05-13 2021-12-30 Vir Biotechnology Inc Compositions and methods for treating hepatitis b virus (hbv) infection
EP3969583A1 (en) 2019-05-14 2022-03-23 F. Hoffmann-La Roche AG Devices and methods for sample analysis
WO2020230047A1 (en) 2019-05-15 2020-11-19 Affinito Alessadra Aptamers against glioblastoma
US20220243203A1 (en) 2019-05-28 2022-08-04 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing fus expression
EP3980541A1 (en) 2019-06-04 2022-04-13 Apterna Limited Aptamers against transferrin receptor (tfr)
TW202113078A (en) 2019-06-14 2021-04-01 美商史基普研究協會 Reagents and methods for replication, transcription, and translation in semi-synthetic organisms
WO2020254872A2 (en) 2019-06-17 2020-12-24 Crispr Therapeutics Ag Methods and compositions for improved homology directed repair
WO2020257489A1 (en) 2019-06-19 2020-12-24 Sarepta Therapeutics, Inc. Methods for treating muscular dystrophy
WO2020257776A1 (en) 2019-06-21 2020-12-24 Yale University Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof
WO2020257779A1 (en) 2019-06-21 2020-12-24 Yale University Hydroxymethyl-modified gamma-pna compositions and methods of use thereof
WO2021011803A1 (en) 2019-07-16 2021-01-21 Omniome, Inc. Synthetic nucleic acids having non-natural structures
JP2022549060A (en) 2019-07-25 2022-11-24 ザ スクリプス リサーチ インスティテュート Methods of identifying dopaminergic neurons and progenitor cells
US11524298B2 (en) 2019-07-25 2022-12-13 Miroculus Inc. Digital microfluidics devices and methods of use thereof
EP3956450A4 (en) 2019-07-26 2022-11-16 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating gfap
WO2021022161A1 (en) 2019-07-31 2021-02-04 Yale University Compositions and methods for treating sickle cell disease
WO2021022109A1 (en) 2019-08-01 2021-02-04 Alnylam Pharmaceuticals, Inc. SERPIN FAMILY F MEMBER 2 (SERPINF2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021022108A2 (en) 2019-08-01 2021-02-04 Alnylam Pharmaceuticals, Inc. CARBOXYPEPTIDASE B2 (CPB2) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
WO2021025899A1 (en) 2019-08-02 2021-02-11 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer pharmaceutical compositions
WO2021030522A1 (en) 2019-08-13 2021-02-18 Alnylam Pharmaceuticals, Inc. SMALL RIBOSOMAL PROTEIN SUBUNIT 25 (RPS25) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
MX2022001770A (en) 2019-08-14 2022-05-20 Codiak Biosciences Inc Extracellular vesicle linked to molecules and uses thereof.
MX2022001776A (en) 2019-08-15 2022-03-17 Synthorx Inc Immuno oncology combination therapies with il-2 conjugates.
CN114555621A (en) 2019-08-15 2022-05-27 Ionis制药公司 Bond-modified oligomeric compounds and uses thereof
MX2022002053A (en) 2019-08-23 2022-03-17 Synthorx Inc Il-15 conjugates and uses thereof.
CA3149421A1 (en) 2019-08-30 2021-03-04 Yale University Compositions and methods for delivery of nucleic acids to cells
CN114616331A (en) 2019-09-03 2022-06-10 阿尔尼拉姆医药品有限公司 Compositions and methods for inhibiting expression of LECT2 gene
CN114728999A (en) 2019-09-05 2022-07-08 赛诺菲 Oligonucleotides containing nucleotide analogs
CA3150233A1 (en) 2019-09-05 2021-03-11 Alireza Rezania Universal donor cells
CN114375300A (en) 2019-09-05 2022-04-19 克里斯珀医疗股份公司 Universal donor cell
TW202124406A (en) 2019-09-10 2021-07-01 美商歐姆尼歐美公司 Reversible modification of nucleotides
US20210070827A1 (en) 2019-09-10 2021-03-11 Synthorx, Inc. Il-2 conjugates and methods of use to treat autoimmune diseases
JP2022547678A (en) 2019-09-11 2022-11-15 ボシュ ヘルス アイルランド リミテッド Methods of treating non-alcoholic fatty liver disease (NAFLD) using IL-17RA antibodies
US11512295B2 (en) 2019-09-12 2022-11-29 Singular Genomics Systems, Inc. Modified thermoccocus polymerases
WO2021067747A1 (en) 2019-10-04 2021-04-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing ugt1a1 gene expression
US20220372522A1 (en) 2019-10-08 2022-11-24 Life Technologies Corporation Compositions and methods for homology-directed recombination
EP4045062A1 (en) 2019-10-14 2022-08-24 Astrazeneca AB Modulators of pnpla3 expression
EP4045652A1 (en) 2019-10-18 2022-08-24 Alnylam Pharmaceuticals, Inc. Solute carrier family member irna compositions and methods of use thereof
CN115176004A (en) 2019-10-22 2022-10-11 阿尔尼拉姆医药品有限公司 Complement component C3 iRNA compositions and methods of use thereof
BR112021018125A2 (en) 2019-10-25 2021-11-16 Illumina Cambridge Ltd Methods for generating an asymmetric closed-end double-stranded nucleic acid template, for generating an asymmetrical double-stranded nucleic acid template from tagged DNA, and sequencing tagged DNA
US20230040920A1 (en) 2019-11-01 2023-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
AR120341A1 (en) 2019-11-01 2022-02-09 Alnylam Pharmaceuticals Inc COMPOSITIONS OF RNAi AGENTS AGAINST HUNTINGTINE (HTT) AND THEIR METHODS OF USE
TW202131952A (en) 2019-11-04 2021-09-01 美商欣爍克斯公司 Interleukin 10 conjugates and uses thereof
BR112022009216A2 (en) 2019-11-13 2022-08-02 Alnylam Pharmaceuticals Inc METHODS AND COMPOSITIONS TO TREAT AN ANGIOTENSINOGEN-ASSOCIATED DISORDER (AGT)
US20230056569A1 (en) 2019-11-22 2023-02-23 Alnylam Pharmaceuticals, Inc. Ataxin3 (atxn3) rnai agent compositions and methods of use thereof
CA3159501A1 (en) 2019-11-27 2021-06-03 Brian Joseph CAFFERTY Methods of synthesizing rna molecules
AU2020398216A1 (en) 2019-12-04 2022-06-30 The Board Of Trustees Of The Leland Stanford Junior University Enhancing blood-brain barrier drug transport by targeting endogenous regulators
BR112022011417A2 (en) 2019-12-13 2022-08-30 Alnylam Pharmaceuticals Inc COMPOSITIONS OF THE IRNA AGENT OF THE OPEN READING PHASE 72 OF HUMAN CHROMOSOME 9 (C9ORF72) AND METHODS OF USE THEREOF
TW202138559A (en) 2019-12-16 2021-10-16 美商阿尼拉製藥公司 Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2021122944A1 (en) 2019-12-18 2021-06-24 Alia Therapeutics Srl Compositions and methods for treating retinitis pigmentosa
JP2023506842A (en) 2019-12-18 2023-02-20 ノバルティス アーゲー Compositions and methods for treating hemoglobinopathies
CA3165862A1 (en) 2019-12-23 2021-07-01 The Regents Of The University Of California Stabilization of mhc complexes
AU2020412459B2 (en) 2019-12-23 2022-12-08 Singular Genomics Systems, Inc. Methods for long read sequencing
CA3166578A1 (en) 2019-12-31 2021-07-08 Singular Genomics Systems, Inc. Polynucleotide barcodes for long read sequencing
WO2021138560A2 (en) 2020-01-02 2021-07-08 The Trustees Of Columbia University In The City Of New York Programmable and portable crispr-cas transcriptional activation in bacteria
MX2022008738A (en) 2020-01-15 2022-09-23 Dicerna Pharmaceuticals Inc 4'-o-methylene phosphonate nucleic acids and analogues thereof.
WO2021154705A1 (en) 2020-01-27 2021-08-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Rab13 and net1 antisense oligonucleotides to treat metastatic cancer
WO2021154941A1 (en) 2020-01-31 2021-08-05 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions for use in the treatment of amyotrophic lateral sclerosis (als)
KR20220140593A (en) 2020-02-10 2022-10-18 알닐람 파마슈티칼스 인코포레이티드 Compositions and methods for silencing VEGF-A expression
WO2021163281A1 (en) 2020-02-12 2021-08-19 Accutar Biotechnology Inc. Antisense oligonucleotides and their use for treating pendred syndrome
IL295496A (en) 2020-02-18 2022-10-01 Alnylam Pharmaceuticals Inc Apolipoprotein c3 (apoc3) irna compositions and methods of use thereof
US11034942B1 (en) 2020-02-27 2021-06-15 Singular Genomics Systems, Inc. Modified pyrococcus polymerases and uses thereof
US20220064638A1 (en) 2020-02-28 2022-03-03 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating smn2
WO2021178607A1 (en) 2020-03-05 2021-09-10 Alnylam Pharmaceuticals, Inc. Complement component c3 irna compositions and methods of use thereof for treating or preventing complement component c3-associated diseases
AU2021232014A1 (en) 2020-03-06 2022-10-06 Alnylam Pharmaceuticals, Inc. Ketohexokinase (KHK) IRNA compositions and methods of use thereof
US11359238B2 (en) 2020-03-06 2022-06-14 Singular Genomics Systems, Inc. Linked paired strand sequencing
JP2023516748A (en) 2020-03-06 2023-04-20 アルナイラム ファーマシューティカルズ, インコーポレイテッド Compositions and methods for inhibiting expression of transthyretin (TTR)
WO2021188611A1 (en) 2020-03-18 2021-09-23 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating subjects having a heterozygous alanine-glyoxylate aminotransferase gene (agxt) variant
JP2023519274A (en) 2020-03-26 2023-05-10 アルナイラム ファーマシューティカルズ, インコーポレイテッド CORONAVIRUS iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US20230190785A1 (en) 2020-03-30 2023-06-22 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajc15 gene expression
US20230295622A1 (en) 2020-04-06 2023-09-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing myoc expression
JP2023521094A (en) 2020-04-07 2023-05-23 アルナイラム ファーマシューティカルズ, インコーポレイテッド Compositions and methods for silencing SCN9A expression
WO2021206922A1 (en) 2020-04-07 2021-10-14 Alnylam Pharmaceuticals, Inc. Transmembrane serine protease 2 (tmprss2) irna compositions and methods of use thereof
EP4133076A1 (en) 2020-04-07 2023-02-15 Alnylam Pharmaceuticals, Inc. Angiotensin-converting enzyme 2 (ace2) irna compositions and methods of use thereof
US11965162B2 (en) 2020-04-16 2024-04-23 The Johns Hopkins University MicroRNA and inhibitors thereof and methods of treatment
EP4117682A4 (en) 2020-04-24 2023-09-13 Singular Genomics Systems, Inc. Modified nucleotides and uses thereof
JP2023523993A (en) 2020-04-27 2023-06-08 アルナイラム ファーマシューティカルズ, インコーポレイテッド Apolipoprotein E (ApoE) iRNA agent compositions and methods of use thereof
CN116096381A (en) 2020-04-30 2023-05-09 阿尔尼拉姆医药品有限公司 Complement Factor B (CFB) iRNA compositions and methods of use thereof
IL297435A (en) 2020-05-01 2022-12-01 Ionis Pharmaceuticals Inc Compounds and methods for modulating atxn1
CN115916176A (en) 2020-05-01 2023-04-04 加利福尼亚大学董事会 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof
US20230227824A1 (en) 2020-05-12 2023-07-20 Mitsubishi Tanabe Pharma Corporation Compound, method and pharmaceutical composition for regulating expression of ataxin 3
US20210355463A1 (en) 2020-05-15 2021-11-18 Crispr Therapeutics Ag Messenger rna encoding cas9 for use in genome-editing systems
WO2021231692A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of otoferlin (otof)
EP4150089A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
EP4150086A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
EP4150078A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
WO2021231827A2 (en) 2020-05-15 2021-11-18 Life Technologies Corporation Sirna sequences targeting coronavirus-2
EP4150076A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
WO2021231675A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
WO2021231679A1 (en) 2020-05-15 2021-11-18 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
EP4150077A1 (en) 2020-05-15 2023-03-22 Korro Bio, Inc. Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
EP4153746A1 (en) 2020-05-21 2023-03-29 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
AU2021274944A1 (en) 2020-05-22 2022-12-15 Wave Life Sciences Ltd. Double stranded oligonucleotide compositions and methods relating thereto
US11408000B2 (en) 2020-06-03 2022-08-09 Triplet Therapeutics, Inc. Oligonucleotides for the treatment of nucleotide repeat expansion disorders associated with MSH3 activity
JP2023530234A (en) 2020-06-05 2023-07-14 ザ・ブロード・インスティテュート・インコーポレイテッド Compositions and methods for treating neoplasms
EP4162050A1 (en) 2020-06-09 2023-04-12 Alnylam Pharmaceuticals, Inc. Rnai compositions and methods of use thereof for delivery by inhalation
CA3184289A1 (en) 2020-06-18 2021-12-23 Alnylam Pharmaceuticals, Inc. Xanthine dehydrogenase (xdh) irna compositions and methods of use thereof
US20230233693A1 (en) 2020-06-19 2023-07-27 Yale University Poly(amine-co-ester) polymers with modified end groups and enhanced pulmonary delivery
CA3182458A1 (en) 2020-06-24 2021-12-30 Laura ROSEN Engineered hepatitis b virus neutralizing antibodies and uses thereof
KR20230027235A (en) 2020-06-25 2023-02-27 신톡스, 인크. Immuno-oncology combination therapy using IL-2 conjugates and anti-EGFR antibodies
US11732263B2 (en) 2020-06-29 2023-08-22 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating PLP1
US20230235315A1 (en) 2020-07-10 2023-07-27 Horizon Discovery Limited Method for producing genetically modified cells
EP4153606A2 (en) 2020-07-13 2023-03-29 Singular Genomics Systems, Inc. Methods of sequencing complementary polynucleotides
EP4192505A1 (en) 2020-08-04 2023-06-14 Dicerna Pharmaceuticals, Inc. Systemic delivery of oligonucleotides
US20220043003A1 (en) 2020-08-04 2022-02-10 Abbott Rapid Diagnostics International Unlimited Company Assays for detecting sars-cov-2
EP4192511A1 (en) 2020-08-07 2023-06-14 Fortis Therapeutics, Inc. Immunoconjugates targeting cd46 and methods of use thereof
WO2022038521A1 (en) 2020-08-18 2022-02-24 Regenacellx.SL Compositions and methods for detecting sars-cov-2 spike protein
EP4204002A1 (en) 2020-08-31 2023-07-05 Yale University Compositions and methods for delivery of nucleic acids to cells
TW202227102A (en) 2020-09-22 2022-07-16 瑞典商阿斯特捷利康公司 Method of treating fatty liver disease
EP4217489A1 (en) 2020-09-24 2023-08-02 Alnylam Pharmaceuticals, Inc. Dipeptidyl peptidase 4 (dpp4) irna compositions and methods of use thereof
US20230392134A1 (en) 2020-09-30 2023-12-07 Crispr Therapeutics Ag Materials and methods for treatment of amyotrophic lateral sclerosis
WO2022076291A1 (en) 2020-10-05 2022-04-14 Alnylam Pharmaceuticals, Inc. G protein-coupled receptor 75 (gpr75) irna compositions and methods of use thereof
EP3978608A1 (en) 2020-10-05 2022-04-06 SQY Therapeutics Oligomeric compound for dystrophin rescue in dmd patients throughout skipping of exon-51
AU2021356610A1 (en) 2020-10-09 2023-06-15 Synthorx, Inc. Immuno oncology therapies with il-2 conjugates
MX2023004029A (en) 2020-10-09 2023-04-27 Synthorx Inc Immuno oncology combination therapy with il-2 conjugates and pembrolizumab.
EP4228637A1 (en) 2020-10-15 2023-08-23 Yeda Research and Development Co. Ltd Method of treating myeloid malignancies
EP4232455A2 (en) 2020-10-20 2023-08-30 Sanofi Novel ligands for asialoglycoprotein receptor
AU2021365822A1 (en) 2020-10-21 2023-06-08 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating primary hyperoxaluria
EP4232582A1 (en) 2020-10-23 2023-08-30 Alnylam Pharmaceuticals, Inc. Mucin 5b (muc5b) irna compositions and methods of use thereof
IL302709A (en) 2020-11-13 2023-07-01 Alnylam Pharmaceuticals Inc COAGULATION FACTOR V (F5) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
AU2021381363A1 (en) 2020-11-18 2023-06-15 Ionis Pharmaceuticals, Inc. Compounds and methods for modulating angiotensinogen expression
WO2022106695A1 (en) 2020-11-23 2022-05-27 Alpha Anomeric Sas Nucleic acid duplexes
US11459372B2 (en) 2020-11-30 2022-10-04 Crispr Therapeutics Ag Gene-edited natural killer cells
CA3201452A1 (en) 2020-12-01 2022-06-09 Alnylam Pharmaceuticals, Inc. Methods and compositions for inhibition of hao1 (hydroxyacid oxidase 1 (glycolate oxidase)) gene expression
EP4259795A1 (en) 2020-12-08 2023-10-18 Alnylam Pharmaceuticals, Inc. Coagulation factor x (f10) irna compositions and methods of use thereof
GB2603454A (en) 2020-12-09 2022-08-10 Ucl Business Ltd Novel therapeutics for the treatment of neurodegenerative disorders
GB202019692D0 (en) 2020-12-14 2021-01-27 Apterna Ltd Aptamer-sirna fusions
WO2022140126A1 (en) 2020-12-21 2022-06-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Dna vector and uses thereof for detecting hiv and siv
WO2022140702A1 (en) 2020-12-23 2022-06-30 Flagship Pioneering, Inc. Compositions of modified trems and uses thereof
WO2022140535A1 (en) 2020-12-23 2022-06-30 Sarepta Therapeutics, Inc. Compositions comprising exon skipping oligonucleotide conjugates for treating muscular dystrophy
EP4271798A1 (en) 2020-12-30 2023-11-08 CRISPR Therapeutics AG Compositions and methods for differentiating stem cells into nk cells
AU2021414617A1 (en) 2020-12-31 2023-08-10 Crispr Therapeutics Ag Universal donor cells
CA3207144A1 (en) 2021-01-05 2022-07-14 Horizon Discovery Limited Method for producing genetically modified cells
WO2022150260A1 (en) 2021-01-05 2022-07-14 Alnylam Pharmaceuticals, Inc. COMPLEMENT COMPONENT 9 (C9) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
US11486001B2 (en) 2021-02-08 2022-11-01 Singular Genomics Systems, Inc. Methods and compositions for sequencing complementary polynucleotides
WO2022174101A1 (en) 2021-02-12 2022-08-18 Synthorx, Inc. Skin cancer combination therapy with il-2 conjugates and cemiplimab
WO2022174102A1 (en) 2021-02-12 2022-08-18 Synthorx, Inc. Lung cancer combination therapy with il-2 conjugates and an anti-pd-1 antibody or antigen-binding fragment thereof
WO2022174000A2 (en) 2021-02-12 2022-08-18 Alnylam Pharmaceuticals, Inc. Superoxide dismutase 1 (sod1) irna compositions and methods of use thereof for treating or preventing superoxide dismutase 1- (sod1-) associated neurodegenerative diseases
IL305176A (en) 2021-02-17 2023-10-01 Lonza Sales Ag Extracellular vesicle-linked to a biologically active molecule via an optimized linker and an anchoring moiety
WO2022182864A1 (en) 2021-02-25 2022-09-01 Alnylam Pharmaceuticals, Inc. Prion protein (prnp) irna compositions and methods and methods of use thereof
AU2022226098A1 (en) 2021-02-26 2023-08-24 Alnylam Pharmaceuticals, Inc. KETOHEXOKINASE (KHK) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
IL305418A (en) 2021-03-04 2023-10-01 Alnylam Pharmaceuticals Inc Angiopoietin-like 3 (angptl3) irna compositions and methods of use thereof
GB202315184D0 (en) 2021-03-05 2023-11-15 Univ Leland Stanford Junior In vivo dna assembly and analysis
WO2022192519A1 (en) 2021-03-12 2022-09-15 Alnylam Pharmaceuticals, Inc. Glycogen synthase kinase 3 alpha (gsk3a) irna compositions and methods of use thereof
EP4263868A1 (en) 2021-03-12 2023-10-25 Singular Genomics Systems, Inc. Nanoarrays and methods of use thereof
WO2022192038A1 (en) 2021-03-12 2022-09-15 Northwestern University Antiviral vaccines using spherical nucleic acids
US11884977B2 (en) 2021-03-12 2024-01-30 Singular Genomics Systems, Inc. Nanoarrays and methods of use thereof
AU2022245323A1 (en) 2021-03-24 2023-09-28 Genentech, Inc. Efficient tcr gene editing in t lymphocytes
AR125230A1 (en) 2021-03-29 2023-06-28 Alnylam Pharmaceuticals Inc COMPOSITIONS OF ANTI-HUNTINGTIN (HTT) RNAi AGENTS AND THEIR METHODS OF USE
EP4314293A1 (en) 2021-04-01 2024-02-07 Alnylam Pharmaceuticals, Inc. Proline dehydrogenase 2 (prodh2) irna compositions and methods of use thereof
AU2022261124A1 (en) 2021-04-22 2023-10-05 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cancer
EP4330392A1 (en) 2021-04-26 2024-03-06 Alnylam Pharmaceuticals, Inc. Transmembrane protease, serine 6 (tmprss6) irna compositions and methods of use thereof
WO2022232308A1 (en) 2021-04-27 2022-11-03 Singular Genomics Systems, Inc. High density sequencing and multiplexed priming
WO2022232343A1 (en) 2021-04-29 2022-11-03 Alnylam Pharmaceuticals, Inc. Signal transducer and activator of transcription factor 6 (stat6) irna compositions and methods of use thereof
EP4330395A1 (en) 2021-04-30 2024-03-06 Sarepta Therapeutics, Inc. Treatment methods for muscular dystrophy
WO2022235537A1 (en) 2021-05-03 2022-11-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for treating transthyretin (ttr) mediated amyloidosis
WO2022245583A1 (en) 2021-05-18 2022-11-24 Alnylam Pharmaceuticals, Inc. Sodium-glucose cotransporter-2 (sglt2) irna compositions and methods of use thereof
EP4341405A1 (en) 2021-05-20 2024-03-27 Korro Bio, Inc. Methods and compositions for adar-mediated editing
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
CN115404240A (en) 2021-05-28 2022-11-29 上海环码生物医药有限公司 Constructs, methods for making circular RNA and uses thereof
WO2022256283A2 (en) 2021-06-01 2022-12-08 Korro Bio, Inc. Methods for restoring protein function using adar
TW202317762A (en) 2021-06-02 2023-05-01 美商艾拉倫製藥股份有限公司 Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
EP4347826A1 (en) 2021-06-02 2024-04-10 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
WO2022256538A1 (en) 2021-06-03 2022-12-08 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and cetuximab
IL308743A (en) 2021-06-04 2024-01-01 Alnylam Pharmaceuticals Inc HUMAN CHROMOSOME 9 OPEN READING FRAME 72 (C9ORF72) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
AR126070A1 (en) 2021-06-08 2023-09-06 Alnylam Pharmaceuticals Inc COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING STARGARDT DISEASE AND/OR DISORDERS ASSOCIATED WITH RETINOL BORDER PROTEIN 4 (RBP4)
EP4101928A1 (en) 2021-06-11 2022-12-14 Bayer AG Type v rna programmable endonuclease systems
IL308896A (en) 2021-06-11 2024-01-01 Bayer Ag Type v rna programmable endonuclease systems
IL309217A (en) 2021-06-18 2024-02-01 Ionis Pharmaceuticals Inc Compounds and methods for reducing ifnar1 expression
WO2022269518A2 (en) 2021-06-23 2022-12-29 Novartis Ag Compositions and methods for the treatment of hemoglobinopathies
US20230014010A1 (en) 2021-06-23 2023-01-19 Crispr Therapeutics Ag Engineered cells with improved protection from natural killer cell killing
US20230194709A9 (en) 2021-06-29 2023-06-22 Seagate Technology Llc Range information detection using coherent pulse sets with selected waveform characteristics
WO2023278410A1 (en) 2021-06-29 2023-01-05 Korro Bio, Inc. Methods and compositions for adar-mediated editing
KR20240026203A (en) 2021-06-30 2024-02-27 알닐람 파마슈티칼스 인코포레이티드 Methods and compositions for treating angiotensinogen (AGT)-related disorders
WO2023285431A1 (en) 2021-07-12 2023-01-19 Alia Therapeutics Srl Compositions and methods for allele specific treatment of retinitis pigmentosa
TW202333748A (en) 2021-07-19 2023-09-01 美商艾拉倫製藥股份有限公司 Methods and compositions for treating subjects having or at risk of developing a non-primary hyperoxaluria disease or disorder
IL309905A (en) 2021-07-23 2024-03-01 Alnylam Pharmaceuticals Inc Beta-catenin (ctnnb1) irna compositions and methods of use thereof
WO2023009687A1 (en) 2021-07-29 2023-02-02 Alnylam Pharmaceuticals, Inc. 3-hydroxy-3-methylglutaryl-coa reductase (hmgcr) irna compositions and methods of use thereof
WO2023014677A1 (en) 2021-08-03 2023-02-09 Alnylam Pharmaceuticals, Inc. Transthyretin (ttr) irna compositions and methods of use thereof
TW202337474A (en) 2021-08-04 2023-10-01 美商艾拉倫製藥股份有限公司 Irna compositions and methods for silencing angiotensinogen (agt)
TW202334413A (en) 2021-08-13 2023-09-01 美商艾拉倫製藥股份有限公司 Factor xii (f12) irna compositions and methods of use thereof
US11833221B2 (en) 2021-09-01 2023-12-05 Ionis Pharmaceuticals, Inc. Oligomeric compounds for reducing DMPK expression
WO2023034515A2 (en) 2021-09-03 2023-03-09 Sarepta Therapeutics, Inc. Delivery of anitsense oligomers by mirror image peptides
WO2023034920A2 (en) 2021-09-03 2023-03-09 Singular Genomics Systems, Inc. Amplification oligonucleotides
EP4144841A1 (en) 2021-09-07 2023-03-08 Bayer AG Novel small rna programmable endonuclease systems with impoved pam specificity and uses thereof
WO2023044370A2 (en) 2021-09-17 2023-03-23 Alnylam Pharmaceuticals, Inc. Irna compositions and methods for silencing complement component 3 (c3)
WO2023044094A1 (en) 2021-09-20 2023-03-23 Alnylam Pharmaceuticals, Inc. Inhibin subunit beta e (inhbe) modulator compositions and methods of use thereof
US20230096386A1 (en) 2021-09-30 2023-03-30 Illumina Cambridge Limited Polynucleotide sequencing
CA3233242A1 (en) 2021-09-30 2023-04-06 Sarepta Therapeutics, Inc. Antisense oligonucleotides having one or more abasic units
WO2023070086A1 (en) 2021-10-22 2023-04-27 Sarepta Therapeutics, Inc. Morpholino oligomers for treatment of peripheral myelin protein 22 related diseases
CA3234835A1 (en) 2021-10-22 2023-04-27 Korro Bio, Inc. Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
WO2023076450A2 (en) 2021-10-29 2023-05-04 Alnylam Pharmaceuticals, Inc. HUNTINGTIN (HTT) iRNA AGENT COMPOSITIONS AND METHODS OF USE THEREOF
TW202333749A (en) 2021-10-29 2023-09-01 美商艾拉倫製藥股份有限公司 Complement factor b (cfb) irna compositions and methods of use thereof
WO2023086292A2 (en) 2021-11-10 2023-05-19 University Of Rochester Gata4-targeted therapeutics for treatment of cardiac hypertrophy
WO2023086295A2 (en) 2021-11-10 2023-05-19 University Of Rochester Antisense oligonucleotides for modifying protein expression
GB202117758D0 (en) 2021-12-09 2022-01-26 Ucl Business Ltd Therapeutics for the treatment of neurodegenerative disorders
WO2023122573A1 (en) 2021-12-20 2023-06-29 Synthorx, Inc. Head and neck cancer combination therapy comprising an il-2 conjugate and pembrolizumab
WO2023118349A1 (en) 2021-12-21 2023-06-29 Alia Therapeutics Srl Type ii cas proteins and applications thereof
WO2023122750A1 (en) 2021-12-23 2023-06-29 Synthorx, Inc. Cancer combination therapy with il-2 conjugates and cetuximab
WO2023118068A1 (en) 2021-12-23 2023-06-29 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
CA3222937A1 (en) 2021-12-29 2023-07-06 Jonathan Mark Boutell Methods of nucleic acid sequencing using surface-bound primers
US11772093B2 (en) 2022-01-12 2023-10-03 Miroculus Inc. Methods of mechanical microfluidic manipulation
WO2023141314A2 (en) 2022-01-24 2023-07-27 Alnylam Pharmaceuticals, Inc. Heparin sulfate biosynthesis pathway enzyme irna agent compositions and methods of use thereof
WO2023159189A1 (en) 2022-02-18 2023-08-24 Yale University Branched poly(amine-co-ester) polymers for more efficient nucleic expression
WO2023168427A1 (en) 2022-03-03 2023-09-07 Yale University Compositions and methods for delivering therapeutic polynucleotides for exon skipping
WO2023172885A1 (en) 2022-03-09 2023-09-14 The Board Of Trustees Of The Leland Stanford Junior University Branched lipid charge-altering releasable transporters for nucleic acid delivery
WO2023172665A2 (en) 2022-03-10 2023-09-14 Singular Genomics Systems, Inc. Nucleic acid delivery scaffolds
WO2023178230A1 (en) 2022-03-17 2023-09-21 Sarepta Therapeutics, Inc. Phosphorodiamidate morpholino oligomer conjugates
WO2023177866A1 (en) 2022-03-18 2023-09-21 Dicerna Pharmaceuticals, Inc. Decarboxylative acetoxylation using mn(ii) or mn(iii) reagent for synthesis of 4'-acetoxy- nucleoside and use thereof for synthesis of corresponding 4'-(dimethoxyphosphoryl)methoxy- nucleotide
WO2023194359A1 (en) 2022-04-04 2023-10-12 Alia Therapeutics Srl Compositions and methods for treatment of usher syndrome type 2a
WO2023212294A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Angiopoietin-related protein 7-specific antibodies and uses thereof
WO2023212293A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Complement factor h related 4-specific antibodies and uses thereof
WO2023212298A1 (en) 2022-04-29 2023-11-02 Broadwing Bio Llc Bispecific antibodies and methods of treating ocular disease
WO2023225665A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2023230201A1 (en) 2022-05-26 2023-11-30 The Board Of Trustees Of The Leland Stanford Junior University Small molecule conjugated charge-altering releasable transporters for nucleic acid delivery
WO2023231959A2 (en) 2022-05-30 2023-12-07 Shanghai Circode Biomed Co., Ltd Synthetic circular rna compositions and methods of use thereof
WO2023233339A1 (en) 2022-06-01 2023-12-07 Crispr Therapeutics Ag Compositions and methods for differentiating stem cells into nk cells
WO2023233342A2 (en) 2022-06-01 2023-12-07 Crispr Therapeutics Ag Gene-edited natural killer cells
WO2023237587A1 (en) 2022-06-10 2023-12-14 Bayer Aktiengesellschaft Novel small type v rna programmable endonuclease systems
WO2024006477A1 (en) 2022-06-29 2024-01-04 Life Technologies Corporation Multiplex dye compounds
WO2024015962A1 (en) 2022-07-15 2024-01-18 Pacific Biosciences Of California, Inc. Blocked asymmetric hairpin adaptors
WO2024015924A2 (en) 2022-07-15 2024-01-18 Entrada Therapeutics, Inc. Hybrid oligonucleotides
WO2024026474A1 (en) 2022-07-29 2024-02-01 Regeneron Pharmaceuticals, Inc. Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle
WO2024039776A2 (en) 2022-08-18 2024-02-22 Alnylam Pharmaceuticals, Inc. Universal non-targeting sirna compositions and methods of use thereof
WO2024044352A1 (en) 2022-08-26 2024-02-29 The General Hospital Corporation Methods and compositions for prognosis and treatment of dilated cardiomyopathy and heart failure
WO2024050261A1 (en) 2022-08-29 2024-03-07 University Of Rochester Antisense oligonucleotide-based anti-fibrotic therapeutics
WO2024059165A1 (en) 2022-09-15 2024-03-21 Alnylam Pharmaceuticals, Inc. 17b-hydroxysteroid dehydrogenase type 13 (hsd17b13) irna compositions and methods of use thereof
WO2024056880A2 (en) 2022-09-16 2024-03-21 Alia Therapeutics Srl Enqp type ii cas proteins and applications thereof
WO2024064237A2 (en) 2022-09-21 2024-03-28 Sarepta Therapeutics, Inc. Dmd antisense oligonucleotide-mediated exon skipping efficiency
WO2024073440A1 (en) 2022-09-27 2024-04-04 Genentech, Inc. Inhibition of genotoxic stress to improve t cell engineering
WO2024073040A1 (en) 2022-09-29 2024-04-04 The Board Of Trustees Of The Leland Stanford Junior University C-myc-targeting charge-altering releasable transporters as anti-tumor agents for breast cancer therapy
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0215942B1 (en) * 1985-03-15 1995-07-12 Antivirals Inc. Polynucleotide assay reagent and method
JPS63303341A (en) * 1987-06-03 1988-12-09 Kuraray Co Ltd Photosensitive composition
EP0491793B1 (en) * 1989-09-15 2005-11-30 Southern Research Institute 2'-deoxy-4'-thioribonucleosides as antiviral and anticancer agents

Also Published As

Publication number Publication date
JPH05504564A (en) 1993-07-15
AU654473B2 (en) 1994-11-10
EP0506845B1 (en) 1998-03-18
ATE164081T1 (en) 1998-04-15
EP0506845A4 (en) 1992-10-21
JP3172174B2 (en) 2001-06-04
KR920703692A (en) 1992-12-18
US5034506A (en) 1991-07-23
EP0506845A1 (en) 1992-10-07
WO1991009073A1 (en) 1991-06-27
KR0154317B1 (en) 1998-12-01
DE69032167T2 (en) 1998-10-29
DE69032167D1 (en) 1998-04-23
AU7158791A (en) 1991-07-18
CA2069906A1 (en) 1991-06-21

Similar Documents

Publication Publication Date Title
CA2069906C (en) Uncharged morpholino-based polymers having achiral intersubunit linkages
US5185444A (en) Uncharged morpolino-based polymers having phosphorous containing chiral intersubunit linkages
EP0962463B1 (en) Uncharged morpholino-based polymers having phosphorus-containing chiral intersubunit linkages
US5235033A (en) Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5521063A (en) Polynucleotide reagent containing chiral subunits and methods of use
US5378841A (en) Alpha-morpholino ribonucleoside derivatives and polymers thereof
US5142047A (en) Uncharged polynucleotide-binding polymers
US5405938A (en) Sequence-specific binding polymers for duplex nucleic acids
KR100225090B1 (en) Sequence-specific binding polymers for duplex nucleic acids
US5217866A (en) Polynucleotide assay reagent and method
EP1046649B1 (en) Solid phase nucleic acid labeling by transamination
US5470974A (en) Uncharged polynucleotide-binding polymers
EP0458876B1 (en) Method of separating oligonucleotides from a mixture
US7098326B2 (en) Methods for the integrated synthesis and purification of oligonucleotides
Antsypovich et al. Synthesis of modified oligonucleotides and production of duplexes with covalently linked chains

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKEC Expiry (correction)

Effective date: 20121202